Activation Date: 05/02/05  
Includes Update #18 
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY  
 
CALGB  50303/CTSU  50303 
PHASE III RANDOMIZED STUDY O F R-CHOP  V. DOSE-ADJUSTED EPOCH -R WITH MOLECULAR PROFILING IN 
UNTREATED DE NOVO DIFFUSE LARGE B-CELL LYMPHOMAS  
 
As of Update #14, enrollment on CALGB 50303 will be limited to institutions and patients participating in the 
required imaging companion study CALGB 580603.  
 
Study Chairs  
Nancy L. Bartlett, MD  Andrew D. Zelenetz, MD, PhD  
  
  
  
  
  
 
Laboratory Co -Chairs  
  
  
  
 
Pathology Co -Chair  Imaging Co -Chair  
  
  
  
Lymphoma Committee Chair  SWOG Co -Chair  
  
  
  
 
PET Committee  Chair  Imaging Committee Chair  
  
  
  
 
Faculty Statisticians  
  
  
  
Staff Statistician  
 
 
Data Manager  Protocol Coordinator  
  
  
  
Participating Organizations:  ALLIANCE /Alliance for  Clinical Trials in Oncology,  SWOG /SWOG , ECOG -
ACRIN/ECOG -ACRIN Cancer Research Group, NRG /NRG Oncology 
Version D ate: 02/15/2018 1 Update #18 

CALGB 50303  
Alliance  Protocol Operations  Program Office  
 
 
 Alliance Statistics and Data Center  
 
 
Adverse Event Reporting  
 
CAEPR for rituximab appears in Section 15.1  Alliance  Patient Registration  
 
 
 
Alliance Biorepository at Ohio State University  
 
 Allian ce Imaging Core Lab  at IROC Ohio  
 
 
 
 
Alliance  Pharmacy Contact  
 Allian ce Nursing Contact  
 
Medidata RAVE® iMedidata portal  
 
This study is supported by the NCI Cancer Trials Support Unit (CTSU).  
Institutions not aligned with the Alliance  will participate through the CTSU mechanism as outlined below and 
detailed in the CTSU logistical appendix  
• The study protocol and all related forms and documents  must be downloaded from the protocol -specific Web page 
of the CTSU Member Web site located at https://www.ctsu.org. 
• Send completed site registration documents to the CTSU Regulatory Office. Refer to the CTSU logistical appendix 
for specific instructions and documents to be s ubmitted.  
• Patient e nrollments  will be conducted by the CTSU. Refer to the CTSU logistical appendix for specific instructions 
and forms to be submitted.  
• Data management will be performed by the Alliance . Case report forms (with the exception of patient enrollment 
forms) , clinical reports, and transmittals  must be sent to the Alliance  unless otherwise directed by the protocol.  Do 
not send study data or case report forms to the CTSU Data Operations.  
• Data query and delinquency reports will be sent directly to the enrolling site by the Alliance  (generally via e -mail but 
may be sent via fax or postal mail). Please send query responses and delinquent data to Alliance  and do not copy the 
CTSU Data Operations. Que ry responses should be sent to the Alliance  via postal mail (no transmittal form needs to 
accompany response). Each site should have a designated CTSU Administrator and Data Administrator and must keep 
their CTEP AMS account contact information current. This will ensure timely communication between the clinical site 
and the Alliance Statistics and Data Center . 
 
The pharmacogenetic component of this study is conducted as part of the NIH Pharmacogenetics Research Network, 
which is funded through a separate U01 mechanism (see http://www.nigms.nih.gov/Init iatives/PGRN/ for details) .
Version Date: 02/15/2018  2 Update #18 

CALGB 50303  
PHASE III RANDOMIZED STUDY OF R-CHOP  V. DOSE-ADJUSTED EPOCH -R WITH MOLECULAR PROFILING IN 
UNTREATED DE NOVO DIFFUSE LARGE B-CELL LYMPHOMAS  
Schema Page 1 of 2  
Eligibility Criteria:  Required Initial Laboratory Values*  
Histologica lly documented de novo stage I mediastinal (thymic) DLBCL or  ANC  ≥ 1000/µL  
any stage II, III, or IV DLBCL.  Platelets  ≥ 100,000/µL  
Patients must have one of the following WHO histologic subtypes without  Creatinine  ≤ 1.5 mg/dL  
evidence of indolent histo logical features in the tissue biopsy or bone   or CrCl  ≥ 50 cc/min  
marrow:  Total Bilirubin  ≤ 2 mg/dL**  
1. CD20+ diffuse large B -cell lymphoma (includes morphological variants: centroblastic; 
immunoblastic; T -cell/histiocyte rich; and anaplastic).   
2. CD20+ mediastinal (thymic) large B -cell lymphoma  *Unless attributable to non -Hodgkin  
3. CD20+ intravascular large B -cell lymphoma  lymphoma  
No prior cytotoxic chemotherapy or rituximab (see Section 4.2 ) **Unless attributable to Gi lbert’s  
Age ≥ 18 years.  Disease   
ECOG Performance Status 0 -2.   
No active ischemic heart disease or congestive heart failure (see Section 4.5 ).  
No known lymphomatous involvement of the CNS (see Section 4.6 ).   
No known HIV disease (see Section 4.7 ).   
Non pregnant and non -nursing (see Section 4.8 ).   
Patients with active medical processes (e.g., uncontrolled bacterial or viral infection, bleeding) not rela ted to their 
lymphoma should be excluded.   
TREATMENT OVERVIEW 
 
CALGB 580603:  REQUIRED FDG -PET/CT Imaging Companion (see Section 8.0 ) 
 
 
 
 
   
     
 
  
 
 
   
  
     
   
 
* A frozen t umor biopsy equivalent to a minimum of 4 at least 16 gauge needle cores is an important component of this study (see repeat 
tissue biopsy guid ance in Section 4.1  and Section 5.4.1 ). Patients  without ade quate frozen material should have a biopsy performed to 
obtain material. If a biopsy is performed and does not yield adequate material, the patient is still eligible for the study. Patients who do 
not have a tissue site that can be safely biopsied may be e nrolled only  if permission is granted in writing (e -mail) by the Study Chairs 
(Drs. Wilson or Zelenetz) or their designees.  
† Baseline PET/CT for patients registered to the optional FDG -PET/CT Imaging Companion (CALGB 580603) is preferred prior to the 
CALG B 50303 baseline excisional biospsy and ≤ 30 days prior to the start of therapy.  
‡ For patients registered to the optional FDG -PET/CT Imaging Companion (CALGB 580603), PET/CT of abd/chest/pelvis will be 
collected at baseline, post -Cycle 2, and post -Cycle 6  (see Section 8.3 ). 
 
No concurrent radiation therapy will be permitted on study except for isolated CNS lesions. Patients who receive radiation to any site other 
than the CNS will be inevaluable. Patients with parenchymal CNS lesi ons should receive whole brain radiation and will only be considered 
treatment failures if the systemic disease progresses.  
The use of epoetin is allowed at the discretion of the investigator. It is recommended that epoetin not be used in this protocol unless hemoglobin 
is ≤ 10 g/dL, and that it be held or the dose modified for hemoglobin > 12 g/dL . R
EGI 
STRA
T
ION
* R
A
N
DOM
I
ZAT
I
O
N C1     C2      C3      C4       C5      C6 Arm A:  R-CHOP  
Arm B:  DA-EPOCH -R C1      C2       C3      C4       C5      C6 Stage  
Stage  
Treatment 
completed  Treatment 
completed  
0          3         6         9        12        15      18 Time Line (Weeks)  
C = Cycle = 21 days  PET/CT  
CAL GB 580603 ‡  
 PET/CT  
CALGB 580603 ‡  
 Baseline  PET/CT † 
CALGB 580603  
 
Version Date: 02/15/2018  3 Update #18 
CALGB 50303  
PHASE III RANDOMIZED STUDY OF R-CHOP  V. DOSE-ADJUSTED EPOCH -R WITH MOLECULAR PROFILING IN UNTREATED 
DE NOVO DIFFUSE LARGE B-CELL LYMPHOMAS  
Schema Page 2 of 2  
 
Arm A: R-CHOP (see Section 7.1 ) 
Dose reductions for subsequent cycles will be determined by the occurrence of grade 4 neutropenia or febrile neutropenia (see  Section 9.1.1 ). 
• Rituximab 375 mg/m2 IV inf usion on Day 1 prior to CHOP chemotherapy.  
• Cyclophosphamide 750 mg/m2 IV on Day 1.  
• Doxorubicin 50 mg/m2 IV on Day 1.  
• Vincristine 1.4 mg/m2 IV (2 mg cap) on Day 1.  
• Prednisone 40 mg/m2/day PO on Days 1 -5. 
• Begin filgrastim or pegfilgrastim if grade 4 neutropenia (ANC < 500/µL) or febrile neutropenia (ANC < 500/µL + fever ≥ 38.5°C [101°F] 
sustained for more than one hour) develops on the previous cycle. Administer filgrastim 480 mcg subcutaneous daily from Day 2 until ANC 
> 5000 after the nadir (nadir  usually between Days 10-12) or for 10 days (Days 2-11) if the ANC is not being monitored, or pegfilgrastim 6 
mg SubQ on Day 2 (may be delayed up to two days for convenience of scheduling due to holidays, weekend, etc.).  
 
Required ancillary medications adm inistered during all cycles: 
• Omeprazole 20 mg/day PO (or equivalent)  
• Stimulant laxative/stool softener (e.g., Pericolace®) 2 tablets PO BID and adjusted as necessary for constipation (prevention ). 
• Lactulose 20 g PO Q 6 hours PRN until resolution or i nstitutional preference for treatment of constipation.  
• Acetaminophen 650 mg PO and diphenhydramine 50-100 mg IV or PO 30 -60 minutes prior to rituximab.  
• Hepatitis B surface Ag+ patients receive lamivudine 100 mg/day PO until 8 weeks past last chemotherapy.  
 
Patients with (1) ≥ 2 extranodal sites and elevated LDH, or (2) bone marrow involvement by large cell lymphoma will receive C NS prophylaxis 
consisting of intrathecal methotrexate 12 mg on Day 1 (or Day 2) of Cycles 3, 4, 5, and 6.  
 
Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.  
 
Arm B: DA-EPOCH -R (see Section 7.2 ) 
Cycle 1 Doses:  
• Rituximab 375 mg/m2 IV infusion on Day 1 prior to EPOCH chemotherapy.  
• Doxorubicin 10 mg/m2/day CIVI on Days 1 -4. 
• Etoposide 50 mg/m2/day CIVI on Days 1 -4. 
• Vincristine 0.4 mg/m2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours).  
• Cyclophosphamide 750 mg/m2 IV on Day 5 (following completion of 96 hour infusions).  
• Prednisone 60 mg/m2 PO BID on Days 1 -5. 
• Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) or for 
10 days (Days 6 -15) if the ANC is not being monitored, during every  cycle.  
 Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle (see 
Section 
7.2.3 ). 
 Required ancillary medications administered during all cycles:  
• Cotrimoxazole DS 1 tablet three times weekly (or equivalent if allergic).  
• Omeprazole 20 mg/day PO (or equivalent)  
• Stimulant laxative/stool softener (e.g., Pericolace®) 2 tablets PO BID and adjusted as necessary for constipation (prevention ). 
• Lactulose 20 g PO Q6 hours PRN until resolution or institutional preference for treatment of constipation.  
• Acetaminophen 650 mg PO and diphenhydramine 50-100 mg IV or PO 30 -60 minutes prior to rituximab.  
• Hepatitis B surface Ag+ patients receive lamivudine 100 mg/day PO until 8 weeks past last chemot herapy.  
 Patients with (1) ≥ 2 extranodal sites and elevated LDH, or (2) bone marrow involvement by large cell lymphoma will receive C NS prophylaxis 
consisting of intrathecal methotrexate 12 mg on Day 1 (or Day 2) of Cycles 3, 4, 5, and 6.  
 Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.  
 
Version Date: 02/15/2018  4 Update #18 
CALGB 50303  
Guide to Companion Study Registration  
 
 
The following table is meant to assist clinical research associates in companion study registration and, if 
applicable, sample procurement.  
 
Frozen Tumor Biopsy  (see 
Section 5.4.1 ) Whole Blood For 
Pharmacogenomics (see Section 
5.4.2 ) 
If “yes ,” register to substudy 
CALGB 60405.  
* Please note that model informed consent questions are mapped to the CALGB registration 
system. As a result, it is h ighly recommended that the wording and order of the model informed 
consent questions be retained in order to facilitate patient registration.  FDG -PET/CT Images  
(see Section 8.0 ) 
Registration to FDG -PET 
imaging study CALGB 580603 
is required at time of patient 
registration to CALGB 50303.  
 Consent Question*:  
None. Req uired of all 
patients with  accessible 
tissue ( see Section 4.1 ) As of Update 14, 
participation in the 
imaging correlative 
study is required.  
Additional Registration  
Required?   No 
Additional 
Registration 
Required?  Yes Additional 
Registration  
Required?  Yes Consent Question*:  
Consent Question #1: “I 
agree that my blood may be 
used for the genetic  research 
studies described above”  Kind of Submission  
Version Date: 02/15/2018  5 Update #18 
CALGB 50303  
TABLE  OF CONTENTS  
1.0 INTRODUCTION  .............................................................................................................................. 9 
1.1 B ACKGROUND  .................................................................................................................................. 9 
1.2 R ITUXIMAB -CHOP  REGIMENS  ...................................................................................................... 10 
1.3 DA-EPOCH -RITUXIMAB REGIMENS  ............................................................................................. 10 
1.4 M OLECULAR PROFILING  ................................................................................................................ 13 
1.5 R ADIOTHERAPY CONSOLIDATION AND CNS  PROPHYLAXIS  .......................................................... 15 
1.6 A NALYSIS OF CANDIDATE GENETIC POLYMORPHISMS AND TREATMENT RESPONSE  ................... 17 
1.7 C OMPREHENSIVE ANALYSIS OF SOMATIC ALTERATIONS TO THE TUMOR GENOME  ..................... 17 
1.8 FDG -PET  ASSESSMENT IN DLBCL  ............................................................................................... 19 
1.9 S TUDY RATIONALE AND SUMMARY  .............................................................................................. 21 
1.10 I NCLUSION OF WOMEN AND MINORITIES  .................................................................................. 21 
2.0 OBJECTIVES  .................................................................................................................................. 22 
2.1 P RIMARY OBJECTIVES  .................................................................................................................... 22 
2.2 S ECONDARY OBJECTIVES ............................................................................................................... 22 
3.0 ON-STUDY GUIDELINES  ............................................................................................................. 22 
4.0 ELIGIBILITY CRITERIA ............................................................................................................. 23 
4.1 D OCUMENTATION OF DISEASE ....................................................................................................... 23 
4.2 P RIOR TREATMENT  ........................................................................................................................ 24 
4.3 A GE ≥ 18 YEARS . ............................................................................................................................ 24 
4.4 ECOG  PERFORMANCE STATUS 0-2................................................................................................ 24 
4.5 C ARDIAC FUNCTION ....................................................................................................................... 24 
4.6 L YMPHOMATOUS  ........................................................................................................................... 24 
4.7 HIV  STATUS  ................................................................................................................................... 24 
4.8 P REGNANCY AND NURSING STATUS  .............................................................................................. 24 
4.9 A CTIVE MEDICAL PROCES SES ........................................................................................................ 24 
4.10 R EQUIRED INITI AL LABORATORY VALUES *: ............................................................................ 24 
5.0 REGISTRATION/RANDOMIZATION, DATA SUBMISSION, HISTOLOGIC REVI EW 
AND SPECIMEN SUBMISS ION FOR CORRELATIVE STUDIES  .................................................. 25 
5.1 R EGISTRATION /RANDOMIZATION  .................................................................................................. 25 
5.2 D ATA SUBMISSION  ......................................................................................................................... 27 
5.3 H ISTOLOGIC REVIEW  ..................................................................................................................... 30 
5.4 S PECIMEN SUBMISSION FOR CORRELATIVE STUDIES  .................................................................... 30 
6.0 REQUIRED DATA  .......................................................................................................................... 32 
6.1 CALGB  580603  FDG-P ET/CT  IMAGING REQUIREMENTS  ............................................................ 34 
7.0 TREATMENT PLAN  ...................................................................................................................... 35 
7.1 A RM A (R-CHOP  TREATMENT [7]) ............................................................................................... 35 
7.2 A RM B (DA- EPOCH -R TREATMENT [20]) .................................................................................... 37 
8.0 FDG -PET/CT IMAGING COMPANION (CALGB 580603) ....................................................... 39 
8.1 I NSTITUTION APPROVAL PROCEDURES FOR FDG- PET/CT  IMAGING COMPANION ....................... 39 
8.2 P ROCEDURES FOR FDG- PET/CT  IMAGING  .................................................................................... 41 
8.3 FDG -PET/CT  IMAGING ACQUISITION  ........................................................................................... 41 
8.4 P OST-TREATMENT STUDY PET/CT  SCANS (CYCLES 2 AND 6) ...................................................... 42  
Version Date: 02/15/2018  6 Update #18 
CALGB 50303  
8.5 FDG -PET/CT  DATA ARCHIVING , STORAGE , AND SUBMISSION  .................................................... 43 
8.6 T RAINING FOR FDG -PET/CT  DATA ACQUISITION AND HANDLING  ............................................. 44 
8.7 CALGB  IMAGING CORE LAB PROCESSING AND STORAGE  ........................................................... 45 
8.8 I NTERPRETATION OF POSITIVE POST-TREATMENT SCANS AND IMPLICATIONS OF PET  IMAGES 
FOR PROGRESSIVE DISEASE  .................................................................................................................... 48 
8.9 PET/CT  SCAN REIMBURSEMENT  ................................................................................................... 49 
9.0 DOSE MODIFICATIONS AND MANAGEMENT OF TOXICITY  .......................................... 49 
9.1 A RM A (R-CHOP)  DOSE MODIFICATIONS  ..................................................................................... 49 
9.2 A RM B (DA- EPOCH -R) DOSE MODIFICATIONS  ........................................................................... 51 
9.3 D OSE MODIFICATION FOR OBESE PATIENTS .................................................................................. 52 
10.0 DRUG FORMULATION, AVAILABILITY, AND PREPARATI ON ................................... 53 
10.1 D OXORUBICIN HCL  (ADRIAMYCIN PFS™,  ADRIAMYCIN RFS™,  RUBEX ®) ........................... 53 
10.2 E TOPOSIDE  (VEPESID®, EPIDOPHYLLOTOXIN , VP-16) ............................................................. 54 
10.3 V INCRISTINE SULFATE (VCR,  LEUROCRISTINE SULFATE , ONCOVIN®, VINCASAR PFS)  ........... 55 
10.4 C YCLOPHOSPHAMIDE (CYTOXAN®; NEOSAR®) ......................................................................... 56 
10.5 P REDNISONE (DELTASONE , MISCELLANEOUS ) .......................................................................... 56 
10.6 R ITUXIMAB  ................................................................................................................................ 57 
10.7 F ILGRASTIM (G-CSF;  R-MET HUG-CSF;  GRANULOCYTE COLONY STIMULATING FACTOR ; 
NEUPOGEN ®) .......................................................................................................................................... 58  
10.8 P EGFILGRASTIM (NEULASTA ®) ................................................................................................. 58 
10.9 M ETHOTREXATE (MTX,  FOLEX ) ............................................................................................... 59 
11.0 ANCILLARY THERAPY ........................................................................................................... 59 
11.1 S UPPORTIVE CARE ..................................................................................................................... 59 
11.2 H ORMONES AND OTHER CHEMOTHERAPEUTIC AGENTS  ........................................................... 60 
11.3 E POETIN  ..................................................................................................................................... 60 
12.0 CRITERIA FOR RESPONSE, PROGRESSION, AND RELAPSE  ....................................... 60 
12.1 D EFINITIONS OF RESPONSE [61] ................................................................................................ 60 
12.2 R ESPONSE ASSESSMENT TABLE  ................................................................................................ 61 
12.3 C RITERIA FOR FDG -PET  RESPONSE  .......................................................................................... 62 
13.0 REMOVAL OF PATIENTS FROM PROTOCOL THERAP Y .............................................. 62 
13.1 D URATION OF TREATMENT ........................................................................................................ 62 
13.2 E XTRAORDINARY MEDICAL CIRCUMSTANCES  .......................................................................... 62 
14.0 STATISTICAL CONSIDERATIONS  ....................................................................................... 63 
14.1 C LINICAL ENDPOINTS  ................................................................................................................ 63 
14.2 I NTERIM ANALYSIS  .................................................................................................................... 64 
14.3 M OLECULAR CHARACTERIZATION STUDIES  ............................................................................. 64 
14.4 S TUDY SIZE REQUIREMENTS TO ACHIEVE PHARMACOGENETIC GOALS  .................................. 66 
14.5 O VERVIEW OF FDG- PET/CT  STUDY (CALGB  580603) ........................................................... 67 
15.0 ADVERSE EVENT REPORTING (AER)  ................................................................................ 70 
15.1 C OMPREHENSIVE ADVERSE EVENTS AND POTENTIAL RISKS LIST (CAEPR)  FOR RITUXIMAB 
(NSC  687451) ......................................................................................................................................... 72 
16.0 REFE
RENCES  ............................................................................................................................. 76 
Version Date: 02/15/2018  7 Update #18 
CALGB 50303  
APPENDIX I  ..... CANCER TRIALS SUPPORT UNIT (CTSU) PARTICIPATION PROCEDURES
 83 
APPENDIX II  CALGB 580603 PET/CT INSTRUMENT TECHNICAL  SPECIFICATIONS 
FORM  88 
APPENDIX III  .............................................. CALGB 580603 IMAGING SITE PERSONNEL FORM
 93 
 
Version Date: 02/15/2018  8 Update #18 
CALGB 50303  
1.0 I NTRODUCTION  
1.1 Background  
Approximately 55,000 cases of non- Hodgkin lymphoma (NHL) are diagnosed yearly in the 
United States. Diffuse large B -cell lymphoma (DLBCL) comprises 25 -30% of these cases, and 
represents a signif icant public health issue; it is the single most common lymphoma in the United 
States with over fifteen thousand new cases each year and a rising incidence. Although 
potentially curable, only 35% of patients achieve a durable complete remission with standa rd 
CHOP chemotherapy, and most of the remaining patients die of their disease [1]. Because of the curative potential of DLBCL, advances in treatment will have a significant impact on patient 
survival and quality of life. Indeed, a 15% increase in cure will  save over 2000 additional lives 
annually with attendant savings in medical costs, social productivity and patient suffering. 
Investigators have worked to develop alternative regimens that reduce toxicity, permit dose 
intensification, and circumvent tumor cell resistance. Strategies to improve chemotherapy have 
been mostly unsuccessful. The second and third generation regimens–m- BACOD, ProMACE -
CytaBOM and MACOP -B and high dose therapy with stem cell transplantation–strategies 
empirically modeled on the Gold ie-Coldman and Dose Intensity hypotheses, have not improved 
survival compared to standard “CHOP” based treatment [1 -3]. 
Several recent reports suggest some advances in the chemotherapy treatment of aggressive 
lymphomas, but are open to interpretation. A randomized comparison of ACVBP, a high-dose 
CHOP variant, and standard CHOP in 708 patients aged 61 to 69 years with aggressive NHL and at least one adverse prognostic factor in the age- adjusted international prognostic index (IPI) 
was recently published [4] . At 5 years, the ACVBP and CHOP groups had an event -free survival 
(EFS) of 39% and 29% (p=0.005), respectively, and an overall survival of 46% and 38% 
(p=.036), showing an improved outcome for ACVBP. The results indicate, however, that some 
of the benefit  of ACVBP may lie in its better control of central nervous system (CNS) disease. 
Because both arms had a similar rate of complete remission (CR) with 58% in the ACVBP and 
56% in the CHOP groups, much of the benefit in the ACVBP arm was due to an improvement 
in disease -free survival (DFS) due in part to a lower rate of CNS progression (9 patients vs. 26 
patients) in the ACVBP compared to the CHOP arm (p=.004). Importantly, only patients in the ACVBP group received intrathecal CNS prophylaxis as well as intravenous methotrexate, which likely improved control of occult CNS lymphoma. 
The German Lymphoma Study Group recently reported the preliminary results of a 4- arm 
comparison of 14- and 21 -day CHOP and CHOEP in younger and older (> 60 years) patients 
with untreated aggressive lymphomas [5,6]. In younger patients with low -risk disease, the 
addition of etoposide (CHOEP) improved overall survival from 74% to 88%, compared to 
CHOP, whereas in older patients with higher risk disease (i.e., at least 1 adverse IPI factor) 
CHOP time intensification (i.e., CHOP -14), compared to CHOP- 21, was associated with an 
improved survival (54% v 45%, respectively). One question with these results is the absence of an obvious biological basis for the findings. Further insight will ha ve to await publication of 
these results.  
The absence of significant advances in the treatment of aggressive lymphomas over the past 30 
years is a sobering testament to the failure of empirically based clinical research and not 
necessarily to the absence o f more effective chemotherapy platforms. Indeed, chemotherapy 
remains the centerpiece of curative therapy for DLBCL, although recent studies indicate the 
importance of targeted agents, such as rituximab. Hence, there is an important need to conduct 
clinica l trials using scientifically engineered therapeutics and to assess biological endpoints.  
Version Date: 02/15/2018  9 Update #18 
CALGB 50303  
1.2 Rituximab -CHOP Regimens  
Recent studies suggest that the monoclonal antibody, rituximab (R), directed against the CD20 
B-cell antigen, may increase the efficacy of chemotherapy. In vitro , rituximab has been shown 
to sensitize drug- resistant lymphoma cell lines to chemotherapy. Recent evidence has shown 
that rituximab increases the benefit of CHOP in aggressive CD20+ lymphomas. A randomized 
study of CHOP versus R -CHOP was performed in 197 patients ≥ 60 years old with DLBCL [7]. 
Patients who received R -CHOP had a higher rate of CR compared to CHOP alone; 76% versus 
63%, respectively. With a median follow -up of 2 years, the EFS of R -CHOP and CHOP was 
57% and 38%, resp ectively, and at 3 years, it was approximately 51% and 38%. Results from a 
phase II study of rituximab and CHOP in untreated aggressive B -cell lymphomas have also been 
reported by Vose et al. [8]. In this study of 33 patients, 61% achieved CR and 90% of pa tients 
were progression -free, with a median follow -up of 26 months. While the 90% PFS is very 
encouraging, 70% of patients in the series were in the low IPI (0- 2) risk group, and at least 21% 
had evidence of a follicular histological pattern. The prelimina ry results of a phase III trial of 
CHOP -R versus CHOP with a second randomization to maintenance rituximab or observation 
in patients 60 years of age and older with DLBCL were recently presented at the American 
Society of Hematology meetings in 2003 [9]. Although the second randomization confounded 
the study interpretation, the results nevertheless suggested that the addition of rituximab 
improves the outcome of CHOP treatment in DLBCL. Hence, R -CHOP has become the de facto 
new standard for DLBCL, although longer follow -up will be needed to assess accurately the 
impact of rituximab. Of note, however, the benefit of rituximab appears to be principally in patients with BCL -2 positive tumors, which is likely a marker for the activated B -cell (ABC) 
subtype of DL BCL [10].  
1.3 DA-EPOCH -Rituximab Regimens  
The dose -adjusted (DA) EPOCH regimen was developed based on in vitro and 
pharmacodynamic principles to help overcome drug resistance [11]. In this regimen, 
doxorubicin, vincristine, and etoposide are administered as a 96 -hour continuous infusion, and 
cyclophosphamide and prednisone are administered on a bolus schedule. The rationale for the administration schedule derived from the laboratory observation that human tumor cell lines, including those with a multi -drug resistance phenotype, are more sensitive to cytotoxic natural 
products given for prolonged periods at low concentrations than to the same agents given for brief periods at higher concentrations. 
EPOCH was initially developed and tested in 131 patients with  relapsed or refractory NHL [12]. 
The response rate in these heavily pre- treated patients was 74% with 24% of patients achieving 
complete remission. Furthermore, among the subset of patients with aggressive histologies, 36% 
achieved complete remissions. Therapy was tolerable with a treatment- related mortality of 2%. 
A study of EPOCH was undertaken to address the role of EPOCH as initial therapy in DLBCL [13]. In this trial, the doses of doxorubicin, etoposide and cyclophosphamide were escalated 20% on every  cycle in which the nadir absolute neutrophil count (ANC) exceeded 500/µL, or 
reduced 20% if the ANC was less than 500/µL for more than 2 CBC measurements (CBC obtained twice weekly only) or the platelet nadir was < 25,000/µL. The rationale for dose -
adjust ment in each patient was based on several factors: 1. Dose intensity has been associated 
with improved outcome in aggressive lymphomas; 2. Small changes in steady state concentrations (Css) for infused agents can significantly affect efficacy (i.e., thresh old 
concentration); 3. Preliminary pharmacokinetics showed up to a 6- fold variation in Css in 
patients treated with the same dose.  
Fifty patients with untreated de novo DLBCL were enrolled. Patients had a median (range) age of 46 (20- 88), and IPI distribution of 56% low (0/1/2) and 44% high (3/4/5) risk disease. 
Complete responses (CR) were obtained in 45 patients (92%) and partial responses in 4 patients. 
Version Date: 02/15/2018  10 Update #18 
CALGB 50303  
There was no difference in CR rate among the IPI risk groups with 19 of 22 high risk and 26 of 
27 low risk patients achieving CR. With a median follow -up of 62 months, the actuarial 
progression- free survival (PFS) is 70% and overall survival (OS) is 73%. The data have recently 
been updated to a median follow -up of 81 months, and no relapses have occurred s ince reported 
at a median follow -up of 62 months as shown below [14]. The PFS at 62 months for low and 
high-risk groups are 79% and 58%, respectively, and the OS is 89% and 55%, respectively. 
Dose -adjusted EPOCH was well tolerated with a 8% incidence of fever and neutropenia.  
 
  
 
    
 
 
 
Potential mechanisms of treatment failure, such as bcl -2 and p53 mutation, which are associated 
with apoptosis, and tumor proliferation rate (MIB -1), which is associated with drug sensitivity, 
were assessed by immunohistochemistry [15- 18]. Overexpression of bcl -2 was the only factor 
associated with treatment failure in both univariate and multivariate Cox models, with 82% of 
bcl-2 negative and only 50% of bcl -2 positive patients progression- free at 52 months (shown 
below le ft). Also of interest was the impact of high tumor proliferation on outcome. In contrast 
to findings with CHOP -based regimens, patients with high tumor proliferation (>80%) were less 
likely to progress than patients with lower proliferation rates, although the result did not reach 
statistical significance (p
2 = 0.09) (shown below right). These results suggest that dose -adjusted 
EPOCH may produce greater cell kill than CHOP -based regimens. Patients with p53 
overexpression had a higher progression rate, although only survival showed a statistically 
significant association.  
 
 
   
 
   
 
 The dose -adjustment paradigm was developed in an attempt to reduce interpatient variation in 
plasma concentrations of chemotherapy by normalizing dose -rate to neutrophil nadirs. Most 
patients required dose escalations to achieve a neutrophil nadir, with 29% of cycles at ≥ 144% 01 2 3 4 5 6 7 820100
80
60
40
Years on Study 9*
*
*
*
*
*
*o
o
o
o
o
o
o
o
oProgression -Free (%)High RiskLow Risk
p2= .15
01 2 3 4 5 6 7 820100
80
60
40
Years on Study 9Progression -Free (%)*
*
*o
o
o
o
o
o
obcl-2 -
bcl-2 +
p2 = .04
01 2 3 4 5 6 7 820100
80
60
40
Years on Study 9Progression -Free (%)MIB-1 ≥80%
MIB-1 < 80%
p2= .24*
*
*
*
*
*o
o
o
o
o*
*
*
*
*
*o
o
o
o
oOverall Survival (74%)
Progression -Free Survival (70%)
Median Follow -up 81 Months 
01 2 3 4 5 6 7 820100
80
60
40
Years on Study Percent
9 10CR = 92%
Version Date: 02/15/2018  11 Update #18 
CALGB 50303  
of dose level 1 and 5% administered below dose level 1. Of note, the first cycle was more often 
associated with greater hematopoietic toxicity than cycle 2  with 38% of patients requiring dose 
escalations on cycle 3. Over all cycles, the mean dose intensification (DI) for the escalated agents were equivalent to the second dose level and were: (mean ± SD: mg/m
2/week) 
cyclophosphamide 296 ± 59; etoposide 80 ± 14; doxorubicin 16 ± 2.8. The vincristine DI was 96% of the planned dose intensity and was (mean ± SD: mg/m
2/week) 0.51 ± 0.06.  
The strategy of normalizing dose rate to the neutrophil nadir allows an opportunity to examine more accurately the influence of clinical factors on DI. This analysis revealed a significant 
inverse correlation between the DI of all adjusted agents and patient age (etoposide: r = -0.48; 
p
2 = 0.0004), but no correlation with any other IPI risk factor, the IPI index itself, or the outc ome 
measures of PFS or OS (shown below left) (unpublished observations) [13]. The lower DI with age could be explained by decreased hematopoietic tolerance and/or decreased drug metabolism 
in older patients. Preliminary pharmacokinetics (PK) of etoposide in 14 patients receiving dose -
adjusted EPOCH revealed an inverse correlation between age and clearance of free etoposide (r = -0.44; p
2 = 0.1), suggesting that older patients may achieve higher serum levels than younger 
patients at similar dose rates (shown  below left). Additionally, in 6 patients with PK on multiple 
cycles, the clearance of free etoposide increased over each cycle, with an average increase of 58% between cycles 1 and 6 (Hochberg adjustment for multiple comparisons: p
2= 0.02), 
indicating tha t, in the absence of dose escalation, the actual etoposide serum levels would 
decrease in many patients (shown below right).  
  
 
  
 
 
  
  These data suggest that the neutrophil nadir can be used as a surrogate to pharmacokinetics for 
normalization of Css. However, the neutrophil nadir will also reflect intracellular mechanisms 
such as drug efflux pumps (e.g., MDR -1), drug metabolism and DNA repair, to name a few.  
These variables all contribute to the variability of tumor response to chemotherapy, and are 
influenced by both germline polymorphisms and mutations within the tumor [19]. Hence, a 
secondary objective of this study will be to investigate the relationship between the pharmacogenomics (genetic polymorphisms) of normal mononuclear cells and clinical outcome 
(EFS, OS and toxicity) and tumor microarray. Although exploratory, this may provide important insights into the effects of genetic polymorphism on pathways of lymphomagenesis and 
treatment response and toxicity. This will be the first study to asse ss pharmacogenomics in 
DLBCL.  
The results with dose -adjusted EPOCH demonstrated that the regimen was well tolerated and 
suggested that this novel schedule and pharmacodynamic -based regimen may improve upon 
results achieved with CHOP -based regimens. However, patients with bcl -2+ lymphomas had a 
significantly worse outcome, compared with bcl -2 negative cases, indicating the need for further 020040060080010001200
10 20 30 40 50 60 70 80Free Etoposide Clearance [ml/min/m2]
Age (Years) r = -0.45
0200400600800100012001400Free Etoposide Clea rance [ml/min/m2]
 1 6 5 4 3 2 7 8
Cycle Number20 18 18 20 18 16 2 2
Version Date: 02/15/2018  12 Update #18 
CALGB 50303  
improvement in the regimen. Thus, based upon in vitro evidence showing synergy between 
rituximab and cytotoxic agents, a phase II study of dose-adjusted EPOCH with rituximab (DA-
EPOCH -R) was begun [20]. Preliminary results are available in 76 previously untreated patients 
with CD20+ DLBCL. The median patient age is 48 (range: 12- 85) years, median ECOG 
performance status is 1 (range: 0- 3), and 36% had high -intermediate or high international 
prognostic index (IPI) scores [14]. Among 71 patients evaluable for response (4 TE; 1 NE), complete responses (CR) were achieved in 92%, which is similar to DA -EPOCH alone. At a 
median follow -up of 26 months, the progression- free and overall survivals are both 82%.  
 
 
   
 
 
 
 
 
Based on the hypothesis that rituximab may help overcome molecular causes of drug resistance, it was investigated whether BCL- 2 and p53 overexpression are associated with drug resistance 
in DA- EPOCH -R, as had been shown with DA -EPOCH alone. As shown below, BCL -2 no 
longer identified an adverse prognostic group in the DA -EPOCH -R regimen, suggesting that 
rituximab may overcome these pathways of resistance, a result which  was confirmed in the 
GELA study of CHOP v R -CHOP [10]. Biologically, BCL -2 is a marker of the activated B -cell 
(ABC) molecular subtype of DLBCL, and this subtype may be the actual target of rituximab. 
 
 
  
   
  
 
 
 
 
The data on dose -adjusted EPOCH and EPOC H-R suggest these regimens may circumvent the 
limitations of conventional CHOP chemotherapy, but this needs to be ultimately confirmed in a 
randomized trial with R -CHOP. Furthermore, the dose -adjustment strategy has made the 
regimen tolerable in all age ra nges and, unlike other approaches, its use is not age dependent.  
1.4 Molecular Profiling  
Historically, treatment studies have been restrained by histological definitions of cancer. Molecular characterization, however, provides the foundation for a biologic al classification that 
weighs the relevance of tumor heterogeneity [21,22]. Without molecular characterization, the 
Percent
020100
80
60
40
Months on Study 6 12 18 24 30Median Follow-up: 2 yearsPFS and OS: 79% 
42 36 48 54 60
DA- EPOCH DA- EPOCH -R
Median Follow-up 60 mos Median Follow-up 23 mosBCL -2 –(82%)
BCL -2+ (50%)
0 1 2 3 4 5 6 7 820100
80
60
40
Years on Study Percent
p2 = .04
Percent
020100
80
60
40
Months on Study 6 12 18 24 30BCL -2+(83%)
42 36 48 54 60BCL -2-(71%)
Version Date: 02/15/2018  13 Update #18 
CALGB 50303  
clinical evaluation of treatments/drugs may fail to reveal important activity if only a portion of 
the tumors possess the molecular target(s) or pathways affected by the therapy. The 
Lymphoma/Leukemia Molecular Profiling Project at the NCI (LLMPP) has used molecular 
profiling to subdivide the most common type of non- Hodgkin lymphoma, diffuse large B -cell 
lymphoma, into distinct diseases with different responses to anthracyline- based multi -agent 
chemotherapy. Diffuse large B -cell lymphoma (DLBCL) presents a unique opportunity to 
incorporate molecular profiling in a clinical study comparing two treatment strategies that may 
have different molecular pathways of resistance. This trial will assess a new regimen (DA -
EPOCH -R) versus the current standard regimen (R -CHOP) for this common and potentially 
curable lymphoma. Through molecular profiling, it may be possible to identify molecular 
subgroups that  are more susceptible to one treatment regimen and will allow the development 
of a molecular prognostic model that may be useful clinically. We believe this study can provide 
proof of principle for the importance of molecular profiling in prospective clini cal trials and 
hasten the translation of molecular diagnosis into routine clinical management of cancer patients.  
Roughly 35% of patients with DLBCL can be cured by conventional anthracycline -based 
chemotherapy regimens (e.g., CHOP), whereas the others eventually succumb to this disease. 
This clinical heterogeneity suggested that this lymphoma type might encompass several 
molecularly distinct subgroups that differ in their responsiveness to therapy. This hypothesis has 
been confirmed in gene expression profiling studies conducted by the LLMPP, which recently analyzed gene expression in 240 retrospectively obtained biopsy specimens of DLBCL and 
correlated gene expression profiles of the tumors with clinical outcome of the patients [23,24]. 
Three broad gene expression subgroups of DLBCL were defined that differed in the expression 
of over 1,000 genes. These subgroups reflected, in part, the cell of origin of the tumors. One subgroup, termed germinal center B -cell-like (GCB) DLBCL resembled normal germinal center 
B cells in gene expression whereas another subgroup, termed activated B -cell-like (ABC) 
DLBCL, resembled mitogenically activated blood B cells. A third minor subgroup, termed Type 
3, did not share gene expression features of either GCB or ABC DLBCL and m ay be 
heterogeneous. Importantly, this gene expression subgroup distinction identified patients with 
distinct clinical outcomes: GCB DLBCL patients had a relatively favorable prognosis, with a 5 -
year survival rate of 60%, whereas ABC and Type 3 DLBCL patie nts had 5- year survival rates 
of 35% and 39%, respectively. One mechanism underlying this differential response to 
chemotherapy may be that GCB DLBCLs, like normal germinal center B -cells, have particularly 
low activity of the NF -kB pathway. This pathway protects cells from apoptosis induced by 
chemotherapy and is constitutively active in ABC DLBCLs, perhaps accounting for their 
relative resistance to CHOP chemotherapy [13].  
 
 
   
 
   
  
Version Date: 02/15/2018  14 Update #18 
CALGB 50303  
Additionally, however, further variation in gene expression was found to account for the residual 
clinical heterogeneity within each of the DLBCL subgroups [24]. A systematic search was 
undertaken for individual genes with expression patterns that correlated with overall survival. 
The majority of predictive genes could be cla ssified into four gene expression “signatures” that 
reflected different aspects of tumor cell biology. Most of the genes that predicted poor outcome belonged to the proliferation gene expression signature that includes genes that are more highly expressed in dividing cells than in quiescent cells.  Many genes that predicted good outcome 
belonged to the germinal center B -cell signature, a finding that reflects the relatively good 
outcome of GCB DLBCL patients. Two other sets of genes that predicted good outc ome 
suggested that host immune responses might contribute to curative outcomes following chemotherapy. The expression of MHC class II genes in the tumor cells correlated with good outcome, suggesting a role for antigen presentation by the tumor cells to infiltrating T 
lymphocytes. Another set of genes that predicted good outcome identified tumors with an 
intense fibrotic reaction characterized by infiltrating macrophage and natural killer cells, and 
may reflect an innate immune response to the tumor. In addition to these four sets of predictive 
genes, a single gene, BMP6, was found to be an independent predictor of poor outcome, and its 
expression may reflect the ability of the lymphoma cells to differentiate towards plasma cells.  
A multivariate predictive m odel of overall survival was created from 17 genes chosen from the 
different functional groups mentioned above [24]. This gene expression- based outcome 
predictor was able to stratify patients into risk groups with strikingly distinct overall survival 
rates. One half of the patients could be placed in a favorable risk group with a 71% 5- year 
survival rate. One quarter of the patients were in a poor risk group with only a 15% 5- year 
survival rate and the remaining quarter of patients had a 36% 5 -year survival  rate. Clearly, these 
findings demonstrate the need to identify alternative therapies for those patients in the poorest risk groups. 
The results of this study will have important implications for future treatment of DLBCL. 
Clinically, the study will determ ine if DA -EPOCH -R provides a significant therapeutic advance 
over R -CHOP, and will determine the therapeutic platform for future trials in DLBCL. Because 
DA-EPOCH -R incorporates several unique strategies, including infusional scheduling, 
etoposide use and pharmacodynamics- based dose optimization, the clinical outcome will 
provide some assessment of these strategies. The microarray tissue analyses and pharmacogenomics will provide important information. This study will be the first to 
prospectively assess microarray histological diagnosis, which is likely to become an important 
pathological diagnostic tool. The study will develop a molecular prognostic model for each 
regimen, which will provide patient prognostic information, identify patients suitable for novel 
therapy approaches, and will identify potential mechanisms of treatment failure important for the rational development of new treatment strategies. Importantly, this study will be the first to 
assess molecular mechanisms of treatment failure with a rit uximab -based regimen. It will also 
be the first to prospectively validate the use of microarray in a lymphoma therapeutic trial, thus providing proof of principle, and serve as a model for future trials. 
1.5 Radiotherapy consolidation and CNS prophylaxis  
A salient question is the role of radiation in the treatment of DLBCL. Radiation has been variably 
used in clinical trials for both advanced and early stage disease. Although several studies have suggested a benefit for radiation consolidation following CHO P chemotherapy in early stage 
DLBCL, longer follow -up has indicated a higher rate of late relapses among patients who receive 
limited chemotherapy and radiation, with an equivalent PFS and OS [25,26 ]. Additionally, 
preliminary results of a randomized study  of ACVBP versus CHOP followed by radiotherapy 
in low risk localized aggressive lymphoma showed a statistically superior EFS and OS for the ACVBP arm, and concluded that ACVBP is superior to CHOP + radiation [27 ]. Radiation has 
Version Date: 02/15/2018  15 Update #18 
CALGB 50303  
also been commonly used following chemotherapy in patients with primary mediastinal 
(thymic) DLBCL (PMLBCL). In a study of 50 patients with PMLBCL initially treated with 
MACOP -B, 66% had a persistently positive gallium scan, suggesting the presence of active 
disease [28 ]. However, following radiation consolidation, only 19% of patients had a positive 
gallium scan. With a median follow up of 39 months, 80% of all patients were event free. 
Importantly, all patients with a negative gallium after radiation were event free, whereas 60% of gallium positive patients relapsed. For comparison, none of the patients with PMLBCL 
treated with DA -EPOCH or DA- EPOCH -R received radiation consolidation. Among 14 
PMLBCL patients treated with DA -EPOCH, PFS and OS were 68% and 79%, respectively, at 
the med ian follow -up of 81 months; all patients in CR or CRu were gallium negative at the end 
of treatment. Furthermore, among 13 PMLBCL patients treated with DA -EPOCH -R, PFS and 
OS is 93% and 100%, respectively, at the median follow -up of 24 months. Although the  patient 
numbers are small, they suggest that rituximab may benefit patients with PMLBCL; a benefit which may also extend to patients receiving CHOP chemotherapy. These studies raise the 
question of whether radiation consolidation is necessary in patients with PMLBCL. Although 
radiation appears to benefit patients treated with MACOP -B, this cannot be extended to the DA -
EPOCH or ACVBP regimens. It is also important to recognize that radiation consolidation has significant adverse long term side effects, including an increased risk of breast cancer in women under 30 years of age (the most common group with PMLBCL), heart disease and other solid 
tumors [29]. Hence, inclusion of PMLBCL patients in this phase III study will provide important 
information on their outcome with rituximab based treatment and in the absence of radiation. 
To provide a measure of safety, all patients with PMLBCL with residual mediastinal abnormalities after completion of treatment will receive a PET scan. Patients whose PET scan is highly suspicious will undergo biopsy. Patients whose PET scan is equivocal will be followed 
monthly with a PET and/or CT scan and undergo a biopsy if the scan indicates increasing 
abnormalities. Only patients with biopsy proven disease following treatment may receive 
radiation and will be considered treatment failures on the study.  
Radiation consolidation has been variably used in patients with more advanced stage DLBCL, 
but has no clear benefit. The 4- arm studies of CHOP 14/21 and CHOEP 14/21 employed 
radiothe rapy consolidation for those patients with initial masses ≥ 7.5 cm, but the studies were 
not designed to assess the role of radiation and its inclusion confounds the interpretation of results [5,6]. In contrast, studies employing ACVBP from the GELA group have not included 
radiation consolidation, including those patients with PMLBCL [4]. Similarly, radiation has not 
been used in the DA -EPOCH or DA -EPOCH -R studies. In conclusion, these studies do not 
suggest that radiation consolidation significantly improv es the cure of DLBCL. Because the 
clinical and scientific objectives of this phase III study are to compare the efficacy of R -CHOP 
and DA -EPOCH -R and to assess mechanisms of treatment failure, inclusion of radiation 
consolidation would confound the interpretation of results and will not be used in the present study. 
Secondary involvement of the central nervous system (CNS) by aggressive B -cell lymphomas 
is an infrequent but nearly always fatal complication [29,30]. Prophylactic treatment reduces the 
incidence of CNS relapse, but increases the toxicity of systemic chemotherapy and is only 
necessary in patients at high risk of CNS spread [4]. This has led to the development of clinical 
risk paradigms to identify patients who might benefit from CNS prophylaxis, but even among 
these patients, only a minority ever develop CNS disease [31,32]. For example, in a study of 
605 newly diagnosed large cell lymphomas, van Besien et al. reported a Kaplan -Meier estimate 
of 17.4% probability of CNS recurrence at 1 year in 93 patients at risk according to their 
multivariate model, which included elevated lactate dehydrogenase (LDH) and more than  one 
extranodal disease site [31 ]. In a randomized study of ACVBP versus CHOP in poor-prognosis 
aggressive lymphoma, there was a significantly higher incidence of CNS failures in the CHOP 
Version Date: 02/15/2018  16 Update #18 
CALGB 50303  
arm, where CNS prophylaxis was not performed [4]. These studies indicate that patients at high 
risk of CNS disease may benefit from prophylaxis, and prophylaxis should be used in such 
patients. For this  reason, patients treated on the DA -EPOCH and DA -EPOCH -R studies who 
were at high risk of CNS disease received CNS prophylaxis with intrathecal methotrexate. Hence, for the phase III study, patients who have a high clinical risk of CNS involvement will 
receive CNS prophylaxis. Patients will be considered to be high risk based on the risk paradigm developed by van Besien et al. This includes: 1. patients with 2 or more extranodal disease sites 
and elevated LDH or; 2. any patient with involvement of the bone marrow or testicle by DLBCL.  
1.6 Analysis of Candidate Genetic Polymorphisms and Treatment Response  
There is increasing evidence suggesting that germline polymorphisms related to the metabolism, 
transport, therapeutic targets and/or therapeutic pathways of  anticancer agents might help predict 
therapeutic outcomes [33,34]. The major aim of this effort is to determine the influence of candidate gene polymorphisms on toxicity and outcome measures, including event free survival 
(EFS), with the ultimate goal of individualized cancer therapy.  
The primary pharmacogenetic hypothesis will be that the ABCB1 3435 CC genotype is 
associated with decreased EFS in both arms of this study. The ABCB1  gene (ATP Binding 
Cassette Beta 1; also called MDR1 ), encodes the P -glycoprotein PGP, a transmembrane protein 
involved  in human cellular transport [35]. PGP achieves the energy dependant efflux of 
doxorubicin, etoposide, vincristine and prednisone out of target cells [36,37]. While many 
ABCB1 polymorphisms have been studied, the synonymous C to T polymorphism at base 
position 3435 of the ABCB1 has been most strongly associated with drug t reatment outcome 
[38]. Individuals with the CC genotype at this position exhibit worse outcomes in response to 
drug therapy for HIV [39], epileps y [40 ], and acute myeloid leukemia (receiving an 
anthracycline based regimen) [41]. We therefore hypothesize that patients with the ABCB1 3435 
CC genotype will exhibit decreased EFS relative to patients with the 3435 CT and 3435 TT genotypes. 
Secondary hypotheses will also be tested to evaluate the association between the presence of 
variants in candidate genes and measures of both toxicity and outcome in both study arms. Assays for genetic variants will be performed for the following genes: CD20 (rituximab ), 
TOP2A (doxorubicin, etoposide), TUBB and MAP4 (Vincristine), CYP3A4/3A5 (doxorubicin, 
vincristine, etoposide, prednisone), CYP2C19, ADH1, and ALDH1A1 (cyclophosphamide) and 
NR3C1 (prednisone).  These candidate genes have been chosen based on their poten tial influence 
on metabolism and activity of the therapeutics used in this study. Additional genes or variants of interest might also be explored as new information relevant to the study emerges.  
In addition to specific hypothesis testing for the above candidate genes, this study will also 
provide the framework for analyzing the relationship between genotypes derived from germline 
vs. tumor DNA. As excess tumor DNA will be collected in the pharmacogenomics component of this study, we will genotype candidate  polymorphisms in DNA derived from both tumor 
tissue and whole blood. This will allow us to assess the accuracy of germline genotypes for predicting tumor genotypes, and to determine the relative power of tumor vs. germline 
genotypes for predicting treatment outcome. 
1.7 Comprehensive Analysis of Somatic Alterations to the Tumor Genome  
Genome sequence characterization is a key to understanding the biology and clinical behavior 
of cancers and to predict the response to therapy. The present study proposes to perform a 
comprehensive analysis of somatic alterations to the tumor genome. To understand which 
genomic alterations are somatically acquired by the tumor and which are encoded in the germ line of the patient, it is necessary to compare the genome of a tum or biopsy sample with that of 
a matched sample of normal tissue, such as blood. Included in this analysis will be DNA 
Version Date: 02/15/2018  17 Update #18 
CALGB 50303  
sequencing of all or part of the tumor and normal cell genomes, which can be achieved by 
classical DNA sequencing of individual genes or b y utilizing high -throughput DNA sequencing 
technologies. Recently, in diffuse large B cell lymphoma (DLBCL), a number of recurrent oncogenic abnormalities have been uncovered by DNA sequencing. These abnormalities track 
with known molecular subtypes of this disease. For example, in the ABC subtype of DLBCL, 
recurrent mutations in CARD11, CD79B, and MYD88 have been described [42-44]. 
Conversely, the GCB DLBCL subtype is characterized by frequent gain-of- function mutations 
of EZH2 [45-47].  
Other genomic methodologies will be used to assess DNA copy numbers in both tumor and normal DNA using, for example, microarrays containing oligonucleotides representing single nucleotide polymorphisms (SNPs) and other non- polymorphic regions of the genome. These 
copy number  changes also segregate according to th e molecular subtype of DLBCL [48]. For 
example, deletion of the INK4A/Arf tumor suppressor locus occurs in roughly one fifth of ABC 
DLBCL cases, but never in GCB DLBCL. Moreover, copy number changes have been 
associat ed with overall survival in r esponse to CHOP chemotherapy [48 ]. Specifically, 
INK4A/Arf locus deletions and trisomy of chromosome 3 were both associated with adverse 
survival among patients with ABC DLBCL.  
The activity of the tumor genome will be assessed by profiling the expression levels of mRNAs 
and microRNAs in a tumor biopsy sample using microarray and multiplexed PCR methods. The 
mRNA expression profiling of samples on CALGB 50303 is a primary endpoint of this trial 
since gene expression signatures have been used to identify molecular subtypes of DLBCL and 
to predict therapeutic response [49 -51]. In addition, new methods have been developed recently 
to identify new RNA species that are expressed from the genome. For example, digital gene expression is based on the high -throughput resequencing of mRNA, an effort that can uncover 
previously unannotated genes and new alternatively spliced isoforms of known genes. This 
effort would be exploratory, aiming to identify new aspects of the biology of DLBCL tumor s 
that are related to therapeutic response. In addition, microRNAs have the capacity to identify molecular subtypes of DLBCL and can yield additional functional information because of their 
ability to regulate the expression of large repertoire of genes [5 2-53].  
The activity of the genome is also dictated by patterns of cytosine DNA methylation. In acute myelogenous leukemia, molecular subtypes have been identified by their DNA methylation 
patterns that are biologic ally and clinically distinct [54 -55]. Appl ication to DLBCL revealed the 
de novo methylation of many targets of the polycomb repression complex PRC2, which may 
play an important role in DLBCL given the recurrent mutations in EZH2, a component of this 
complex [56 ]. 
The technology platforms that are able to interrogate genomic structure and function are constantly in flux. Therefore, the exact nature of the methodologies that will be employed will be assessed at the time that the samples are collected and ready for analysis. The following are 
technologies that are currently in use for each task.  
Genomic DNA and total RNA will be extracted from tumor and normal samples using a Qiagen 
All-prep kit. MicroRNAs will be extracted from the samples using a Qiagen  miRNeasy Mini 
Kit. 
For individual target genes that are recurrently mutated in DLBCL (CARD11, CD79B, MYD88, 
EZH2), classical Sanger sequencing will be performed on PCR amplicons, using primers 
surrounding the known sites of mutation in DLBCL. 
To broadly assess mutation, next generation sequencing (e.g.  on an Illumina HiSeq 2000 
platform) will be employed, using a paired end sequencing strategy of libraries constructed from 
tumor and matched normal DNA. DNA will either be sequenced in its entirety from a whole 
genome library or will be first enriched for  exonic sequences using the Agilent Sure Select 
Version Date: 02/15/2018  18 Update #18 
CALGB 50303  
system, aiming for 30X or 100X average coverage per base, respectively. The sequence 
fragments will be mapped back to genome using the BWA algorithm [57]. Of sequences 
overlapping a particular base pair in the genome, the percent mutant cells greater than 20% with 
a minimum of 25X coverage will be considered as an arbitrary threshold for single nucleotide 
variants (SNVs). SNVs that are not present in the matched normal sample will be considered 
candidate somat ic mutations.  
A related technology, RNA -Seq, utilizes RNA from the tumor specimen to create a cDNA 
library for high -throughput sequencing. RNA -seq will be performed using Illumina kits 
followed by high- throughput sequencing on an Illumina HighSeq 2000 machine. The cutoffs for 
coverage and percent mutant calls mentioned above will also be used to identify putative SNVs.  RNA sequencing will also be used to read out digital gene expression across the genome as 
described [58 ]. 
MicroRNAs will be profiled using  an Illumina kit to construct a library from tumor RNA 
samples and will be sequenced using the Illumina HighSeq 2000 platform. 
Array comparative genomic hybridization (e.g. on Agilent 240K or Affy SNP 6.0 microarrays) 
will be used to assess DNA copy number  alterations as described, in both tumor and normal 
genomic DNA [59 ]. The comparison of these two profiles will yield somatically acquired 
regions of copy number gain and loss. 
Methylated DNA will be immunoprecipitated as described and used to prepare a Il lumina 
genomic DNA library, followed by sequencing usi ng the HighSeq 2000 platform [59].  
1.8 FDG -PET Assessment in DLBCL  
1.8.1 Oncology Biomarker Qualification Initiative (OBQI)  
In February 2006, the Federal Drug Administration (FDA), National Cancer Insti tute 
(NCI), and Centers for Medicare and Medicaid Services (CMS) announced the Oncology 
Biomarker Qualification Initiative (OBQI) – an agreement to collaborate on improving the 
development of cancer therapies and the outcomes for cancer patients through bi omarker 
development and evaluation. The goal of OBQI is to validate particular biomarkers so that 
they can be used to evaluate new, promising technologies in a manner that will shorten clinical trials, reduce the time and resources spent during the drug process, improve the 
linkage between drug approval and drug coverage, and increase the safety and 
appropriateness of drug choices for cancer patients.  
Under the OBQI, biomarker research will be focused in four key areas: standardizing and evaluating imaging technologies to see in more detail how treatments are working; 
developing scientific bases for diagnostic assays to enable personalized treatments; instituting new trial designs to utilize biomarkers; and pooling data to ensure that key 
lessons are shared from one trial to another. By working with academic and industry 
scientists, as well as professional organizations, the OBQI teams can foster the 
development of key information on biomarkers through clinical trials. 
This CALGB imaging companion to the trea tment trial study will be carried out under a 
public- private partnership (PPP) formed by the partners in the OBQI with pharmaceutical 
manufacturers (represented by the Pharmaceutical Manufacturers’ Association [PhRMA]) 
and administered under the auspices of the Foundation of the National Institutes of Health 
(FNIH). The project will be overseen by a Lymphoma FDG -PET Working Group 
comprised of PET experts and oncologists from the NCI, FDA, CALGB, and PhRMA. 
1.8.2 FDG -PET Imaging -Derived Biomarkers  
In oncology, the gold standard clinical trial endpoint is overall survival, which may require long- term studies and may be confounded by deaths from causes other than the patient’s 
Version Date: 02/15/2018  19 Update #18 
CALGB 50303  
cancer. Over the years, the oncology community and the FDA have come to rely on other  
endpoints that from a scientific perspective are regarded as correlates of clinical benefit. 
These endpoints are objective response (OR), time to progression (TTP), disease- free 
survival (DFS), and progression free survival (PFS). All are determined by bi omarkers 
measuring the cancer’s extent. Anatomic imaging using one- or two -dimensional 
measurements to characterize cancers has been used traditionally to make these 
measurements in all aspects of cancer patient management from diagnosis and staging to 
therapy and disease progression.  
However, measurements made using standard anatomic imaging techniques are often 
inadequate for characterizing the cancer, especially for monitoring the effects of drugs that do not cause tumor shrinkage or for cancers that progress slowly or metastasize diffusely. 
Newer imaging modalities including volumetric and functional imaging show high promise 
as the basis for characterizing better biomarkers of cancer (reviewed in [69 ]). In lymphoma, 
FDG -PET has the potential to improve patient management, particularly by signaling the 
need for early therapeutic changes in non- responders (NR) [70-74] and by refining the IWG 
response criteria to better differentiate complete responses (CR), partial responses (PR), and 
complete response wit h residual mass (CRu, unconfirmed  due to residual tumor mass) [68, 
70, 71, 74-76]. Thus, if the utility of FDG -PET as a biomarker can be confirmed in such 
settings, unnecessary chemotherapy may be avoided for some patients and the costs of 
unnecessary long- term follow up reduced. As an early surrogate endpoint for clinical 
benefit, FDG -PET also has the potential to facilitate oncologic drug development by 
shortening phase II trials and detecting clinical benefit earlier in phase III investigations.  
FDG -PET and FDG -PET/CT imaging are increasingly being used in oncology clinical 
trials. However, there are as yet no standardized criteria for PET imaging or established procedures detailing transmission, storage, quality assurance, and analysis of PET images. 
This companion trial is one of the first steps toward developing the standardized protocols 
and endpoints that wi ll be needed to move forward [77 ]. 
1.8.3 CALGB 580603 Companion: Evaluating the Prognostic Utility of PET Scanning in 
Lymphoma  
Considerable evidence supports the association of post -therapy FDG -PET results with 
outcome in lymphoma patients. Specifically, FDG uptake has been a significant early predictor of residual or recurrent disease and disease progression, as well as PFS and overall survival (OS ) [73, 78-83]. FDG -PET is especially useful in differentiating tumor from 
fibrosis within residual radiographic masses [84, 85]. Such masses are present in half (NHL) 
to two -thirds (Hodgkin lymphoma (HL)) of patients, of whom only 25% (NHL) to 30% 
(HL) eve ntually relapse. In a prospective study of 58 patients (43 with HL) with residual 
masses following treatment, FDG -PET (SUV ≤ 3) predicted recurrence (p = 0.004) and PFS 
(p < 0.00001) [83]. Disease progression was observed after two months in 16/19 versus 3 /22 
lymphoma patients with positive and negative FDG -PET resul ts, respectively (p < 0.001) 
[81]. FDG- PET results obtained after the first cycle of chemotherapy in 30 NHL and HL 
patients predicted PFS at 18 months (p ≤ 0.001) [86 ]. A recent meta- analysis fo und that 
persistence of FDG -avid lesions after therapy predicted relapse, with up to 100% of patients 
with positive FDG- PET scans experiencing  recurrence within two years [87 ]. Conversely, 
absence of disease by FDG -PET scan is an indicator of a favorable p rognosis. Indeed, the 
negative predictive value of FDG -PET was 96% in  one study of 81 HL patients [88], and 
several studies have also reported a higher positive predictive value for FDG -PET versus 
conventional imaging modalities [68, 88-90]. Evidence also supports the integration of 
FDG -PET with the IWG response criteria to increase the predictability of outcome [70, 71, 
74-76].  
Version Date: 02/15/2018  20 Update #18 
CALGB 50303  
1.9 Study Rationale and Summary  
The proposed study is a phase III randomized comparison of R -CHOP, the de facto standard for 
DLBCL , to dose -adjusted (DA) -EPOCH -R, a regimen developed from studies on drug schedule 
and resistance and pharmacokinetics. Importantly, this study will incorporate tumor microarray 
analysis using Affymetrix genome arrays in all patients to identify molecular mechanisms of drug resistance, develop molecular prognostic models and to assess microarray tissue diagnosis. 
Microarray is an important new tool, which has altered our understanding of lymphoma biology 
and has important clinical value. An important aim of  the microarray is to identify the next 
therapeutic hurdles to allow rational treatment design and this is one of the goals of the proposed randomized study. Retrospective microarray results with CHOP -based treatment in DLBCL, for 
example, has already iden tified that tumor proliferation and the Activated B cell (ABC) 
signature are the most important adverse molecular prognostic hurtles [ 23]. Results with DA -
EPOCH show that it can abrogate tumor proliferation as an adverse prognostic factor, making 
the testing of DA-EPOCH a rational next step approach based on the microarray. 
Update #02: Change from 8 Cycles to 6 Cycles of Therapy in Treatment Arms 
The necessary number of treatment cycles for R -CHOP and DA- EPOCH -R were based on 
standard practice. In the case of R -CHOP, 6 or 8 cycles have been routinely administered. 
Because the present phase III trial was based on the GELA randomized study of CHOP versus 
R-CHOP for 8 cycles, 8 cycles were selected for the R- CHOP arm of this trial [7, 65]. However, 
a recent lar ge phase III randomized study of CHOP versus R -CHOP for 6 or 8 cycles have 
demonstrated no difference in outcome [66]. On an intent -to-treat basis, there was no difference 
in failure free survival between 6 cycles (n=414) and 8 cycles (n=413) of R -CHOP (p= 0.23). 
Furthermore, an analysis of the GELA study shows the potential for increased cardiac toxicity with R -CHOP, which would be impacted by  8 versus 6 treatment cycles [65 ]. Specifically, there 
was a higher incidence of deaths among patients in complete remission that received R -CHOP 
compared to CHOP. Although the authors attributed this disparity to the higher number of 
patients in complete remission in the R -CHOP arm that would be at risk of dying, further 
consideration may be warranted. A general estimate of the risk of dying in remission at 5 years, 
calculated from the number of patients who died in remission and those who were event free, 
yields 8% (5/60) and 15% (17/113) for the CHOP and R -CHOP arms, respectively. Furthermore, 
there was a trend toward a higher incidence of death in remission from cardiac disease among 
R-CHOP (9/17) compared to CHOP (0/5) patients (p
2=0.054; Fisher’s exact test). These findings 
indicate that 6 cycles of R- CHOP is equivalent to 8 cycles and hence are likely to be associa ted 
with lower cardiac toxicity. 
DA-EPOCH -R was developed to administer 2 cycles beyond stable disease (defined as < 30% 
reduction in bi -dimensional measurements between the end of cycles 4 and 6) for a minimum of 
6 cycles. Based on this paradigm, over 85% of patients ha ve only required 6 cycles [13,67 ]. No 
comparative trial has been performed to determine if the additional 2 cycles are even necessary 
in this small minority of patients and this paradigm was based on general accepted practices that 
had not been validated in a randomized study.  
Based on the evidence from a randomized study of R -CHOP for 6 versus 8 cycles, there is no 
evidence that 8 cycles is necessary and may be more toxic. Hence, effective with Update #02, 
the treatment plan was modified to administer a total of 6 cycles of treatment in both arms of the 
trial. This change should not affect the study outcome given the low number of patients accrued 
and have reached > 4 cycles (approximately 5 patients).  
1.10 Inclusion of Women and Minorities  
It is the intent of the Alliance to enroll patients regardless of gender or race. In the development 
of this protocol, the possibility of inherent gender or racial/ethnic differences in treatment 
Version Date: 02/15/2018  21 Update #18 
CALGB 50303  
response has been considered. Although lymphocytic lymphomas are more common in males 
than females and the incidence is higher in whites than in blacks, data derived from prior studies 
involving human subjects, other relevant research, and subjective observation support the 
conclusion that there is no evidence which  would require gender or racial/ethnic subgroupings 
and a commensurate sample size change. However, detailed analysis of the data will include these as well as other parameters examined for responsiveness to either regimen.  
2.0 O
BJECTIVES  
2.1 Primary Obje ctives 
2.1.1 To compare the event -free survival of R -CHOP versus DA -EPOCH -R chemotherapy in 
untreated CD20+ diffuse large B- cell lymphomas.  
2.1.2  To develop a molecular predictor of outcome of R -CHOP and DA -EPOCH -R chemotherapy 
using molecular profiling. 
2.2 Secondary Objectives  
2.2.1 To compare the response rates, overall survival and toxicity of R -CHOP versus DA-
EPOCH -R. 
2.2.2 To define the pharmacogenomics of untreated DLBCL and correlate clinical parameters (toxicity, response, survival outcomes and laboratory results) with molecular profiling. 
2.2.3 To assess the use of molecular profiling for pathological diagnosis.  
2.2.4 To identify new therapeutic targets using molecular profiling. 
2.2.5 To perform a comprehensive analysis of somatic alterations to the tumor genome and to 
understand which genomic alterations are somatically acquired by the tumor and which are 
encoded in the germ line of the patient.  
2.2.6 To identify biomarkers of response to chemotherapy by FDG -PET/CT imaging that are 
predictive of histopathologic remissions and survival in patients with stage I (mediastinal), 
II, III, or IV untreated DLBCL. 
2.2.7 To evaluate the use of semiquantitative measurements of FDG uptake in defining FDG -
PET/CT based biomarkers of response to chemotherapy in patients with DLBCL.  
2.2.8 To determine whether FDG -PET/CT measurements of tumor response after the second cycle 
of chemotherapy can predict clinical response.  
2.2.9 To establish a standardized protocol for FDG -PET/CT image acquisition.  
2.2.10  To determine  additional FDG -PET/CT parameters (e.g., the ratio of tumor  SUVmax to 
liver SUVmean; SUVs corrected for body surface area and lean body mass; nuclear medicine physician’s assessment) and evaluate their utility in refining FDG -PET/CT based 
biomarkers of re sponse to therapy.  
2.2.11 To evaluate inter -institutional reproducibility of FDG -PET/CT measurements for this 
indication.  
3.0 O
N-STUDY GUIDELINES  
All relevant medical and other considerations should be taken into account when deciding whether 
this protocol  is appropriate for a particular patient. To maximize patient safety, patients should be 
treated on this protocol only at centers having ready access to blood product support and adequately 
Version Date: 02/15/2018  22 Update #18 
CALGB 50303  
staffed to care for the severely neutropenic patient. Physicians should consider the risks and benefits 
of any therapy and, therefore, only enroll patients for whom the agents administered are appropriate. 
Although they will not be considered as formal eligibility criteria, as part of this decision- making 
process physicians should recognize that the following may increase the risk to the patient entering this protocol: 
• Other serious illnesses which would limit survival to < 2 years, or a psychiatric condition which 
would prevent compliance with treatment or informed consent.  
• Patients with a “currently active” second malignancy other than non -melanoma skin cancers. 
Patients are not considered to have a “currently active” malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one 
year.  
• Patients with severe active medical processes (e.g., active uncontrolled bacterial or viral 
infection, bleeding, etc.) not related to their lymphoma should be excluded. 
• All patients must be screened for hepatitis B i nfection before starting treatment (see Section 6.0
). 
Those patients who test positive for hepatitis B should be closely monitored for evidence of active HBV infection and hepatitis during and for several months after rituximab treatment, and should 
be managed as indicated (see 
Sections 7.1.1 and 7.2.1 ). 
4.0 E LIGIBILITY CRITERIA  
As of protocol update #14, the PET/CT imaging companion study CALGB 580603 will be required of all patients enrolling onto the treatment study CALGB 50303. Participation on CALGB 580603 
will no longer be optional in order to participate in CALGB 50303.  
4.1 Documentation of Disease 
Histologically documented de novo CD20+ DLBCL with stage II, III or IV disease. Stage I primary mediastinal (thymic) DLBCL is also eligible. Patients with an underlying low -grade 
lymphoma, such as a transformed lymphoma or low -grade lymphoma in the bone marrow, are 
not eligible. Diagnosis should be based on an adequate tissue sample, including open biopsy or 
core needle biopsy. Needle aspiration for primary diagnosis is unacceptable. Patients must have 
one of the following WHO [21] classification subtypes:  
• Diffuse large B -cell lymphoma (includes morphological variants: centr oblastic; 
immunoblastic; T -cell/histiocyte rich; and anaplastic).  
• Mediastinal (thymic) large B -cell lymphoma  
• Intravascular large B -cell lymphoma  
Note:  Failure to submit a pathology block within 60 days of patient registration will be 
considered a major  protocol violation (see Section 5.3
). 
Fresh (frozen) tumor biopsy must be available or attempted (see repeat tissue biopsy guidance below and Section 5.4
). A frozen tumor biopsy equivalent to a minimum of four at least 16 
gauge needle cores is an important component of this study. Patients without adequate frozen material should have a biopsy performed to obtain material. If a biopsy is performed and does not yield adequate material, the patient is still eligible for the study. If a biopsy cannot be done 
safely, the patient may still be eligible for the study if permission is granted  in writing (e -mail) 
by the Study Chairs (Drs. Wilson or Zelenetz) or their designees.  
Drs. Wilson or Zelenetz may be consulted to discuss situations involving invasive biopsy procedures that may pose an increased risk to the patient. 
NOTE:  THIS STUDY DOES NOT ALLOW CONCURRENT RADIATION UNLESS A 
PATIENT HAS A DOCUMENTED CNS TREATMENT FAILURE WITH NO SYSTEMIC 
FAILURE. PLEASE DO N OT ENROLL A PATIENT YOU MIGHT WISH TO RADIATE.  
Version Date: 02/15/2018  23 Update #18 
CALGB 50303  
4.2 Prior T reatment 
No prior cytotoxic chemotherapy or rituximab. Patients may be entered if they have received 
prior limited field radiation therapy or a short course of glucocorticoids (< 10 days) for an urg ent 
local disease complication at diagnosis (e.g., cord compression, SVC syndrome). Patients who 
have received chemotherapy for prior malignancies are not eligible.  
4.3 Age ≥ 18 years. 
4.4 ECOG Performance Status 0 -2. 
4.5 Cardiac Function  
No active ischemic heart disease or congestive heart failure. If there is suspicion of cardiac 
disease, a cardiac ejection fraction must show LVEF > 45%, but the study is not required.  
4.6 Lymphomatous 
No known lymphomatous involvement of the CNS. A lumbar puncture prior to study is 
not required in the absence of neurological symptoms.  
4.7 HIV  Status  
No known HIV dise ase. Patients with a history of intravenous drug abuse or any other  behavior 
associated with an increased risk of HIV infection should be tested for exposure to the HIV virus. The mechanism of disease in patients with HIV may be different from de novo diffuse 
large B cell lymphoma. Additionally, the immunocompromised stat e of patients with HIV 
infection may result in more extensive dose reductions than intended for the intensive therapeutic regimens used in this study. Therefore, patients who test positive or who are known to be infected are not eligible. An HIV test is no t required for entry on protocol, but is required 
if the patient is perceived to be at risk.  
4.8 Pregnancy and Nursing Status  
Non pregnant and non -nursing. Treatment would expose an unborn child to significant risks. 
Women and men of reproductive potential  should agree to use an effective form of 
contraception. 
4.9 Active medical processes  
Patients with active medical processes (e.g., uncontrolled bacterial or viral infection, bleeding) 
not related to their lymphoma should be excluded. 
4.10 Required Initial  Laboratory Values*: 
ANC  ≥ 1000/µL  
Platelets  ≥ 100,000/µL  
Creatinine  ≤ 1.5 mg/dL or creatinine clearance ≥ 50 cc/min.  
Total Bilirubin  ≤ 2 mg/dL**  
* Unless attributable to non- Hodgkin lymphoma  
** Unless a history of Gilbert’s Disease  
Version Date: 02/15/2018  24 Update #18 
CALGB 50303  
5.0 R EGISTRATION /RANDOMIZATION , DATA SUBMIS SION , HISTOLOGIC REVIEW AND SPECIMEN 
SUBMISSION FOR CORRELATIVE STUDIES  
5.1 Registration/Randomization 
5.1.1 Registration/Randomization Requirements  
5.1.1.1 Informed Consent  
The patient must be aware of the neoplastic nature of his/her disease and willingl y 
consent after being informed of the procedure to be followed, the experimental nature 
of the therapy, alternatives, potential benefits, side effects, risks, and discomforts. Human protection committee approval of this protocol and of its consent form are  
required. 
5.1.1.2 Fresh (frozen) Tumor Biopsy  
A fresh (frozen) tumor biopsy must be available or attempted (see guidance for 
repeat tissue biopsy i n Section 4.1
). A fro zen tumor biopsy equivalent to a minimum 
of 4 at least 16 gauge needle cores is an important component of this study (see Section 
5.4.1 ). Pa tients without adequate frozen material should have a biopsy performed to 
obtain material . If a biopsy is performed and does not yield adequate mate rial, the 
patient is still eligible for the study. If a biopsy cannot be done safely, the patient may 
still be eligible for the study if permission is granted  in writing (e -mail) by the Study 
Chairs (Drs. Wilson or Zelenetz) or their designees.  
5.1.1.3 Pharmacogenomic Correlative Science Companion  
All participating institutions must ask patients for their consent to participate in 
CALGB 60405 (see Section 5.1.2  “Registration to Companion Studies”), although 
patient participation is optional. Se e Section 5.4.2  for instructions for the collection 
and shipment of samples for pharmacogenomics.  
5.1.1.4 FDG -PET/CT Companion Study (CALGB 580603): Institutional Approval 
Procedures  
As of protocol update #14 , par ticipation in the PET/CT imaging companion study 
CALGB 580603 is required of all patients enrolling onto the treatment study CALGB 
50303. Starting on August 1, 2012, registration will be limited to patients and 
institutions participating in CALGB 580603. P articipation i n CALGB 580603 will no 
longer be optional in order to participate in CALGB 50303. Please note:  if a PET/CT 
scan has already been performed for clinical evaluation, it may be possible to submit 
the scan as the baseline image for the correlativ e study CALGB 580603. Please contact 
the Imaging Co -Chair to determine suitability for submission as a baseline image.  
Institutions must be approved to participate in the FDG -PET/CT companion to this 
protocol (see Section 8.1 ).  
The following documentation is required to participate in CALGB 580603: 
1) Submit to the Imaging Core Laboratory: 
• PET Instrument Technical Specifications Form (Appendix II ) 
• Imaging Site Personnel Form ( Appendix III ) 
Institutional approval to participate in this imaging companion is contingent upon 
receipt of this documentation. 
Version Date: 02/15/2018  25 Update #18 
CALGB 50303  
5.1.2 CALGB Registration/Randomization Procedures  
Registration and randomization will be accepted only through CALGB M ain Member 
institutions, at -large members, selected affiliate institutions, and CCOPs. Registration and 
randomization must occur prior to the initiation of therapy. 
Confirm eligibility criteria ( Section 4.0 ). Complete the Registra tion Worksheet. Either fax 
the worksheet to  or call the CALGB Registrar ( , Monday -
Friday, 9:00 AM – 5:00 PM, Eastern Time) with the following information: 
Study 
Name of group (CALGB) 
Name of institution where patient is being treat ed 
Name of treating physician  
Name of treating physician or responsible CRA Other group patient ID #, if applicable 
CALGB patient ID #, if applicable  
Patient’s initials (last initial, first initial, middle initial)  
Patient’s Social Security #, date of birth, and hospital ID # 
Patient’s gender  
Patient’s race  
Patient’s height, in centimeters (optional) Patient’s weight, in kilograms (optional) 
CTC performance status (if required by CDUS) 
Type of insurance (method of payment)  
Disease, type and stage, if applicable 
Patient’s Postal Code, if applicable  
Treatment start date  
Date of signed consent 
Date of HIPAA authorization  
Patient demographics, if applicable  
Companion studies, if applicable (see below)  
Eligibility criteria met (no, yes)  
 
When the patient is regis tered, a patient identification number will be generated. Please write 
the number in your records. Registration to any mandatory or optional companion studies 
will be done at the same time as registration to the treatment study. Registration to both 
treatm ent and companion studies will not be completed if eligibility requirements are not 
met for all selected trials (treatment and companions). Please see “Registration to 
Companion Studies” below.  
After registration is complete the patient may be randomized. Once the randomization is 
complete, note the patient's treatment assignment in your records. 
The Main Member Institution and registering institution will receive a Confirmation of 
Randomization. Please check for errors. Submit corrections in writing to the Alliance 
Statistics and Data Center,   
 
Registration to Companion Studies  
Within CALGB 50303 there are two sub-studies. The sub- studies included within CALGB 
50303 are: 
• Pharmacogenomics in CALGB 50303 (CALGB 60405) 
Version Date: 02/15/2018  26 Update #18 

CALGB 50303  
• FDG -PET/CT Imaging in CALGB 50303 (CALGB 580603) 
As of protocol update #14, the PET/CT imaging companion study CALGB 580603 will be 
required of all patients enrolling onto the treatment study CALGB 50303. Starting o n August 
1, 2012, registration will be limited to patients and institutions participating in CALGB 
580603. Participation i n CALGB 580603 will no longer be optional in order to participate 
in CALGB 50303. Please note:  if a PET/CT scan has already been performed for clinical 
evaluation, it may be possible to submit the scan as the baseline image for the correlative 
study CALGB 580603. Please contact the Imaging Co -Chair to determine suitability for 
submission as a baseline image.  
These embedded companion stud ies must be offered to all patients enrolled on CALGB 
50303. P atients may opt not to participate  on CALGB 60405, however the imaging 
companion study 580603 is required.  
The rationales for performing the correlative science substudies are discussed in Sections 1.6  
and 1.8. If a patient answers “yes” to “I agree that my blood may be used for the genetic 
research studies described above” (Question #1) in the model consent, they have consented 
to participate in the correlative science pharmacogenomic substudy. Patients should be  
registered to CALGB 60405. Although it is preferable that patients be registered to CALGB 60405 at the same time they are registered to CALGB 50303, registration to CALGB 60405 may occ ur up to 60 days following registration to the treatment trial. Samples should be 
submitted according to the instructions in  
Section 5.4.2.  If the institution is approved to 
participate in CALGB 580603 (see Section 8.1  for approval procedures) and the patient 
consents to participate in the treatment study CALGB 50303, then they have consented to 
participate in the correlative science FDG -PET/CT imaging  correlative study . Patients 
should be registered to CALGB 580603. Images should be submitted according to the 
instructions in Section 8.5 . 
5.2 Data Submission  
As of Update #18 to the protocol, this study will use Medidata Rave® for remote data capture 
(RDC) of all future data colle ction. All data originally received by the Alliance and Statistics 
and Data Center (SDC) (either electronically using the “Print and/or Submit to CALGB” button [i.e. Teleform form] or by mail) has been transferred to Medidata Rave ® and can be accessed 
via the Medidata Rave ® system. If necessary, data originally submitted to the SDC 
electronically (or by mail) can be amended via the Medidata Rave ® system.  
The Rave system can be accessed through the iMedidata portal at  
For additional information regarding account setup or training, please visit the training section of the Alliance website. Forms should be submitted in compliance with the table below, and a 
copy of the All Forms Packet  can be downloaded from the Alliance and CTSU websites. 
Site personnel with Rave roles assigned on the appropriate roster may receive a study invitation e-mail from iMedidata. To accept the invitation, site users must log into the Select Login 
 using their CTEP -IAM user name and password, and 
click on the “accept” link in the upper right -corner of the iMedidata page. Please note, site users 
will not be able to access the study in Rave until all required Medidata and study specific 
trainings are completed. Trainings will be in the form of electronic learnings (eLearnings), and can be accessed by clicking on the link in the upper right pane of the iMedidata screen. Personnel 
who did not receive an invitation should cont act the Alliance Service Center.  
Users who have not previously activated their iMedidata/Rave account at the time of an initial site registration approval for a study in RSS will also receive a separate invitation from 
iMedidata to activate their account. Account activation instructions are located on the CTSU website’s Rave tab under the Rave Resource Materials heading (Medidata Account Activation 
Version Date: 02/15/2018  27 Update #18 

CALGB 50303  
and Study Invitation Acceptance). Additional information on iMedidata/Rave is available on the 
CTSU members’ w ebsite under the Rave tab at www.ctsu.org/RAVE/ or by contacting the 
CTSU Help Desk at  or by e- mail at . 
 
Version Date: 02/15/2018  28 Update #18 

CALGB 50303  
Form   Submission  Schedule  
   
C-1319  CALGB 50303 On -Study Form   
C-1321  Lymphoma Measurement Form   
C-1332  Tumor Biopsy Specimen Submission Form  Within one week of registration.  
C-1333  Pharmacogenomic Sample Submission Form*   
   
 Pathology Reports   
   
C-1331  Copy of C -1331 & Block to Alliance 
Biorepository at OSU  Within 60 days of registration. See Section 5.3 . 
   
C-1323  Chemotherapy Dose Form  Every cycle while on therapy.  
   
C-1627 50303 PET and CT Measurement Form** As of protocol update #14, submission is 
required:  
Prior to therapy; post -Cycle 2; and post -Cycle 6 
per Section 8.3 . 
   
C-1657 50303 Imaging Adjunctive Data Sheet**  Prior to therapy; post -Cycle 2; and post -Cycle 6 
per Section 8.3 . 
   
C-1322 CALGB 50303 Follow -Up Form  Every 2 cycles while on therapy, then q3 months 
for 2 years, then q6 months for 5 years from study 
registration, at relapse, and at death.  
   
C-1320  CALGB 50303 Treatment Form  Every 2 cycles while on ther apy. C-1324  CALGB 50303 Adverse Event Form  
   
C-1321 Lymphoma Measurement Form  Post-Cycle 4; post -Cycle 6; q3 months for 2 
years, then q6 months for 5 years from study 
registration, and at relapse.  
   
C-1001  New Primary Malignancy Form  At time of new  primary malignancy.  
   
C-1742 CALGB: Confirmation of Lost to Follow -up Form  Follow form directions.  
C-2089 CALGB 50303 Consent for Additional Genomic 
Research Studies ††  Only for patients already enrolled on study prior 
to Update #12 (4/15/2011); submi t once patient 
has read the Addendum to the Model Consent 
and answered Question #6.  
† Submit legible copies of all institutional pathology, immunophenotyping, and baseline CT scan reports documenting 
diagnosis.  
‡ Submit legible copies of all pathology, immunophenotyping, and CT scan reports documenting response and/or 
progression.  
* Patient may be enrolled on pharmacogenomic correlative science study (CALGB 60405) as many as 60 days after enrollment on CALGB 50303.  
** Send forms to the Imaging Core Labora tory and th e Alliance Statistics and Data Center . See Section 8.5
 for image 
submission.  
†† Submit only for patients already enrolled on study prior to Update #12 (4/15/2011), NOT those who are new patients 
on study. For patients already enrolled on study, submit C -2089 once the patient has read the Addendum to the 
Model Consent, answered Question #6, and provided a signature. (New patients being enrolled onto CALGB 50303 
will also receive the Addendum to the Model Con sent, answer Question #6, and provide a signature, but their 
answers to Question #6 are to be recorded within the registration system.)  
Version Date: 02/15/2018  29 Update #18 
CALGB 50303  
5.3 Histologic Review 
Submission of either a nodal or extranodal biopsy from the original diagnosis is required. 
An ade quate specimen of tissue must be available for central review of morphology, 
architecture and appropriate immunohistochemical stains to confirm the diagnosis. Diagnosis should be based on an adequate tissue sample, including open biopsy or core 
needle biop sy. Needle aspiration for primary diagnosis is unacceptable.  
Within 60 days of registration, send a formalin -fixed, paraffin- embedded block of well -fixed 
lymphoma tissue containing adequate material for histologic confirmation of diagnosis.   Please 
label the block with the CALGB patient ID number, institution, date of acquisition, protocol number, and tissue source.  A block at least 2 cm x 1 cm x 0.5 cm is preferable, although smaller 
is acceptable if no other block is suitable. If only one block exists, and the tissue is sufficiently 
large, it is acceptable to split the block into two and submit  one. Contact Dr. Eric Hsi (216-444-
5230) with questions. Submit the labeled block and a copy of the pathology report (include consultative pathology reports, if available), CT scan report(s), and a copy of the completed 
Lymphoma Pathology Submission Form C -1331 to the Alliance Biorepository at Ohio State 
University (ABOSU).  
Alliance Biorepository at Ohio State University  
 
 
 
 
 
 
 
Failure to submit a pathology block within 60 days  of patient registration will be considered a 
major protocol violation. Send the original  C-1331 form to the Alliance Statistics and Da ta 
Center.  
The Alliance  has instituted special considerations for the small percentage of institutions whose 
policies prohibit the  release of any blocks. If, due to institutional policy, a block cannot be sent, 
please call  the A lliance Biorepository at OSU  at  to obtain a protocol for 
submission of representative tissue from your institution.  
5.4 Specimen Submission for Correlative Studies  
A frozen tumor biopsy equivalent to a minimum of 4 at least 16 gauge needle cores is an important component  of this study. Patients without adequate frozen material should have a 
biopsy performed to obtain material. If a biopsy is performed and does not yield adequate material, the patient is still eligible for the study. If a biopsy cannot be done safely, the 
patient may still be eligible for the study if permission is granted  in writing (e -mail) by the 
Study Chairs (Drs. Wilson or Zelenetz) or their designees.  
All participating institutions must ask patients for their consent to participate in the additional 
pharmacogenomic companion substudy in CALGB 50303, although patient participation in the 
pharmacogenomic study is optional (see Section 5.4.2 ). Instructions for the collection and 
shipment of samples are detailed below.  
Samples shipped from Alliance  institutions should be logged and shipped via the CALGB 
LabTrak application. All samples should be labeled with the CALGB patient ID, CALGB protocol number (CALGB 50303), institution, date of acquisition, and tissue source. Instruction s 
for the procurement and shipping of samples are included below.  
Version Date: 02/15/2018  30 Update #18 

CALGB 50303  
5.4.1 Fresh (Frozen) Tumor Biopsy Sample (ALL PATIENTS)  
• Fresh (Frozen) Tumor Biopsy Sample Procurement 
Contact one of the following individuals to obtain shipping packages: 
     
     
  
     
      
Shipping packages will be sent to each participating institution. To ensure timely arrival 
of shipping packages, place a request for multiple packages (at least 2 more than is needed) at the time of local IRB review. Packages will consist of the followin g items: 
(1) Fresh (Frozen) Tumor Biopsy Sample Procurement Instructions 
(1) Styrofoam Box 
(1) Cardboard Box 
(1) Biohazard Labeled Ziplock Bag 
(10)  2 mL cryopreservation screw cap tube  
Each package should be used to mail only one set of samples from a single patient.  DO 
NOT CONSOLIDATE SAMPLES FROM MULTIPLE PATIENTS INTO A 
SINGLE BOX.  
Remove the collection tubes from the styrofoam container. Label all tubes with the 
CALGB patient ID number, CALGB protocol number, institution, date of acquisition, 
and tissue source.  
Use the 2 mL cryotubes to collect tumor samples. A minimum of a hundred milligrams (100 mg) of tissue should be provided. This corresponds to a minimum of 4 core needle 
biopsy specimens (16 gauge needle at least)  or an excisional biopsy that is at least 100 
cubic mm in volume (i.e., the size of a pea). Fill the Nunc tubes 2/3 full and use as many 
Nunc tubes as necessary. REMOVE ALL LIQUID FROM SAMPLE BEFORE 
FREEZING.  Immediately preserve by freezing in dry ice or liquid nitrogen and 
transfer them from the liquid n itrogen or dry ice container, to a -70°/-80° C freezer 
(preferable), or to a - 20°C freezer for storage until time of shipment.  
• Fresh (Frozen) Tumor Biopsy Sample Shipment  
Note: Must have patient identification number before shipping sample.  Place all 
tubes with samples into the styrofoam box filled with at least 2 lbs. of dry ice. Position the tubes so that they are roughly in the center of the container (i.e., surrounded by dry 
ice). Remember: ONE PATIENT SAMPLE SET PER “ZIPLOC K” BAG/BOX.  
Complete the Tumor Biopsy Specimen Submission Form (C -1332) and place in the 
document compartment of the waterproof “Ziploc k” plastic bag. Place in the styrofoam 
box. Send a copy of Form C-1332 to the Alliance Statistics and Data Center. 
Tape the styrofoam box. Put the box inside the provided cardboard box. Close with tape. Affix a FedEx label. Make a note of the air bill number on the FedEx label. Please mail 
overnight on a Monday through Thursday so shipment will arrive during the week.  
After mailing, send an e -mail to:   with the subject: “URGENT: 
CALGB 50303 Fresh/Frozen Biopsy Sample Sent” indicating the DAY, TIME, 
INSTITUTION, CALGB PATIENT ID NUMBER AND AIR BILL NUMBER OF 
THE PACKAGE  in which the sample set was mailed. Mail the samples to:  
 
 
 
Version Date: 02/15/2018  31 Update #18 

CALGB 50303  
 
 
Quest
ions or problems with sample procurement or shipment should be directed to the 
following individuals: 
   
   
  
   
Institutions without access to CALGB LabTrak application for shipping samples should send  
an e -mail to  with the subject “URGENT. CALGB 50303 
Fresh/Frozen Biopsy Sample Sent” indicating the day, time, institution, CALGB patient ID 
number, and the airbill number of the package in which the sample was sent. Questions or 
problems with sample procurement may be directed to the individuals identified above. 
Please note : it is necessary to submit CALGB form C -1332 in order to receive 
reimbursement, regardless of whether biopsy was successful. In this instance, complete form 
C-1332 and indicate that biopsy specimen does not accompany the form, and fax it to  
 as well as to the Alliance Statistics and Data Center,  Data 
Operations. Reimbursement for sample procurement will not be made for patients who are 
exempted from the biopsy requirement. 
5.4.2 Pharmacogenomic Sample (Must be offered to all patients enrolled on CALGB 50303)  
• Pharmacogenomic Sample Procurement  
Prior to initiation of therapy obtain 2 EDTA (purple top) tubes of peripheral blood (each containing approximately 10 mL) for pharmacogenetic studies. A mailing label should be completed that contains the CALGB patient ID number, CALGB protocol number, 
institution, date of sample acquisition, sample collection time point (prior to initiation 
of therapy), tissue source, and sample purpose (i.e., CALGB 50303 Pharmacogenetic 
Sample).  
• Pharmacogenomic Sample Shipment  
Samples should be shipped on a cold/gel pack in an approved container using an express courier. Ship samples to: 
 
 
 
 
 
 
 
 
A copy of the 50303 Pharmacogenomic Specimen Submission Form (C -1333) should 
accompany all samples sent to the ABOSU. Note : If specimen is sent on Friday, 
CHECK SATURDAY DELIVERY on the FEDERAL EXPRESS INVOICE. Also, 
send a copy of the completed forms to the Alliance Statistics and Data Center  at the time 
of shipment. 
 
6.0 R EQUIRED DATA 
Guidelines for Pre- Study Testing  
Version Date: 02/15/2018  32 Update #18 

C A L G B 5 0 3 0 3  
T o be c o m plete d wit hi n 1 6 D A Y S bef ore re gistrati o n: 
-  All bl o o d w or k 
-  Hist or y a n d p h ysical 
T o be c o m plete d wit hi n 2 8 D A Y S bef ore re gistrati o n: 
- A n y X -ra y, sca n of a n y t y pe or ultras o u n d w hic h is utilize d f or t u m or meas ure me nt 
T o be c o m plete d wit hi n 4 2 D A Y S bef ore re gistrati o n:  
-  A n y baseli ne e xa ms use d f or scree ni n g, i.e., E K G, L V E F or M U G A 
- A n y X -ra y, sca n of a n y t y pe or ultras o u n d of u ni n v ol ve d or ga ns w hic h is n ot utilize d f or t u m or 
meas ure me nt; b o ne marr o w bi o ps y a n d as pirate.  
   D a y 1  At   P ost - 
 Pri or 
t o  B et w ee n  of E ac h  Ti me of  Tre at me nt  
Tests & O bser v ati o ns  St u d y  C ycles  C ycle ‡ Rest a gi n g *  F oll o w -u p * *  
Hist or y & Pr o gress N otes  X  X X X 
P h ysical E xa mi nati o n  X  X X X 
P ulse, Bl o o d Press ure  X  X X X 
Hei g ht/ W ei g ht/ B o d y S urface Area  X  A   
P erf or ma nce Stat us ( E C O G)  X  X X X 
T u m or Meas ure me nts  X  B X X 
Dr u g T o xicit y Assess me nt    X X X 
St u dies       
C B C, Diff, Platelets  X 2 x/ wee k †  X X X 
Ser u m Creati ni ne, B U N  X  X   
A S T, Al k P h os, Bilir u bi n, L D H  X  X X  
T otal Pr otei n, Al b u mi n  X     
HI V  ser ol o g y (if necessar y, se e Secti o n  4. 7 ) X     
Ser u m of uri ne H C G  G     
E K G  X     
L V E F  (ec h o  or  M U G A)  (if  necessar y,  s ee 
Secti o n 4. 5 ) X     
H B S A g a n d ser ol o g y  X, E      
Fres h T u m or Bi o ps y ( Secti o n  5. 4. 1 ) X     
P har mac o ge n o mic Sa m ple (se e Secti o n 5. 4. 2 ) X     
St a gi n g       
C T/ M RI Sca n C hest, A b d, P el vis  X   X X 
B o ne Marr o w As pirate & Bi o ps y  X   C  
Hea d sca n ( M RI preferre d) & C S F e xa m, if 
ris k fact ors  F     
P E T Sca n ( C A L G B 5 0 3 0 3)     D D 
Hist ol o gic Re vie w  X     
‡ Pre -re gistrati o n  tests,  o bser vati o ns,  a n d  la b  st u dies  c o m plete d  wit hi n  7  da ys  pri or  t o  t he  first  da y  of  C ycle  1 
treat me nt nee d n ot be re peate d. La bs a n d p h ysical e xa m ma y be o btai ne d wit hi n 4 8 h o urs pri or t o treat me nt f or 
all ot her c ycles.  
* I n Ar ms A a n d B, resta ge aft er C ycles 4 a n d 6.  
* *  E ver y 3 m o nt hs f or 2 years, t he n q 6 m o nt hs u ntil 5 years fr o m st u d y re gistrati o n or rela pse ( w hic he ver occ urs 
first).  
† T wice wee kl y (e. g., o n M o n d a y & T h urs da y or T ues da y & Fri da y) t o ass ure t hat c o u nts are c hec ke d e ver y t hree -
f o ur da ys. T he t wice -w ee kl y m o nit ori n g is re q uire d f or Ar m B ( D A -E P O C H -R) o nl y.  
A T he wei g ht at C ycle 1 s h o ul d be use d f or d ose calc ulati o ns f or all c ycles, u nless t here is a ≥ 1 0 % c ha n ge o ver a 
peri o d of o ne c ycle. If a wei g ht c ha n ge ≥ 1 0 % occ urs, d oses s h o ul d be recalc ulate d a n d t he ne w d ose use d fr o m 
t hat ti me f or war d.  
B If accessi ble t o p h ysical e xa mi nati o n, please rec or d meas ure me nts o n Da y 1 of eac h c ycle.  
C If b o ne marr o w  i nitiall y p ositi ve, re peat t o c o nfir m a c o m plete res p o nse.  
Versi o n Date: 0 2 /1 5/ 2 0 1 8  3 3  U p date # 1 8 
CALGB 50303  
D PET scan is recommended at end of treatment in patients who achieve CRu. If positive, biopsy site. If 
borderline positive, biopsy site OR follow closely with repeat PET and CT scan monthly as indicated to 
assess sites. Contact Study Chair for guidance concerning “borderline” PET positivity. If scans show 
progression, perform a biopsy. NO patient will be considered to have failed treatment based on a positive 
PET scan alone.  
E All patients must b e screened for hepatitis B infection before starting treatment. Carriers of hepatitis B should be 
closely monitored for evidence of active HBV infection and hepatitis during and for several months after rituximab treatment.  
F Patients with (1) ≥ 2 extranod al sites and elevated LDH, or (2) bone marrow involvement by large cell lymphoma 
will receive CNS prophylaxis according to Sections 7.1.3 (Arm A) or 7.2.3
 (Arm B). 
G In women of childbearing potential  
6.1 CALGB 580603 FDG -PET/CT Imaging  Requirements 
As of protocol update #14, the PET/CT imaging companion study CALGB 580603 will be 
required of all patients enrolling onto the treatment study CALGB 50303. Participation on 
CALGB 580603 will no longer be optional in order to participate in CALGB 50303. Please 
note:  if a PET/CT scan has already been performed for clinical evaluation, it may be possible 
to submit the scan as the baseline image for the correlative study CALGB 580603. Please contact 
the Imaging Co-Chair to determine suitability for submission as a baseline image.  
Tests & Observations  Prior to 
Study  Day of FDG -
PET/CT 
Imaging  Post-Cycle 2  Post-Cycle 6  
Blood glucose  X X   
Height/Weight/Body 
Surface Area X X   
     
Staging and Imaging      
PET/CT  Scan‡  X X A B 
Biopsy     C 
‡ Baseline PET/CT scan preferred prior to the CALGB 50303  baseline excisional biopsy and ≤ 30 days 
prior to start of therapy (see Section 8.3 ). If a PET/CT scan has already been performed for clinical 
evaluation, please contact the Imaging Co -Chair to determine suitability for submission as a baseline 
image.  
A To be p erformed 17- 21 days post -Cycle 2 therapy and 0 -4 days prior to start of Cycle 3.  
B To be performed post -Cycle 6 (3 -8 weeks after last dose of chemotherapy). At Cycle 6, if PET is 
positive, but CT negative, another PET/CT scan will be performed after 2 -3 mo nths.  
C If PET remains positive after the second post -Cycle 6 PET/CT scan, the site should be biopsied to 
determine histopathology. If a PET/CT scan shows progression, results will be provided to treating 
physician to assist in further evaluation of the patient, and the site should be biopsied to document active disease. Patients with a 4+ positive PET scan after Cycle 6 may undergo biopsy immediately at treating physician’s discretion. No patient will be considered to have failed treatment based on a 
posit ive PET scan alone. 
Version Date: 02/15/2018  34 Update #18 
CALGB 50303  
7.0 T REATMENT PLAN 
No investigational or commercial agents or therapies other than those described below may be 
administered with the intent to treat the patient’s lymphoma.  
No radiation therapy will be permitted on study except for is olated CNS lesions. Patients who receive 
radiation to any site other than the CNS will be inevaluable. Patients with parenchymal CNS lesions 
should receive whole brain radiation and will only be considered treatment failures if the systemic 
disease progres ses. 
Patients must begin treatment within seven days of registration/randomization. Patients will be randomized to either Arm A (R- CHOP) or Arm B (DA -EPOCH -R). 
All patients must be screened for hepatitis B infection before starting treatment. Those patient s who 
test positive for hepatitis B should be closely monitored for evidence of active HBV infection and 
hepatitis during and for several months after rituximab treatment, and should be managed as indicated 
(see Sections 7.1.1 and 7.2.1
). 
Institutions must be approved to participate in the optional FDG -PET/CT companion CALGB 
580603 (see Section 8.1 ). 
7.1 Arm A (R- CHOP Treatment [7])  
7.1.1 Required Ancillary Medications  
• Omepr azole 20 mg/day PO (or equivalent).  
• Stimulant laxative/stool softener (e.g., Pericolace®) 2 tablets PO BID (adjusted as 
necessary) or institutional preference for prevention of constipation.  
• Lactulose 20 g PO Q 6 hours PRN until resolution or institut ional preference for 
treatment of constipation.  
• Acetaminophen 650 mg PO and diphenhydramine 50- 100 mg IV or PO 30 to 60 minutes 
prior to starting each rituximab infusion. 
• Hepatitis B surface Ag+ patients receive lamivudine 100 mg/day PO until 8 weeks past 
last chemotherapy.  
7.1.2 R- CHOP Chemotherapy  
• Rituximab 375 mg/m2 IV infusion on Day 1 prior to CHOP chemotherapy. See Section 
10.10  for dose rate information.  
• Cyclophosphamide 750 mg/m2 IV Day 1  
• Doxorubicin 50 mg/m2 IV Day 1  
• Vincristine 1.4 mg/m2 (2 mg cap) IV Day 1  
• Prednisone 40 mg/m2/day PO on Days 1-5 
• Begin filgrastim or pegfilgrastim if grade 4 neutropenia (ANC < 500/µL) or febrile neutropenia (ANC < 500/µL + fever 38.5° (101°F) lasting for more than one hour) 
developed on the previous cycle. Administer filgrastim 480 mcg subcutaneous daily 
from Day 2 until ANC > 5000 after the nadir (nadir usually between Days 10- 12) or for 
10 days (Days 2 -11) if the ANC is not being monitored, or pegfilgrastim 6 mg 
subcutaneous on Day 2 (may be delayed up to two days for convenience of scheduling 
due to holidays, weekend, etc.) . 
• Repeat cycles every 21 days. To begin a cycle, ANC must be ≥ 1500/µL and platelets 
≥ 100,000/µL. Delay cycle by up to 2 weeks if these values are not met on Day 1 of 
cycle. Contact the Study Chair if delay is greater than two weeks.  
Version Date: 02/15/2018  35 Update #18 
CALGB 50303  
7.1.3 CNS Prophylaxis  and Treatment  
7.1.3.1 CNS Prophylaxis  
Patients with (1) ≥ 2 extranodal sites and elevated LDH, or (2) bone marrow 
involvement by large cell lymphoma will receive CNS prophylaxis consisting of 
intrathecal methotrexate 12 mg on day 1 (or day 2) of Cycles 3, 4, 5, and 6. 
7.1.3.2 Treatment of CNS Disease 
• Treatment of CNS Disease 
If the CSF is cytologically positive at the time CNS prophylaxis is scheduled to 
begin (Cycle 3), the patient should receive active treatment of the CSF with 
methotrexate (see below). If this treatment either is not tolerated or found to be not 
effective, then cytarabine alone or in combination with methotrexate may be used. Additionally, a brain MRI should be obtained and radiation consolidation 
administered at the end of chemotherapy if there are parenchymal lesions.  
• CNS Induction Treatment  
CNS induction treatment will be administered twice per week for two weeks 
beyond negative cytology with a minimum of 4 weeks of treatment. CNS induction 
may consist of one of the following: 
- Intrathecal methotrexate 12 mg or intraventricular (via Ommaya) methotrexate 6 
mg  
OR 
- Intrathecal or intraventricular (via Ommaya) cytarabine 70 mg  
OR 
- Intrathecal methotrexate 12 mg + cytarabine 30 mg + hydrocortisone 15 mg or 
intraventricular (via Ommay a) methotrexate 6 mg + cytarabine 30 mg + 
hydrocortisone 15 mg 
• CNS Consolidation Treatment  
CNS consolidation will consist of the same treatment as induction, but 
administered weekly x 6. 
• CNS Maintenance Treatment  
CNS maintenance will consist of the sam e treatment as induction, but administered 
monthly x 4. 
If CNS treatment must be modified due to unforeseen circumstances or 
investigator preference, please consult with the Alliance  Study Chair. 
7.1.4 Restaging and Treatment Duration 
Perform PET/CT scan p ost-Cycle 2  and after Cycles 4 and 6. Repeat CT/MRI scans at site(s) 
of initial involvement. If initial bone marrow biopsy is positive, a bone marrow examination should be repeated at each restaging point until it is negative and then no further biopsy is 
necessary. Patients will receive a maximum of 6 cycles.  
Submit PET/CT scan documentation post -Cycle 6. If patient is PET positive but CT negative, 
then repeat PET/CT scan 2 -3 months later and submit documentation (see Section 8.3
). 
Version Date: 02/15/2018  36 Update #18 
CALGB 50303  
7.2 Arm B (DA- EPOCH -R Treatment [20])  
7.2.1 Required Ancillary Medications  
• Cotrimoxazole DS 1 tablet three times weekly (or equivalent if allergic).  
• Omeprazole 20 mg/day PO (or equivalent). 
• Stimulant laxative/stool softener (e.g., Pericolace®) 2 ta blets PO BID (adjusted as 
necessary) or institutional preference for prevention of constipation.  
• Lactulose 20 g PO Q6 hours PRN until resolution or institutional preference for 
treatment of constipation.  
• Acetaminophen 650 mg PO and diphenhydramine 50-100 mg IV or PO 30 to 60 minutes 
prior to starting each rituximab infusion. 
• Hepatitis B surface Ag+ patients receive lamivudine 100 mg/day PO until 8 weeks past last chemotherapy.  
7.2.2 Dose -Adjusted EPOCH -R Chemotherapy  
All patients initiate therapy at Dose Level 1 of DA -EPOCH -R shown below.  Subsequent 
treatment doses are determined by hematological toxicity experienced on the previous cycle 
according to the dose -adjustment paradigm in Section 9.2
. Dose adjustment is based on 
measurements of twice weekly CBC only (e.g., Monday and Thursday, or Tuesday and 
Friday), even if additional CBCs are obtained.  
Cycle 1 Doses  
• Rituximab 375 mg/m2 IV infusion on Day 1 prior to EPOCH chemotherapy. See Section 
10.10  for dose rate information.  
• Doxorubicin 10 mg/m2/day CIVI on Days 1-4 (total 40 mg/m2 over 96 hours) 
• Etoposide 50 mg/m2/day CIVI on Days 1-4 (total 200 mg/m2 over 96 hours) 
• Vincristine 0.4 mg/m2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96  hours)  
• Cyclophosphamide 750 mg/m2 IV on Day 5 (following completion of 96 hour infusions)  
• Prednisone 60 mg/m2 PO BID on Days 1 -5 
• Administer filgrastim 480 mcg subcutaneous daily from Day 6 until  
ANC > 5000 after the nadir (nadir usually between Days  10-12) or for 10 days (Days 6 -
15) if the treating physician is not actively monitoring the required twice -weekly 
CBC/differential/platelets, during every  cycle.  
Note:  DA-EPOCH -R dosing has only been validated using filgrastim. Pegfilgrastim has 
different kinetics of neutrophil recovery and its use may adversely affect dosing and 
reduce disease cure rates. Use of pegfilgrastim (6 mg subcutaneous Day 6) must be approved by the Study Chair and will only be approved if the patient cannot receive 
filgrastim.  
• Repeat cycles every 21 days. To begin a cycle, ANC must be ≥ 1000/µL and platelets ≥ 
100,000/µL. Delay cycle by up to 2 weeks if these values are not met on Day 1 of cycle. Filgrastim may be used for several days to increase ANC. Contact the Study Chair if  
delay is greater than two weeks.  
Version Date: 02/15/2018  37 Update #18 
CALGB 50303  
7.2.3 CNS Prophylaxis and Treatment  
7.2.3.1 CNS Prophylaxis  
Patients with (1) ≥ 2 extranodal sites and elevated LDH, or (2) bone marrow 
involvement by large cell lymphoma will receive CNS prophylaxis consisting of 
intrathecal methotrexate 12 mg on day 1 (or day 2) of Cycles 3, 4, 5, and 6. 
7.2.3.2 Treatment of CNS Disease 
• Treatment of CNS Disease 
If the CSF is cytologically positive at the time CNS prophylaxis is scheduled to 
begin (Cycle 3), the patient should receive ac tive treatment of the CSF with 
methotrexate (see below). If this treatment either is not tolerated or found to be not effective, then cytarabine alone or in combination with methotrexate may be used. Additionally, a brain MRI should be obtained and radiation consolidation 
administered at the end of chemotherapy if there are parenchymal lesions.  
• CNS Induction Treatment  
CNS induction treatment will be administered twice per week for two weeks 
beyond negative cytology with a minimum of 4 weeks of treatment. CNS induction 
may consist of one of the following: 
- Intrathecal methotrexate 12 mg or intraventricular (via Ommaya) methotrexate 6 
mg  
OR 
- Intrathecal or intraventricular (via Ommaya) cytarabine 70 mg  
OR 
- Intrathecal methotrexate 12 mg + cytarabine 30 mg + hydrocortisone 15 mg or 
intraventricular (via Ommaya) methotrexate 6 mg + cytarabine 30 mg + 
hydrocortisone 15 mg 
• CNS Consolidation Treatment  
CNS consolidation will consist of the same treatment as induction, but 
administered weekly x 6. 
• CNS Mainte nance Treatment  
CNS maintenance will consist of the same treatment as induction, but administered 
monthly x 4. 
If CNS treatment must be modified due to unforeseen circumstances or 
investigator preference, please consult with the Alliance  Study Chair. 
7.2.4 Restaging and Treatment Duration for DA- EPOCH -R 
If institution and patient are participating in the optional imaging companion study (CALGB 
580603), perform PET/CT scan post -Cycle 2. Otherwise, restage patients after Cycles 4 and 
6. Patients will receive a maximum of 6 cycles. Repeat CT/MRI scans at site(s) of initial 
involvement. If initial bone marrow biopsy is positive, a bone marrow examination should 
be repeated at each restaging point until it is negative, and then no further biopsy is necessary.  
Version Date: 02/15/2018  38 Update #18 
CALGB 50303  
If institution and patient are participating in the optional imaging companion study, submit 
PET/CT scan documentation post -Cycle 6. If patient is PET positive but CT negative, then 
repeat PET/CT scan 2 -3 months later and submit documentation (see Section 8.3 ). 
8.0 FDG -PET/CT  IMAGING COMPANION (CALGB  580603) 
As of protocol update #14, the PET/CT imaging companion study CALGB 580603 will be required 
of all patients enrolling onto the treatment study CALGB 50303. Participation on CALGB 580603 
will no longer be optional in order to participate in CALGB 50303. Please note:  if a PET/CT scan 
has already been performed for clinical evaluation, it may be possible to submit the scan as the 
baseline image for the correlative study CALGB 580603. Please contact the Imaging Co -Chair to 
determine suitability for submission as a baseline image.  
If the CT scan for the PET/CT imaging companion (CALGB 580603) is performed with (a) both oral 
and IV contrast with contrast enhancement in the arterial and/or portal venous phase; (b) is at least a 
2-slice CT; and (c) is acquired with at least 40 -60 mAs and CT scans are obtained with contiguous 
sections with a maximum of 5 mm slice thickness, then the pre- study and post -Cycle 6 PET/CT scan 
alone will suffice fo r patients enrolled on both CALGB 50303 and the PET/CT imaging companion. 
8.1 Institution Approval Procedures for FDG -PET/CT Imaging Companion 
Prior to enrollment of patients, institutions must be approved by the Alliance Imaging Core Lab 
at IROC Ohio . Institutions will be responsible for evaluating PET/CT scans as they do for 
clinical care, while th e Alliance Imaging Core Laboratory will be responsible for the 
standardized central imaging reads and the quantitative SUV analyses.  
8.1.1 FDG -PET/CT Equipment  
All institutions participating in the FDG -PET/CT imaging companion are required to have 
a hybrid PET/CT scanner. All PET/CT scanners manufactured by General Electric, Philips, 
and Siemens meet the technical specifications of this companion. If an instituti on uses a 
scanner not listed above, the Imaging Core Laboratory must approve the equipment. For infor mation regarding whether the PET/CT scanner to be used complies with this protocol, 
contact the Alliance Imaging Core Laboratory. Institutional approval for participation in 
the imaging companion is contingent upon submission of the PET/CT Instrument Technical Specifications Form ( Appendix II
) to the Imaging Core Laboratory (see 
Section 5.1.1.4 ). 
8.1.2 Institution FDG -PET/CT Imaging Approval 
The Alliance Imaging Core Lab at IROC Ohio  will adhere to the ACRIN criteria for PET 
imaging approval procedures. In order for an institution to be approved to participate in this FDG -PET/CT companion, they are required to submit two de -identified test patient studies, 
as well as a submission of a uniform phantom image for technical  and quality review by the 
Alliance I maging Core Laboratory (see Section 8.1.3
 below). After approval, the  
participating institution will be provided with an institution- specific (equipment -specific) 
instruction manual that details all components of the image acquisition and reconstruction throughout the study. The Imaging Core Laboratory will continue to veri fy that the 
acquisition and reconstruction performed at the participating sites are in compliance with 
set guidelines.  
Institutional approval for participation in the imaging companion is contingent upon 
submission of the PET/CT Instrument Technical Specif ications Form ( Appendix II ) to 
the Imaging Core Laboratory.  
8.1.3 Approval Procedures for PET/CT Imaging  
Approval requirements for the optional imaging companion CALGB 580603 are equivalent to ACRIN credentialing procedures fo r PET/CT imaging.  
Version Date: 02/15/2018  39 Update #18 
CALGB 50303  
Each institution must submit FOR ALL PET/CT instruments utilized: 1) Two test patient 
studies; 2) Uniform phantom data (with the SUV measurement of the phantom); and 3) 
PET/CT Instrument Technical Specifications Form ( Appendix II ). Each institution must 
also submit the Imaging Site Personnel Form ( Appendix III ) to the Imaging Core 
Laboratory. 
1) Two test patient studies  
Images of two unidentified patients shall consist of three v olume or multi -slice files as 
follows: a) Whole body CT from PET/CT scanner; b) Whole body (torso) emission 
with attenuation correction (A/C); and c) Whole body (torso) emission without A/C. 
2) Uniform phantom images 
Water -fillable uniform phantom: The phantom must be filled with water, and a known 
amount of F -18 (either as fluoride or as FDG) should be injected into the phantom. The 
activity injected should be determined by measurement of the syringe before and after 
the injection in a properly calibrated dose calibrator. The injected activity should be 
chosen to result in an activity concentration similar to that encountered in clinical FDG imaging (i.e., 1-1.5 mCi of F-18 should be added to the 6,283 mL phantom; 2 mCi for 
the 9,293 mL phantom). After thoroughly mixing the phantom, the phantom must be 
scanned with the same protocol used for the patient imaging. The images also must be 
reconstructed with the same algorithm and filters used for patient imaging. A circular 
or elliptical region of interest (ROI) covering most of the interior of the phantom must be drawn over all slices, and the average SUV and standard deviation must be measured 
and reported in the PET/CT Instrument Technical Specifications Form ( Appendix II
). 
The e xpected SUV for the uniform phantom is 1.0 and the acceptable range is 0.9 to 
1.1. 
(Alternatively) Ge -68/Ga- 68 calibration phantom: This phantom can readily be 
scanned with the same protocol used for patient imaging. The assay date and activity 
from the calibration certificate of this phantom must be reported on the PET/CT 
Instrument Technical Specifications Form ( Appendix II ). The images must be 
reconstructed with the same algorithm and filters used for patient imaging. A circ ular 
or elliptical ROI covering most of the interior of the phantom must be drawn over all slices, and the average SUV and standard deviation must be measured and reported in 
the PET Instrument Technical Specification form. The expected SUV for the uniform  
phantom is 1.0 and the acceptable range is 0.9 to 1.1. 
3) PET/CT Instrument Technical Specifications Form  
The PET/CT Instrument Technical Specifications Form may be found in Appendix II . 
Please fax, e-mail, or send this form to: 
 
 
 
 
 
 
 
 
 
Version Date: 02/15/2018  40 Update #18 

CALGB 50303  
8.2 Procedures for FDG -PET/CT Imaging  
8.2.1 Patient Preparation  
Patients should avoid any strenuous exercise for 24 hours prior to the PET/CT scan. Patients 
with poorly controlled diabetes (based on HbA1C) will be excluded. Patients must fast for 
≥ 4 hours prior to the injection of FDG, and must have a fasting blood glucose level ≤ 200 
mg/dL prior to FDG injection. Howeve r, an attempt will be initially made to control the 
blood glucose level, which will require the rescheduling of the injection. If the glucose level cannot be controlled (i.e., the blood glucose still exceeds 200 mg/dL), the patient will not 
be included in the FDG- PET/CT imaging companion. Patients should be adequately 
hydrated with plain water. Weight (kg), height (cm), and blood glucose (mg/dL) will be 
measured and recorded prior to the injection of FDG. 
Sedation (alprazolam, 0.5- 1 mg, po, 30 minutes pre -FDG injection) is allowed, but not 
mandatory and should be used consistently by the patient for all scans. Filgrastim, 
pegfilgrastim, and epoetin are known to affect FDG uptake, and so their use by the patient 
should be recorded.  
Patients should wait in a w arm room to avoid false positive brown fat FDG uptake. Patients 
will rest comfortably in a quiet room during the FDG uptake period. 
FDG will be synthesized and prepared in accordance with the institution’s standard 
procedures or obtained from a commercial supplier. 
8.2.2 FDG Dosing and Administration 
The administered activity of FDG should be based on the PET/CT scanner manufacturer’s 
recommendation. The recommended FDG dose is 0.14- 0.21 mCi/kg. The actual FDG dose 
should be a bolus of 8- 20 mCi, followed by  a saline flush (per institutional procedure). A 
dose at the higher end of the range is recommended, if feasible, with appropriate reduction 
in the per kilogram dose for heavier patients (in accordance with the manufacturer’s 
recommendation). The effective FDG dose injected and time of injection should be 
documented on CALGB form C-1657 (50303 Imaging Adjunctive Data Sheet). 
8.3 FDG -PET/CT Imaging Acquisition  
The FDG- PET/CT Imaging protocol must be followed exactly for every examination and for 
every patien t. Any changes must be approved in advance by the Imaging Core Laboratory 
 and changes will be documented in  
a revised Technical PET Site Manual. It is highly suggested that the baseline exam is available 
for comparison at the time of the follow-up examination. 
The following PET/CT images will be collected digitally for evaluation and archival:  
• Baseline (preferred ≤ 30 days prior to start of therapy and before baseline excisional  biopsy). 
If an eligible patient has a baseline PET/CT scan after the baseline excisional biopsy, the 
biopsied site must be excluded from quantitative evaluation. Please contact the Imaging 
Core Laboratory with questions. For qualified local sites participating in the evaluation of 
semi -quantitative PET parameters, study- specific baseline scans are required;  
• 17-21 days after the beginning of Cycle 2 therapy and 0- 4 days prior to start of Cycle 3;  
• Post-Cycle 6 (3 -8 weeks after last dose of chemotherapy); 
• Any PET/CT image obtained post- Cycle 6.  
Whole body emission acquisition at both pre-therapy (baseline) and post- therapy (Cycles 2 and 
6) MUST start 60 (± 10) minutes after FDG injection. The starting time will be recorded. Oral 
and/or IV contrast is optional. The field of view is to encompass the region between the base of 
the skull and the mid -thighs, but the entire head or distal lower extremities should be included 
Version Date: 02/15/2018  41 Update #18 

CALGB 50303  
if these are known sites of disease at baseline. Patient will be scanned supine with arms 
positioned comfortably above the head, if possible. It is critical that follow -up emission scans 
be performed in an identical way to the baseline scan, with the same scanner, same scan direction (skull to thighs or thighs to skull), and consistent arm positioning (arms up or 
arms down).  The interval between FDG injection and initiation of emission scanning should be 
the same as the baseline scan (no more than a ± 10 minute difference). All emission scans should 
be started between 50 -70 minutes after injection of FDG. Preferably, schedule the patien t for 
both baseline and follow -up scans at the same time of day (AM or PM) to improve 
reproducibility. Patient should empty his/her bladder immediately before the acquisition of 
images.  
For baseline scans, if the start time of the PET emission acquisition is outside of the protocol 
time window (60 ± 10 minutes post -injection), a non- compliance notification will be sent to the 
institution and the Alliance  Imaging Committee. The Imaging Core Laboratory will coordinate 
with the Imaging Committee to decide whether or not (a) the patient should be included in 
follow- up studies, and if yes, (b) if the follow -up emission scans should be performed identically 
to the baseline scan in which the uptake time departed from the protocol, or if an adjustment will 
be necessary. The Imaging Core Laboratory will notify the institution of the decision and the 
case-specific procedure required for follow-up exams on that specific patient. 
If emission scans in follow -up exams are not performed identically to the baseline scan 
according to the protocol or to the decision by the Alliance Imaging  Committee in a case of an 
accepted deviation, the same procedure outlined in the paragraph above will be used to clarify 
the acceptance of such an examination.  
For the emission scanning, the acquisition should be performed in 2D or 3D mode in accordance 
with the manufacturer’s recommendations defined in the Technical PET Site Manual. The 
emission scanning must be consistent between examinations and bed positions. The duration of 
acquisition for emission data should be in accordance with the manufacturer’s recommendations 
and the data must be corrected for scatter, random events, and dead -time losses using the 
manufacturer’s recommended procedure defined in the Technical PET Site Manual. Images 
should be attenuation corrected using CT data (note that if IV contrast is used, blood FDG SUV 
may be altered; therefore attenuation correction must be done without contrast). 
The patient will empty his/her bladder again immediately following PET/CT imagin g. 
8.4 Post-Treatment Study PET/CT Scans (Cycles 2 and 6)  
The post -treatment PET/CT scans are to be done according to the same specifications described 
in Section 8.0
. The post -treatment PET/CT scans should be done on the same scanner within the 
same qualified institution used for the baseline PET. If there is a need to change the scanner, the 
institution must notify the Imaging Core Laboratory. 
The first post -treatment PET/CT scan will be done 17 -21 days after completion of Cycle 2 of 
chemotherapy, and 0-4 days prior to initiation of Cycle 3 chemotherapy. 
The final post -treatment PET scan will be done at 3 -8 weeks after the completion of Cycle 6 in 
order to allow for resolution of post -treatment inflammatory effects that can cause false positive 
PET scan results. If the patient is unable to complete six cycles of chemotherapy, a PET/CT scan 
should be performed at a similar interval after the last treatment.  
Each post -treatment PET/CT scan will be read and interpreted together with t he baseline 
PET/CT scan and knowledge of other relevant clinical information. There will be a separate 
central review by the Imaging Core Laboratory.  
Version Date: 02/15/2018  42 Update #18 
CALGB 50303  
In addition to the tumor SUV and background SUV determinations described below (see Section 
8.7.4 ), an overall PET response scale will be reported for each patient, and the presence of any 
new lesions will be recorded and a confidence assessment indicated. The scale is as follows:  
Negative 
0 No abnormal activity (tumor cold compared with background)  
1+ Minimal activity (tumor less than background) 
2+ Equivocal (tumor = background) 
Positive 
3+ Moderately increased activity (tumor greater than background; i.e., greater than 
ABP)  
4+ Markedly increased activity (tumor much greater than b ackground) 
After completion of standard chemotherapy, 
(1) Are there new foci of FDG activity (yes/no)?  
(2) Are these judged to represent lymphoma (yes/no)? 
8.5 FDG -PET/CT Data Archiving, Storage, and Submission 
The complete PET/CT scan will be submitted to the Imaging Core Laboratory in digital DICOM 
format as defined in the Technical PET Site Manual. BMP files, JPG files, or hard copies 
(films) are not acceptable. The raw data of the entire study should be saved until the scan is 
accepted by the Imaging Core Labor atory. De -identify the patient data using institutional 
procedures to remove patient name and medical record number while preserving the CALGB 
ID number and protocol number. The de -identified digital images may be burned to a CD or 
transferred to a PC base d system. The following complete data sets must be sent:  1) 
Transmission CT data; 2) emission data with attenuation correction; and 3) emission data 
without attenuation correction. 
Data may be transferred by 1) FTP transfer or 2) mail/express courier trans fer. 
1) FTP Transfer : Any FTP software can be used to initiate access to the secure FTP Server of 
the Imaging Core Laboratory. The standard FTP access information will be provided separately 
through the specific trial e -mail , per the request by 
participating sites before their first data submission.  
Once you have access to the main data directory of the FTP server at the Imaging Core 
Laboratory, create a folder using the CALGB 50303 Subject Identifier assigned to the image 
data set you wish to FTP (upload). Then create another sub- folder with the date of the exam 
(YYYYMMDD), followed by the abbreviation of the study performed (PET, CT). Upload (copy) the imaging files to the appropriate sub- directory (the imaging files can be ex ported as a 
single file series). Once the upload is complete, you must send an e -mail to the Imaging Core 
Laboratory at  to inform them that the images have 
been uploaded from your institution. Please include the CALGB patient ID number and the 
date of the scan.  
2) Shipment/Mail Transfer : If FTP data transfers cannot be achieved, the de- identified images 
in digital DICOM format should be burned to a CD and mailed to the Imaging Core Laboratory. 
Please submit only one patient’s images per CD, with the patient’s CALGB ID number, study 
types (i.e., PET/CT baseline, post -Cycle 2, post -Cycle 6, or any other follow -up study), date of 
scans, date of first study treatment, and name of submitting institution. Alternatively, where institut ional information systems allow, the images can be e- mailed to the Alliance  Imaging  
Core Laboratory at the Ohio State University.  
Version Date: 02/15/2018  43 Update #18 

CALGB 50303  
Submit these data to:  Alliance  Imaging Core Laboratory 
 
 
 
 
 
 
Once 
the image acquisition has been completed, the entire study (complete PET/CT data in 
digital DICOM format), along with CALGB fo rm C -1657 (50303 Imaging Adjunctive Data 
Sheet), must be submitted to the Imaging Core Laboratory within no more than 3 business days. 
Institutions must send C -1657 to the Alliance Statistics and Data Center , Data Operations. 
Please note  that it is optiona l to submit the CALGB form C -1627 (50303 PET and CT 
Measurement Form). If C -1627 is submitted, it should be submitted to the Imaging Core 
Laboratory and the Alliance Statistics and Data  Center, Data Operations at the same time as 
CALGB form C -1657 (50303 Imaging Adjunctive Data Sheet). 
If there are any difficulties or questions concerning the FDG -PET/CT data submission, please 
contact the Imaging Core Laboratory. 
The Alliance Imaging Core Laboratory will acknowledge receipt of the imaging data via e- mail 
confirmation to the institution within one business day of receipt. The data will be reviewed for 
quality (see Section 8.7.2 ). After completion of the quality check, another e- mail assessing the 
protocol compliance will be sent to  the institution.  
8.6 Training for FDG -PET/CT Data Acquisition and Handling  
As part of the approval process, the Imaging Core Laboratory will train the technologists and responsible imaging physicians for the institutions in all aspects of patient handling , image 
acquisition, and image transfer. The Imaging Core Laboratory will use a virtual site visit concept 
based on WebEx that can facilitate communication on any computer that has access to the 
Internet. Outlined below is the WebEx conference information that will be included in the 
institution -specific manual.  
WebEx conferencing allows the simultaneous display of images/text/help instructions (desktop presentations/desktop applications, such as Power Point) in a secure manner to participating sites 
to any  computer with Internet access. For a WebEx conference, computers must have broadband 
Internet access and users must have the authority to download a WebEx client. For another level of safety and quality, the Imaging Core Laboratory will use a CALGB call -in number that should 
preferably be used from a conference phone if there is more than one participant from your 
location. 
The Imaging Core Laboratory will create a video stream that includes didactic information and 
training for technologists on any of the  institution -specific issues. This information can be 
accessed at any time and/or downloaded at the institution for viewing. Furthermore, the Imaging Core Laboratory will offer a training course/workshop on a needed basis that can be attended by 
site perso nnel. 
The Imaging Core Laboratory will train intra- and inter -institutional image readers using other 
independent data sets including imaging data import/export using the Workstations; image 
integrity/completeness check with the support of software tools; PET/CT fusion; ROI/VOI 
placements; SUV calculation.  
Version Date: 02/15/2018  44 Update #18 

CALGB 50303  
The readers will be benchmarked against a gold standard established for those images by a 
consensus assessment of the experienced nuclear medicine physicians selected by the Imaging 
Committee, to include the protocol Imaging Co -Chair. Readers will be required to assess their 
consistency in assessment at least every six months. Furthermore, a web -based training module 
for nuclear medicine attendings reading trial studies will be developed. The Imaging Core 
Laboratory will not provide basic skills, but a dedicated training on all assessment aspects of this trial.  
8.7 CALGB Imaging Core Lab Processing and Storage 
8.7.1 HIPAA Compliance  
The image data sets must be sent in a HIPA A-compliant manner. Upon receipt,  the Imaging 
Core Laboratory will verify that the images are de- identified and contain the trial and 
CALGB patient ID. In the case that they do contain patient private information, the Imaging 
Core Laboratory will issue a non- compliance statement to the in stitution and will de -identify 
the submitted data sets. The Imaging Core Laboratory will work in a completely de -
identified manner and will use study and patient identification alpha- numerics according to 
CALGB procedures.  
8.7.2 Quality Assurance and Quali ty Control of PET/CT Images  
During institutional approval, institution- specific manuals will be established. All submitted 
PET/CT images will be reviewed regarding technical specifications such as dosage, timing, 
acquisition, and reconstruction, and that t hey are compliant with the protocol. Any non -
compliance or discrepancies will be reported in the quality assessment and compliance 
review. This procedure will be performed for every submitted data set and will occur within 
72 hours upon receipt of the data set at the Alliance Imaging Core Lab at IROC Ohio. The 
quality of the PET/CT systems will be verified on a daily and monthly basis. The review of the institution - and equipment -specific quality management, including daily quality 
assurance set -up and compliance to the policies, will be established at the approval 
assessment and verified on an ongoing basis.  
If, at the approval review of the institution, the Imaging Core Laboratory determines that there are insufficient quality standard operating procedures  established for the site, it will 
propose that established procedures for the specific equipment type, based upon the 
manufacturer’s recommendation and established guidelines, be used. If at any time the 
institution is deemed to be non- compliant, a non- compliance statement will be issued and a 
remedy procedure suggested. If an institution does not remedy quality compliance concerns, the Imaging Core Laboratory will revoke the approval of the institution. The institution 
would then become ineligible for participation in the FDG -PET/CT companion until 
resolution of the defined issues. Imaging Core Laboratory guidelines will be in alignment 
with the ACRIN guidelines. 
The quality of each PET/CT image will be assessed in three steps: 1) confirmation that 
images have been received and are electronically accessible; 2) image review for 
completeness and image quality by an experienced research associate or technologist who will have access to staff nuclear medicine physicians in case of questions; and 3) review of 
images and post -processing results by an experienced staff member (nuclear medicine 
physician or radiologist). All ROI and calculation steps will be electronically documented and the quantitative data transferred into the trial database.  
There are two components regarding readability of images. One is the technical readability (e.g., the images are in a DICOM format, which is a requirement, or in a data format of any 
of the three major equipment vendors: General Electric, Philips, and Siemens). The other aspect is the image quality. As described above, every data set received will be reviewed 
Version Date: 02/15/2018  45 Update #18 
CALGB 50303  
regarding compliance to the acquisition and reconstruction protocol. Patient images that 
show artifacts due to patient motion, extravasation of radiotracer, or other tec hnical issues, 
including non -compliance of the timeline, will be identified as such during the quality 
compliance review and reported as compliant/non- compliant or acceptable/unacceptable to 
the institution.  
Submitted images will be classified as “optimal”  if they are compliant with all acquisition, 
reconstruction, and quality criteria without showing any artifacts. The classification “readable but not optimal” will be reserved for those images which are compliant in the 
essential components, but are sub -optimal due to patient motion or non -detrimental 
deviation from the expected performance. The classification “not readable” will be used for 
any other cases that cannot be characterized in the other two categories (i.e., no evaluable 
lesions; too much motion; wrong body location; data broken; images incomplete; non-
DICOM image formats, such as JPEG images, bitmap images, screen -captured images, 
scanned films or hardcopies, etc.) and that are non -compliant. 
An initial QA check will be performed within 72 hours  by the Imaging Core Laboratory 
upon receipt of each imaging study from the sites. The imaging studies will be stratified as (1) optimal, (2) readable but not optimal, and (3) not readable, based upon predetermined 
rules. Imaging studies that are not reada ble will be communicated to the site and Imaging 
Co-Chair by the Imaging Core Laboratory and will be encouraged to be immediately 
repeated. Imaging studies that are readable but not optimal will be discussed with the Imaging Co -Chair to decide upon status in the analysis. It may be that these studies are 
included in the qualitative analysis, but not semiquantitative analysis.  
Strict enforcement of compliance and quality assessment is necessary in order to ensure the 
highest quality of the data collected in this trial. The assessment of every submitted study 
and image within 72 hours of submission to the Imaging Core Laboratory regarding 
compliance and quality enables not only the appropriate third party review, but also a timely 
notification about non-compli ance to the institution and the Alliance . The Imaging Core 
Laboratory will copy non- compliance notices to the Alliance  Imaging Committee and the 
Alliance Statistics and Data  Center, and it will support the institution  to ensure that 
compliance is achieved through appropriate measures. The Imaging Core Laboratory will 
propose remedy options that will include expected timelines and will revoke the institutional approval if compliance is not achieved within reasonable timelines. Any such action will be 
coordinated with the Alliance Imagi ng Committee.  
For non- compliant images: If images received by the Imaging Core Laboratory are not able 
to be analyzed (i.e., no evaluable lesions; data broken; images incomplete; non -DICOM 
image formats, such as JPEG images, bitmap images, screen -captured images, scanned films 
or hardcopies) and these potential problems cannot be resolved, then the following scenarios may apply:  
a) If the problem occurs with the baseline images, then an imaging quality check 
report will be sent t o both the institution and the Alliance  Imaging Committee 
Leadership, in which the Imaging Core Laboratory will suggest that the baseline 
scans be rescheduled/reperformed, as well as that the imaging data be 
retransmitted. Otherwise, if the patient has been in follow -up studies, then the 
Alliance Imaging Committee Leadership will decide whether and how the patient 
can be included in the analyses.  
b) If the problem occurs with the Cycle 2 images, but the baseline images are 
compliant, then an inquiry will be  sent to the Alliance  Imaging Committe e 
Leadership to decide if the patient will be included in follow -up studies. If so, an 
imaging quality check report will be sent to both the institution and the Alliance  
Version Date: 02/15/2018  46 Update #18 
CALGB 50303  
Imaging Committee Leadership in which the Imagin g Core Laboratory will remind 
the institution to avoid these problems in the follow -up scans and to provide 
DICOM -formatted imaging data for Cycle 6 and post- Cycle 6 images.  
c) If the problem occurs with the Cycle 6 images, but both baseline and Cycle 2 
images are compliant, then an inquiry will be sent to the Alliance  Imaging 
Committee Leadership to decide if the patient will be included in any follow -up 
studies. If so, then an imaging quality check report will be sent to both the 
institution and the Allia nce Imaging Committee Leadership in which the Imaging 
Core Laboratory will remind the institution to avoid these problems in post- Cycle 
6 scans. Otherwise, if the Cycle 2 images were also non- compliant, then an 
imaging quality check report will be sent to both the institution and the Alliance 
Imaging Committee Leadership, and the Alliance Imaging Committee Leadership 
will decide if the patient will be excluded from further post -Cycle 6 PET/CT scans.  
If the images received are analyzable, then an imaging quality check report will be 
sent to both the institution and the Alliance Imaging Committee Leadership, and 
the Alliance  Imaging Committee Leadership will decide if the analysis for the 
patient is to be finished by the Imaging Core Laboratory. 
Summary Report s: The Imaging Core Laboratory will generate a monthly summary report 
for each institution that will report on the number of cases submitted, specification of images received, quality assurance failures and queries outstanding, and details of reconciliatio n 
processes in terms of images received/acquired, the quality/compliance assessment, etc. In 
addition to these institution -specific reports, the Imaging Core Laboratory will create 
summary reports for the entire trial, including recruitment quality status and number of non-
compliance queries. The Imaging Core Laboratory will submit quarterly and yearly reports 
to the Lymphoma FDG -PET Working Group (including experts from the NCI, FDA, 
Alliance , and PhRMA), the Imag ing Co -Chair, and the Alliance Statistics and Data Center. 
8.7.3 Imaging Core Laboratory Image Reconstruction and Analysis 
Image reconstruction (i.e., an interactive reconstruction method with preference for OSEM reconstruction, 8 subsets, 2 iterations, followed by smoothing with a 6 mm 3 -D Gaussian 
kernel) will be performed using the manufacturer -recommended parameters and specified 
in the Technical PET Site Manual. Both visual/qualitative and semi -quantitative (SUV) PET 
data analysis will be performed.  
Both visual/qualitative and semi -quantitative  (SUV) PET/CT data analysis will be 
performed locally by the sites, as well as by the Alliance  Imaging  Committee in 
collaboration with the Imaging Core Laboratory. Data analysis of the study endpoints will 
be based on readings by three qualified independent nuclear medicine 
physicians/radiologists, selected by the Imaging Committee. Readings will be performed according to procedures outlined by the FDA imaging reports and will consist of two 
independent reads. Any discordance (defined by endpoints in the im aging analysis plan) 
will be adjudicated by a third independent nuclear medicine physician/radiologist. The adjudicator can only select one of the two initial independent reads, as outlined by FDA 
independent read documentation. Quantitative assessments (e.g., tumor location, tumor size, ROI/VOI information, SUV, etc.) will be electronically documented (screen captured from 
the Workstation) independently and used for determining consensus of readings, as well as 
inter-observer variability. Both Cycle 6 and Cycle 2 endpoints are dichotomous, and so will 
be determined by consensus of two or three readings. If an eligible patient has a baseline PET/CT scan after the baseline excisional biopsy, the biopsied site must be excluded from quantitative evaluation. Please contact the Imaging Core Laboratory with questions. 
Version Date: 02/15/2018  47 Update #18 
CALGB 50303  
8.7.4 Institutional & Imaging Core Laboratory Determination of Tumors and SUVs 
Tumor Selection: Up to six tumor masses > 2 cm will be selected for analysis at baseline, 
and their locations and size (l ength and width) will be defined. Tumor dimensions will be 
determined in a single plane on the transverse CT image where the tumor appears largest. 
The maximum dimension (length) should be measured, followed by the width, which should be perpendicular to t he length. Tumor #1 will be the tumor site with highest SUVmax; the 
others will be selected in descending order of SUV. Location and dimensions of the index tumors will be determined at baseline and at all subsequent PET/CT scans. For post -
treatment assessment of lesions other than the six index lesions, see Section 8.8
. 
SUVs:  SUVs for the study endpoints will be calculated using decay -corrected administered 
dose and uncorrected body weight. SUVs will be calculated at baseline and at all subsequent PET/CT scans. These procedures are described briefly below.  
Tumor SUVmax: For the purposes of this study, the primary SUVs for calculation and 
reporting will be the SUVmax within each of the index (up to 6) tumor volumes. This will 
be det ermined by the nuclear medicine physician visually identifying the region or regions 
on the PET images that qualitatively appear to have the most intense FDG uptake and that correspond to known tumor based on other data (e.g., CT scan). SUVmax should be 
determined on the transverse slice where the tumor visually appears the brightest, as well as 
on several adjacent slices above and below, to be certain that the reported maximum is 
correct. Determinations will be made on a 128 x 128 image matrix size image. VOIs can be 
placed where the tumor visually appears the brightest by 3- D ellipse/spherical or 3 -D 
isosurface tools.  
Prints of the image and the SUV cursor should be acquired and retained for source 
documentation. As noted above, for the purposes of this pr otocol, up to six lesions will be 
analyzed. The one with the highest SUVmax will be reported as lesion #1; the others should be identified in descending order of SUV. 
ABP SUVmean: Place the ROI on a transverse image or the spherical VOI with a 1 cm oval 
in the middle third of the aorta, well away from the edge. Take the mean SUV of the 
ROI/VOI.  
Liver SUVmean: Place the ROI on a transverse image (a 3 -5 cm long by 2 cm irregular 
region) or the spherical VOI (a 3 -5 cm long by 2 cm irregular volume) through the  mid liver 
with relative uniform intensities, which excludes the central hilum of the liver. Take the 
mean SUV of the ROI/VOI.  
Other SUV  data will be determined. As noted above, SUVs obtained and used for the 
endpoints of this study will be based on body weight and will not be corrected for body 
surface area or other measures of patient size/shape. However, patient height data will be 
collected, and exploratory analysis of SUV corrected for body surface area and lean body mass will be performed to determine  whether this correction provides more useful data than 
conventional, uncorrected SUV.  
8.8 Interpretation of Positive Post -Treatment Scans and Implications of PET Images for 
Progressive Disease 
At Cycle 6, if a scan is PET positive but CT negative, another  PET/CT scan will be performed 
after 2 -3 months. If PET remains positive, the PET -positive site(s) should be biopsied to 
determine histopathology, if feasible, or additional follow -up PET scans should be performed 
until the activity resolves or is stable f or six months or longer. If a PET scan shows progression, 
results will be provided to the treating physician to assist in further evaluation of the patient. No 
patient will be considered to have failed treatment based on a positive PET scan alone.  
Version Date: 02/15/2018  48 Update #18 
CALGB 50303  
PET/CT r esults obtained post -Cycle 2 will not be provided to treating physicians during the 
course of the trial, since these data are exploratory in nature and their utility in patient 
management is unknown. Exceptions are the rare occurrences of any results sugge sting the 
presence of progression or life- threatening disease. These data will be provided to the treating 
physician as soon as possible after they are obtained to aid the further evaluation of the patient.  
8.9 PET/CT Scan Reimbursement  
The patient and/or his/her health plan/insurance company will need to pay for the costs of the 
PET/CT scans performed at prior to treatment, 3- 8 weeks post -Cycle 6, and (if necessary) 2 -3 
months after the post -Cycle 6 scan. The costs for as many as two PET/CT scans – a repea t 
baseline PET/CT scan if the original is non -compliant (i.e., not performed per protocol 
specifications), and the PET/CT scan performed at post -Cycle 2 – will be reimbursed by funding 
provided by the Cancer Trials Support Unit, funded by the National Canc er Institute. The 
reimbursement form can be found on the 50303 study page on the Alliance Web site, 
www.allianceforclinicaltrialsinoncology.org. 
9.0 D OSE MODIFICATIONS AND MANAGEMENT OF TOXICITY  
9.1 Arm A (R- CHOP) Dose Modifications  
9.1.1 Hematologic Toxic ity 
9.1.1.1 Neutropenia  
• To begin a cycle, ANC must be ≥ 1500/µL and platelets ≥ 100,000/µL. Delay cycle 
by up to 2 weeks if these values are not met on Day 1 of cycle. If delay is greater 
than two weeks. then contact Study Chair. 
• If a patient develops grade 4 neutropenia (ANC < 500/µL) or any febrile 
neutropenia (defined as ANC < 500/µL + fever ≥ 38.5°C (101°F) sustained for more than one hour), filgrastim or pegfilgrastim should be administered for all subsequent cycles. Administration of colony stimulating factors at time of 
neutropenia is at the discretion of treating physician. 
• If febrile neutropenia (defined as ANC < 500/µL + temperature ≥ 38.5°C (101°F) 
sustained for more than one hour) occurs despite filgrastim or pegfilgrastim 
support, reduce doses of cyclophosphamide and doxorubicin by 25% for 
subsequent cycles. If toxicity recurs, cyclophosphamide and doxorubicin doses 
should be reduced by an additional 25% for subsequent cycles. 
• If grade 4 neutropenia or febrile neutropenia persists despite two dose reductions, remove patient from protocol therapy. 
9.1.1.2 Thrombocytopenia 
• If grade 3 (platelets < 50,000/µL and ≥ 25,000/µL) or 4 thrombocytopenia 
(platelets < 25,000/µL) occurs, reduce doses of cyclophosphamide and doxorubicin by 25% for subsequent cycles. If toxicity recurs, cyclophosphamide and doxorubicin doses should be reduced by an additional 25% for subsequent 
cycles.  
• If grade 3 (platelets < 50,000/µL and ≥ 25,000/µL) or 4 thrombocytopenia 
(platelets < 25,000/µL) recurs despite two dose reductions, remove patient from 
protocol therapy.  
9.1.2 Ileus and Constipation  
Symptomatic ileus/constipation may occur with vincristine. If ileus or constipation require 
hospitalization, the next dose of vincristine should be reduced by 25%. If symptoms do not 
Version Date: 02/15/2018  49 Update #18 
CALGB 50303  
recur at the reduced dose, then the vincristine dose may be re -escalated on  subsequent 
cycles.  
9.1.3 Neuropathy  
Sensory and motor neuropathy may occur with vincristine. Vincristine doses should only be 
reduced if the patient develops neuropathy that interferes with activities of daily living. Most 
vincristine associated neuropath y resolves after completion of treatment.  
• Sensory neuropathy : If grade 3 toxicity develops, reduce vincristine 25%. If symptoms 
improve, doses may be increased to previous levels. If patient experiences grade 4 
toxicity, discontinue vincristine. 
• Motor  neuropathy : If patient experiences grade 2 toxicity, reduce vincristine 25%. If 
patient experiences grade 3 toxicity, reduce vincristine 50%. If symptoms improve, doses 
may be increased to previous levels. If patient experiences grade 4 toxicity, disconti nue 
vincristine.  
9.1.4 Hyperbilirubinemia  
• Doxorubicin  
No doxorubicin dose modifications will be made for increased bilirubin ≤ 7 mg/dL. Doxorubicin should be held for bilirubin > 7 mg/dL, until it returns to ≤ 7 mg/dL. 
Pharmacokinetic data from Dr. Wilson et al. (unpublished data) has shown no 
significant effect of bilirubin on doxorubicin clearance. Specifically, doxorubicin 
pharmacokinetics were measured in 47 patients during multiple cycles of DA -EPOCH 
in which doxorubicin was administered as a continuous infusion. Seven patients 
presented with bilirubin levels above normal. Although doxorubicin clearance was 
delayed in cycle one in these seven patients, the clearance values were within the range 
of those seen in patients with normal bilirubin, and no patients experienced excessive 
toxicity. Significant reductions in doxorubicin clearance were observed primarily in patients with bilirubin levels ≥ 2 mg/dL. Bilirubin levels above 2 mg/dL did not 
demonstrate a quantitative relationship with doxorubicin clearance. Clinically, all of these patients received full dose doxorubicin, and no patient experienced excessive 
toxicity. Additionally, these patients showed significant increases in doxorubicin 
clearance in cycle 2.  
• Vincristine  
Vincristine dose will be decreased for elevated bilirubin only secondary to lymphoma 
as follows:  
Bilirubin (mg/dL)  Vincristine Dose  
> 1.5 - < 3 decrease by 25%*  
≥ 3 decrease by 50%*  
* Vincristine dose will be re -escalated as hyperbilirubinemia improves.
Version Date: 02/15/2018  50 Update #18 
CALGB 50303  
 
9.2 Arm B (DA- EPOCH -R) Dose Modifications  
9.2.1 Hematologic Toxicity  
Delay cycle by up to 2 weeks if ANC < 1000/µL or platelets < 100,000/µL. Filgrastim may 
be used for several days to increase ANC. If no recovery after 2 weeks, contact the Study 
Chair for guidance.  
Doses for doxorubicin, etoposide and cyclophosphamide will be based on measurements of the previous cycle ANC or platelet nadir whichever is lower (i.e., twice weekly starting 3 -
4 days after completion of chemotherapy). 
If ANC ≥ 500/µL on all measurements:  ↑ one dose level*   
If ANC < 500/µL on 1 or 2 measurements  
(3-4 days apart):  maintain dose level  
If ANC < 500/µL ≥ 3 measurements:  
(3-4 days apart):  ↓ one dose level**  
OR 
If platelet < 25,000/µL on ≥ 1 measurement:  ↓ one dose level  
* to a maximum of Dose Level 7. 
** to a minimum of Dose Level –2. Recurrence of a toxicity requiring a dose reduction below Dose 
Level –2 will result in removal of patient from protocol therapy.  
9.2.2 DA-EPOCH Dose Levels  
Dose adjustments for hematologic toxicity apply only to etoposide, doxorubicin and 
cyclophosphamide. Only cyclophosphamide is reduced in Dose Levels –1 through –3. 
 Dose Levels  
Adjusted Agents  -3 -2 -1 1 2 3 4 5 6 7 
Doxorubicin (mg/m2/day)  10 10 10 10 12 14.4 17.3 20.7 24.8 29.8 
Etoposide (mg/m2/day)  50 50 50 50 60 72 86.4 103.7  124.4  149.3  
Cyclophosphamide (mg/m2) 384 480 600 750 900 1080  1296  1555  1866  2239  
           
Non-Adjusted Agents            
Rituximab (mg/m2) 375 375 375 375 375 375 375 375 375 375 
Vincristine (mg/m2/day) (No cap)  0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 
Prednisone (mg/m2 BID)  60 60 60 60 60 60 60 60 60 60 
9.2.3 Non-Hematologic Toxicity 
9.2.3.1 Ileus and Constipation  
Symp tomatic ileus/constipation may occur with vincristine. If ileus or constipation 
requires hospitalization, the next dose of vincristine should be reduced by 25%. If 
symptoms do not recur at the reduced dose, then the vincristine dose may be re-
escalated on subsequent cycles.  
9.2.3.2 Neuropathy  
Sensory and motor neuropathy may occur with vincristine. Vincristine doses should 
only be reduced if the patient develops neuropathy that interferes with activities of 
Version Date: 02/15/2018  51 Update #18 
CALGB 50303  
daily living. Most vincristine associated neuropathy resolves after completion of 
treatment.  
• Sensory neuropathy: If grade 3 toxicity develops, reduce vincristine 25%. If 
symptoms improve, doses may be increased to previous levels. If a patient experiences grade 4 toxicity, discontinue vincristine.  
• Motor neuropathy:  If grade 2 toxicity develops, reduce vincristine 25%. If a 
patient experiences grade 3 toxicity, reduce vincristine 50%. If symptoms improve, 
doses may be increased to previous levels. If a patient experiences grade 4 toxicity, 
discontinue v incristine.  
9.2.3.3 Hyperbilirubinemia  
• Doxorubicin  
No doxorubicin dose modifications will be made for increased bilirubin ≤ 7 mg/dL. 
Doxorubicin should be held for bilirubin > 7 mg/dL, until it returns to ≤ 7 mg/dL.. 
Pharmacokinetic data from Dr. Wilson et al. (unpublished data) has shown no significant effect of bilirubin on doxorubicin clearance. Specifically, doxorubicin 
pharmacokinetics were measured in 47 patients during multiple cycles of DA -
EPOCH in which doxorubicin was administered as a continuous infusion. Seven patients presented with bilirubin levels above normal. Although doxorubicin 
clearance was delayed in cycle one in these seven patients, the clearance values were within the range of those seen in patients with normal bilirubin, and no 
patients experien ced excessive toxicity. Significant reductions in doxorubicin 
clearance were observed primarily in patients with bilirubin levels ≥ 2 mg/dL. Bilirubin levels above 2 mg/dL did not demonstrate a quantitative relationship with 
doxorubicin clearance. Clinical ly, all of these patients received full dose 
doxorubicin, and no patient experienced excessive toxicity. Additionally, these 
patients showed significant increases in doxorubicin clearance in cycle 2.  
• Vincristine  
Vincristine dose will be decreased for elevated bilirubin only secondary to 
lymphoma as follows: 
Bilirubin (mg/dL)  Vincristine Dose  
> 1.5- < 3  decrease by 25%*  
≥ 3 decrease by 50%*  
* Vincristine dose will be re -escalated as hyperbilirubinemia improves.  
9.2.3.4 Dose Modifications Based on Creatinine Clearance Secondary to Lymphoma  
No etoposide dose modifications will be made for decreased creatinine clearance or 
increase creatinine. It is anticipated that decreased clearance or increased creatinine 
will improve after the first treatment cycle.  
9.3 Dose Modification for Obese Patients  
All dosing is based on the patient’s BSA as calculated from actual weight. There  is no clearly 
documented adverse impact of treatment of obese patients when dosing is performed according to actual body weight.  Failure to use actual body weight in the calculation of drug dosages will 
be considered a major protocol deviation. Physicians who are uncomfortable with administering 
chemotherapy dose based on actual body weight should not enroll obese patients on Alliance  
protocols. 
Version Date: 02/15/2018  52 Update #18 
CALGB 50303  
10.0 D RUG FORMULATION , AVAILABILITY , AND PREPARATION  
Qualified personnel who are familiar with procedures that minimize undue exposure to themselves 
and to the environment should undertake the preparation, handling, and safe disposal of 
chemotherapeutic agents in a self -contained, protective environment.  
Discard unused portions of injectable chemotherapeutic agents  that do not contain a bacteriostatic 
agent or are prepared with unpreserved diluents (i.e., Sterile Water for Injection USP or 0.9% Sodium 
Chloride for Injection USP) within eight hours of vial entry to minimize the risk of bacterial 
contamination. 
The total administered dose of chemotherapy may be rounded up or down within a range of 5% of 
the actual calculated dose.  
The weight at Cycle 1 should be used for dose calculations for all cycles unless there is a ≥10% change over a period of one cycle. If a weight change ≥ 10% occurs, then doses should be recalculated 
and the new dose used from that time forward.  
10.1 Doxoru bicin HCL (Adriamycin PFS™, Adriamycin RFS™, Rubex®)  
A
VAILABILITY  
Doxorubicin is commercially available as a lyophilized powder for reconstitution in 10, 20, 50, 
and 100 mg vials. Also available are 2 mg/mL solutions for injection in 10, 20, 50, and 200 mg 
vials. Please refer to the FDA -approved package insert for doxorubicin for product information, 
extensive preparation instructions, and a comprehensive list of adverse events.  
STORAGE & STABILITY  
Intact vials of doxorubicin solution should be stored in the refrigerator. Intact vials of powder for reconstitution should be stored at room temperature. Reconstituted solutions are stable for 7 
days at room temperature and 15 days under refrigeration when protected from light. 
Commercially available solutions labeled as such are intended to be multidose vials. 
Compatibility and stability studies were conducted by the Pharma ceutical Development Service 
[60], Pharmacy Department, NIH Clinical Center, simulating concentrations of each drug that 
would be applicable to this trial. Admixtures of vincristine, doxorubicin, and etoposide in 0.9% 
Sodium Chloride Injection, in polyolefin- lined IV bags were stable for up to 72 hours at room 
temperature, provided that the concentration of etoposide was < 250 mcg/ml. 
P
REPARATIO N 
Reconstitute the vials of doxorubicin powder with 5, 10, 25, or 50 mL, respectively, of sodium 
chloride for injection, USP, resulting in a concentration of 2 mg/mL. 
In Arm A (CHOP -R), withdraw the desired volume into a syringe for IV injection.  
In Arm B (EPOCH -R), doxorubicin will be admixed in 0.9% sodium chloride, along with 
vincristine IV for infusion over 24, 48 or 72 hours. Etoposide may be mixed with doxorubicin 
and vincristine, or it may be infused separately. See reference 49 for specific compatib ility and 
stability information base on concentration of each agent. 
ADMINISTRATION  
In Arm A (CHOP -R), doxorubicin is administered intravenously over 3- 5 minutes. Avoid 
extravasation, as severe local tissue necrosis may result.  
In Arm B (EPOCH- R), doxorubi cin will be administered as a 96 -hour continuous IV infusion, 
along with vincristine and etoposide in the same infusion solution (see “Storage and Stability” 
above). The chemotherapy will be administered with a suitable infusion pump via a central venous a ccess device. Temporary PICC lines or permanent lines may be used. Extravasation of 
Version Date: 02/15/2018  53 Update #18 
CALGB 50303  
these diluted agents has not caused local tissue damage due to their low concentrations in the 
solution.  
TOXICITIES  
Hematologic:  Leukopenia (dose -limiting), thrombocytopeni a, anemia. Nadir in 10 -14 days with 
recovery usually in 21 days. 
Dermatologic: alopecia (usually complete; reversible) radiation recall reactions; increased 
sensitivity to sunlight.  
Gastrointestinal: nausea and vomiting (doxorubicin is generally considered moderately to highly 
emetogenic), anorexia, diarrhea, mucositis (stomatitis, esophagitis).  
Cardiovascular:  cardiomyopathy may occur and is related to total cumulative lifetime dose. The 
risk for cardiomyopathy increases with total doses > 450 mg/m2. ECG c hanges and less often, 
arrhythmias, are seen. Rarely, sudden death has occurred. 
Other:  Red discoloration of urine for 24- 48 hours after drug administration. Doxorubicin is a 
vesicant and can cause tissue necrosis if extravasated, especially at the concent ration usually 
employed for bolus injections (i.e., 2 mg/mL). 
10.2 Etoposide (VePesid®, Epidophyllotoxin, VP-16) 
AVAILABILITY  
Etoposide is commercially available as a solution for injection in 5 mL, 7.5 mL, 25 mL, and 50 mL vials containing 20 mg/mL. Pleas e refer to the FDA -approved package insert for etoposide 
for product information, extensive preparation instructions, and a comprehensive list of adverse 
events.  
S
TORAGE & STABILITY  
Intact vials of etoposide for injection should be stored at room temperature and protected from light.  
Compatibility and stability studies were conducted by the Pharma ceutical Development Service 
[60], Pharmacy Department, NIH Clinical Center, simulating concentrations of each drug that 
would be applicable to this trial. Admixtu res of vincristine, doxorubicin, and etoposide in 0.9% 
Sodium Chloride Injection, in polyolefin- lined IV bags were stable for up to 72 hours at room 
temperature, provided that the concentration of etoposide was < 250 mcg/ml. 
P
REPARATION  
Etoposide will be admixed in 0.9% sodium chloride for IV infusion over 24, 48 or 72 hours. 
Etoposide may be mixed with doxorubicin and vincristine or it may be infused separately. See reference 49 for specific compatibility and stability information based on concentration of  each 
agent. Infusion solutions should be changed every 24 hours. The volume of the infusion solution will be determined by the 24 hour etoposide dose. If etoposide ≤ 150 mg per 24 hours, then 
dilute drugs in 500 mL 0.9% sodium chloride; if etoposide > 150 mg per 24 hours, then dilute 
drugs in 1000 mL 0.9% sodium chloride. 
A
DMINISTRATION  
Etoposide is administered in Arm B only. Etoposide will be administered as a 96-hour 
continuous IV infusion, along with vincristine and doxorubicin (see “Storage & Stabilit y” 
above). The chemotherapy will be administered with a suitable infusion pump via a central 
venous access device. Temporary PICC lines or permanent lines may be used. Extravasation of 
these diluted agents has not caused local tissue damage due to their lo w concentrations in the 
solution.  
 
Version Date: 02/15/2018  54 Update #18 
CALGB 50303  
TOXICITY  
Myelosuppression, predominantly neutropenia and thrombocytopenia, is the most common 
toxicity associated with etoposide. Nausea and vomiting range from mild to severe in severity, 
depending on the dose. At the dose used in this study, etoposide is moderately highly 
emetogenic. Mucositis is also more common at the dose used in this study. Alopecia is likely. Hypotension is associated with too rapid administration of etoposide. This would be unlikely to 
occur in thi s trial.  
10.3 Vincristine sulfate (VCR, Leurocristine sulfate, Oncovin
®, Vincasar PFS)  
AVAILABILITY  
Vincristine is commercially available in 1 mL, 2 mL, and 5 mL vials in a concentration of 1 
mg/mL. Please refer to the FDA -approved package insert for vincristine sulfate for product 
information, extensive preparation instructions, and a comprehensive list of adverse events.  
STORAGE & STABILITY  
Unopened vials should be stored under refrigeration and proteced from light. Commercially available solutions labele d as such are intended to be multidose vials. 
Compatibility and stability studies were conducted by the Pharmaceutical Development Service 
[49], Pharmacy Department, NIH Clinical Center, simulating concentrations of each drug that 
would be applicable to this trial. Admixtures of vincristine, doxorubicin, and etoposide in 0.9% Sodium Chloride Injection, in polyolefin- lined IV bags were stable for up to 72 hours at room 
temperature, provided that the concentration of etoposide was < 250 mcg/ml. 
P
REPARATION  
In Arm A (CHOP -R), withdraw the desired volume into a syringe for IV injection.  
In Arm B (EPOCH- R), vincristine will be admixed in 0.9% sodium chloride for IV infusion 
over 24, 48 or 72 hours. Etoposide may be mixed with doxorubicin and vincristine or it may be 
infused separately. See reference 49 for specific compatibility and stability information based 
on concentration of each agent. Infusion solutions should be changed every 24 hours. The 
volume of the infusion solution will be determined by the 24 hour etoposide dose. If etoposide 
≤ 150 mg per 24 hours, then dilute drugs in 500 mL 0.9% sodium chloride; if etoposide > 150 mg per 24 hours, then dilute drugs in 1000 mL 0.9% sodium chloride. Infusion solutions should 
be protected from light. 
A
DMINISTRATION  
In Arm A (CHOP -R), administer without further dilution by slow IV push.  Precaution: 
Maximum single dose is 2 mg. 
In Arm B (EPOCH -R), vincristine will be administered as a 96 -hour continuous IV infusion, 
along with etoposide and doxorubicin (see “Storage & St ability” above). The chemotherapy will 
then be administered with a suitable infusion pump via a central venous access device. 
Temporary PICC lines or permanent lines may be used. Extravasation of these diluted agents 
has not caused local tissue damage due to their low concentrations in the solution.  
TOXICITY  
The most common toxicity associated with vincristine is neurotoxicity. Peripheral manifestations of neurotoxicity include: numbness of extremities, paresthesias, loss of deep tendon reflexes, neuropathi c pain and muscle weakness. GI manifestations of neurotoxicity 
include constipation, and adynamic ileus. Cranial nerve manifestations include: diplopia, hoarseness, tinnitus, jaw pain (the latter usually occurring with the first dose of vincristine). 
Ortho static hypotension & SIADH may also be seen. Vincristine is a vesicant and may cause 
Version Date: 02/15/2018  55 Update #18 
CALGB 50303  
tissue necrosis upon extravasation. This is more likely with bolus injections as opposed to dilute 
infusions. 
10.4 Cyclophosphamide (Cytoxan®; Neosar®) 
AVAILABILITY  
Commer cially available as a powder for reconstitution in 100 mg, 200 mg, 500 mg, 1 gram, and 
2 gram vials. Please refer to the FDA -approved package insert for cyclophosphamide for product 
information, extensive preparation instructions, and a comprehensive list of adverse events.  
PREPARATION  
Reconstitute 100 mg, 200 mg, 500 mg, 1 gram and 2 gram vials with 5, 10, 25, 50, or 100 mL of sterile water for injection or normal saline to give a final concentration of 20 mg/mL. Vigorous shaking and/or gentle warming may be necessary for non –lyophilized preparations. 
Bacteriostatic water for injection (paraben preserved only) may be used; benzyl alcohol derivatives may NOT be used.  
S
TORAGE & STABILITY  
Intact vials should be stored at room temperature. Reconstituted and dil uted solutions are stable 
for 24 hours at room temperature and 6 days if refrigerated. 
ADMINISTRATION  
The total dose of cyclophosphamide will be administered by IV. 
All patients should receive hydration with normal saline at the following volumes (based on 
cyclophosphamide dose levels) and rates with half administered before and half administered 
after cyclophosphamide. 
R-CHOP and DA -EPOCH -R Levels 1 -2 (see § 9.2.2): 1 liter NS @ 300-500 cc/hr 
DA-EPOCH -R Levels 3 -5 (see § 9.2.2) : 2 liter NS @ 300-500 cc/hr 
DA-EPOCH -R Level ≥ 6 (see § 9.2.2) : 2.5 liter NS @ 300-500 cc/hr 
TOXICITY  
Myelosuppression, hemorrhagic cystitis (patients must be well -hydrated before, during, and 
after treatment and have adequate renal function). Syndrome of inappropriate antidiureti c 
hormone (SIADH), fatigue, alopecia, anorexia, nausea, vomiting, hyperuricemia, azospermia, amenorrhea, cardiotoxicity (myocardial necrosis) usually at doses higher than those used in this 
study. 
D
RUG INTERACTIONS  
Cyclophosphamide undergoes metabolic activation via cytochrome P450 3A4 in the liver and 
may potentially interact with any drug affecting the same isoenzyme. Inhibitors of 3A4 (e.g., 
itraconazole) could theoretically inhibit activation and inducers of 3A4 (e.g., phenytoin) could 
theoretically enh ance activation of cyclophosphamide to active alkylating species. For the most 
part, such interactions have not yet been documented clinically. 
10.5 Prednisone (Deltasone, miscellaneous)  
AVAILABILITY  
Commercially available in 1, 2.5, 5, 10, 20, 25, and 50 mg tablets, or as an oral solution or syrup 
- 5 mg/5 ml (in 5% alcohol); solution concentrate - 5 mg/ml (with 30% alcohol). Please refer to 
the FDA- approved package insert for prednisone for product information, and a comprehensive 
list of adverse events.  
STORAGE & STABILITY  
Version Date: 02/15/2018  56 Update #18 
CALGB 50303  
Store tablets, solutions and syrup in tightly closed containers at room temperature.  
ADMINISTRATION  
Oral.  
TOXICITY  
Side effects likely to be encountered with intermittent high doses include: GI (dyspepsia, 
ulceration), insomnia, and hyperglycemia. Occasionally a “withdrawal syndrome” after short -
term high doses, such as in this study, manifest muscle aches and pains. Immunosuppression with risk of infection is also seen.  
10.6 R ituximab  
A
VAILABILITY  
Rituximab is commercially available in 10 mL and 50 mL single -use vials containing 100 mg 
or 500 mg rituximab solution, respectively, at a concentration of 10 mg/mL. Please refer to the 
FDA -approved package insert for rituximab for product information, extensive preparation 
instructions, and a comprehensive list of adverse events.  
STORAGE & STABILITY  
Intact vials should be stored under refrigeration. Dilute solutions for infusion (1- 4 mg/mL) are 
stable for 24 hours under refrigeration, and for an additional 24 hours at room temperature. 
PREPARAT ION 
The desired dose of rituximab should be diluted in 0.9% NaCl or D 5W to a final concentration 
of 1-4 mg/mL. The solution should be mixed by gently inverting the bag. A
DMINISTRATION  
Oral pre -medication 650 mg of acetaminophen and 50- 100 mg diphenhydramine hydrochloride 
will be administered 30 to 60 minutes prior to starting each infusion of rituximab. Rituximab 
will be administered as an intravenous infusion at 375 mg/m2 on day 1 of each cycle of R -CHOP 
or DA- EPOCH -R, immediately prior to the start of che motherapy. The first rituximab infusion 
should be started at 50 mg/hr, and increased in 50- mg/hr increments every 30 minutes to a 
maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rat e of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes 
to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS 
PUSH OR BOLUS.  
T
OXICITY  
The most severe serious adverse events associated with rituximab include severe infusion reactions, tumor lysis syndrome, and severe mucocutaneous reactions. Severe infusion reactions 
consisting of hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation or cardiogenic shock may be fata l. Most reported fatal 
reactions occurred within 24 hours of the first dose of rituximab. 
Tumor lysis syndrome resulting in renal failure has been described, and occasional fatalities 
noted. Tumor lysis syndrome is more likely in patients with high numbers  of circulating 
malignant cells (≥ 25,000/µL). 
Severe mucocutaneous reactions associated with rituximab include Stevens- Johnson syndrome 
and toxic epidermal necrolysis. The onset of these reactions has been from 1 -3 weeks.  
Less severe infusion reactions ar e common with rituximab. These include fever, chills, and 
dyspnea. The mechanism of rituximab infusion reactions is thought to be secondary to release 
of cytokines. If a reaction occurs, then the infusion should be stopped until the symptoms 
resolve, and then restarted at a 50% slower rate.  
Version Date: 02/15/2018  57 Update #18 
CALGB 50303  
Recent reports describe hepatitis B reactivation with fulminant hepatitis, hepatic failure and 
death in some patients with hematologic malignancies treated with rituximab. The majority of 
these patients received rituximab in combination with chemotherapy. The median time to 
diagnosis of hepatitis was approximately 4 months after starting rituximab and approximately 1 
month after the last dose.  
Exacerbation or reactivation of other viral infections has also been reported w ith rituximab. 
Recent reports describe JC virus reactivation leading to progressive multifocal 
leukoencephalopathy (PML) in patients who were receiving rituximab. Patients presenting with 
new neurologic findings (e.g., major changes in vision, unusual eye movements, loss of balance 
or coordination, confusion) should be evaluated for PML. 
10.7 Filgrastim (G -CSF; r -met HuG -CSF; Granulocyte Colony Stimulating Factor; 
Neupogen®)  
AVAILABILITY   
Commercial filgrastim is available in 1 mL and 1.6 mL vials containin g 300 mcg and 480 mcg 
filgrastim, and in prefilled syringes containing 300 mcg/0.5 mL or 480mcg/0.8 mL. Please refer 
to the FDA -approved package insert for filgrastim for product information, extensive 
preparation instructions, and a comprehensive list of adverse events.  
STORAGE & STABILITY  
Intact vials and prefilled syringes should be stored in the refrigerator at 2 -8° Centigrade (36-46° 
Fahrenheit). Do not freeze.  
ADMINISTRATION  
Filgrastim will be administered as a subcutaneous injection. In both arms, t he daily dose will be 
480 mcg. In Arm A (CHOP -R), filgrastim (or pegfilgrastim) will be administered after subsequent cycles 
following the occurrence of grade 4 neutropenia or febrile neutropenia. Filgrastim will be given 
daily from Day 2 until ANC > 5000 after the nadir (nadir usually between Days 10 -12) or for 
10 days (Days 2 -11) if the ANC is not being monitored. 
In Arm B (EPOCH -R), filgrastim will be given daily from Day 6 until ANC > 5000 after the 
nadir (nadir usually between Days 10 -12) or for 10 day s (Days 6 -15) if the ANC is not being 
monitored, in all cycles.  
T
OXICITY  
The most common side effect associated with filgrastim is medullary bone pain. Bone pain is usually reported as mild or moderate and, if necessary, may be treated with non- opioid or opioid 
analgesics.  
10.8 Pegfilgrastim (Neulasta®) 
A
VAILABILITY  
Pegfilgrastim is commercially available prefilled single -dose syringes containing 6 mg/0.6 mL 
of pegfilgrastim (10 mg/mL). Please refer to the FDA -approved package insert for pegfilgrastim 
for p roduct information, extensive preparation instructions, and a comprehensive list of adverse 
events.  
STORAGE & STABILITY  
Intact syringes should be stored under refrigeration and protected from light. Pegfilgrastim 
syringes are reportedly stable at room temp erature for up to 48 hours prior to injection, if 
protected from light. Syringes that are frozen unintentionally may be allowed to thaw in the refrigerator. Pegfilgrastim syringes that have been frozen a second time should be discarded.  
Version Date: 02/15/2018  58 Update #18 
CALGB 50303  
ADMINISTRATION  
The dosage of pegfilgrastim is a single subcutaneous injection of 6 mg administered between 24 
and 36 hours after the completion of the cyclophosphamide infusion. Pegfilgrastim will be 
administered as a subcutaneous injection. In Arm A, pegfilgrastim (or filgr astim) will be 
administered after subsequent cycles following the occurrence  of grade 4 neutropenia or febrile 
neutropenia. Pegfilgrastim will be administered at a dose of 6 mg one time per cycle. If 
pegfilgrastim is given, the patient should not receive additional filgrastim.  
Note:  DA-EPOCH -R dosing has only been validated using filgrastim. Pegfilgrastim has 
different kinetics of neutrophil recovery and its use may adversely affect dosing and reduce 
disease cure rates. Use of pegfilgrastim must be approv ed by the Study Chair and will only be 
approved if the patient cannot receive filgrastim.  
TOXICITY  
The most common side effect associated with pegfilgrastim is bone pain. Bone pain is usually 
reported as mild or moderate, and, if necessary, may be treated with non- opioid or opioid 
analgesics.  
Other reported side effects include reversible elevations in LDH, alkaline phosphatase, and uric 
acid. These laboratory abnormalities are not usually of clinical significance and do not require 
any intervention. 
10.9 M ethotrexate (MTX, Folex)  
AVAILABILITY  
Methotrexate is commercially available in 2 mL (25 mg/mL) vials or 20 mg, 25, mg, 50 mg, or 100 mg vials for reconstitution. Read the manufacturer’s package labeling carefully for solution 
concentrations. Please refer to the agent’s package insert for additional information.  
S
TORAGE & STABILITY  
Unopened vials of methotrexate should be stored at room temperature, and protected from light.  
PREPARATION  
For intrathecal injection:  reconstitute to a concentration of 1 -5 mg/mL  with an appropriate 
sterile, preservative free medium such as Sodium Chloride Injection, USP.  
ADMINISTRATION  
In this study, methotrexate will be administered as an intrathecal injection of 12 mg. 
Methotrexate will be given to select patients in Arm A and Arm B, as described in Section 7.1.3  
and 7.2.3 . 
TOXICITY  
Toxicities associated with intrathecal administration:  arachnoiditis, ataxia, coma, confusion, 
dementia, encephalopathy, headache, paresis, sei zures.  
DRUG INTERACTIONS  
The use of NSAIDs, probenecid, salicylates, sulfonamides may prolong methotrexate levels and enhance toxicity. 
11.0 A
NCILLARY THERAPY  
11.1 Supportive Care  
Patients should receive full supportive care, including transfusions of blood and blood products, 
antibiotics, antiemetics, etc., when appropriate. The reason(s) for treatment, dosage, and the 
dates of treatment should be recorded on CALGB Form C-260 (Remarks Addenda). 
Version Date: 02/15/2018  59 Update #18 
CALGB 50303  
11.2 Hormones and Other Chemotherapeutic Agents  
Treatment with  hormones or other chemotherapeutic agents may not be administered except for 
steroids given for adrenal failure or hormones administered for non- disease- related conditions 
(e.g., insulin for diabetes) Use of dexamethasone and other steroidal anti -emetics is prohibited 
in this protocol.  
11.3 Epoetin  
The use of epoetin is allowed at the discretion of the investigator. It is recommended that epoetin 
not be used in this protocol unless hemoglobin is ≤ 10 g/dL, and that it be held or the dose 
modified for hemog lobin > 12 g/dL. 
12.0 C RITERIA FOR RESPONSE , PROGRESSION , AND RELAPSE  
R-CHOP patients will be re -evaluated after Cycles 4 and 6. DA -EPOCH -R patients will be re-
evaluated after Cycles 4 and 6.  
12.1 Definit ions of Response [61 ] 
12.1.1 Complete Response (CR) 
• Complete disappearance of all detectable clinical and radiographic evidence of target 
lesions and disappearance of all disease- related symptoms if present prior to therapy, as 
well as normalization of those biochemical abnormalities (e.g., LDH, etc.) def initely 
assignable to DLBCL.  
• All lymph nodes and nodal masses must have regressed to normal size (≤  1.5 cm in their 
greatest transverse diameter for nodes > 1.5 cm prior to therapy). Previously involved 
nodes that were 1.1 to 1.5 cm in their greatest tra nsverse diameter prior to treatment 
must have decreased to ≤ 1 cm in their greatest transverse diameter after treatment, or by more than 75% in the sum of the products of their greatest transverse diameters 
(SPD).  
• The spleen, if considered to be enlarged  before therapy on the basis of a CT scan, must 
have regressed in size and must not be palpable on physical examination. (No normal 
size can be specified, however, because of the difficulties in evaluating splenic and hepatic size.) Any macroscopic nodules  in any organs detectable on imaging studies 
should no longer be present. Similarly, other organs considered to be enlarged prior to therapy due to involvement of lymphoma (i.e., kidneys, liver, etc.) must have decreased 
in size.  
• If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must be cleared on repeat bone marrow aspirate and biopsy of same site.  
12.1.2 Complete Response Unconfirmed (CRu)  
Complete response/unconfirmed will include those patients who have met the criteria in  
Section 12.1.1
 bullet points 1 and 3, but with one or more of the following: 
• A residual node > 1.5 cm in greatest transverse diameter that has regressed more than 75% in the product of its diameters. Individual nodes that were previously confluent must 
have regressed more than 75% in the product of their diameters compared with the size 
of the original mass. PET is recommended at the end of treatment in patients with 
CRu. If positive, follow with repeat PET or biopsy. 
• Indet erminate bone marrow (increased number or size of aggregates without cytologic 
or architectural atypia).  
Version Date: 02/15/2018  60 Update #18 
CALGB 50303  
12.1.3 Partial Response (PR)  
• A decrease of ≥ 50% in the SPD of the six largest dominant nodes or nodal masses. 
These nodes or masses should be selected according to the following features: a) they should be clearly measurable in at least two perpendicular measurements; b) they should 
be from as disparate regions of the body as possible; and c) they should include mediastinal and retroperitoneal areas of disease whenever these sites are involved. PET 
is recommended at the end of treatment in patients with PR. If positive, follow with repeat PET or biopsy.   
• No increase in the size of other nodes, liver, or spleen. 
• Splenic and hepatic nodules must regress by at least 50% in SPD.  
• With the exception of splenic and hepatic nodules, involvement of other organs is 
considered assessable and not measurable disease.  
• Bone marrow assessment is irrelevant for determination of a PR because it is assessable 
and not measurable disease; however, if positive the cell type should be specified in the report, e.g., large -cell lymphoma.  
• No new sites of disease.  
12.1.4 Stable Disease (SD)  
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking 
as reference the smallest SPD since the treatment started.  
12.1.5 Progression (PD) or Relapse  
• ≥ 50% increase from nadir in the SPD of any previously identified abnormal node for 
PRs or nonresponders. 
• Appearance of any new lesion during or after completion of therapy. 
• PET+ is not a criterion for progressive disease. Patients only with PET+ findings must have evidence of progression on CT or biopsy proven. 
12.2 Response Assessment Table  
Response 
Category  Lymph Nodes  Splenic or Extranodal Sites  Bone Marrow  
CR Normal size  Negative  Negative for tumor  
CRu > 75% decrease and PET 
negative. If PET e quivocal, 
observe or biopsy. PET + is 
not a criterion for treatment 
failure.    Measurable sites > 75% decrease 
and PET negative. If PET equivocal, 
observe or biopsy. PET + is not a 
criterion for treatment failure. Non -
measurable (e.g. bone), MRI and CT 
improved and PET negative.  Negative for tumor  
PR   50-75% decrease or CRu 
with PET positive or biopsy 
positive.  Measurable sites 50 -75% decrease 
or CRu with PET positive or biopsy 
positive.  If positive for tumor, must 
have PR in measurable 
disease sites.  
SD  No Change ( Section 12.1.4 ) No change ( Section 12.1.4 ) No change ( Section 12.1.4 ) 
PD/Relapse  ≥ 50% increase from nadir 
or new site. PET + alone is not a criterion for treatment 
failure. Measurable sites ≥ 50% increase 
from nadir or new site. Non -
measurable (e.g. bone), evidence of progressive worsening on MRI/CT and PET positive. Strongly suggest 
biopsy.   Newly positive for tumor.  
Version Date: 02/15/2018  61 Update #18 
CALGB 50303  
12.3 Criteria for FDG -PET Respon se 
12.3.1 Primary Endpoint: IWG Criteria + FDG -PET Response 
The primary FDG -PET response endpoint is defined by visual reading of FDG uptake after 
Cycle 6 of chemotherapy. For responders, tumor FDG uptake is  
≤ ABP FDG uptake in all tumors, and no new avid lesions are seen. 
In a recent study, 54 patients with aggressive NHL underwent CT and PET exams 1 -16 
weeks after completing four to eight cycles of CHOP therapy. Each patient was assessed  for 
one of the following using the standard IWG criteria or the IWG criteria with PET: a 
complete response (CR), an unconfirmed complete response (CRu), a partial response (PR), 
stable disease (SD), and progressive disease (PD). Progression -free survival was also 
compared between IWG cri teria and IWG criteria + PET [70 ]. 
The study found that with IWG alone, 17 patients had a CR, seven had a CRu, 19 had a PR, 
nine had SD, and two had PD. By comparison, IWG + PET produced a significantly higher 
response rate: 35 patients had a CR, 12 had a PR, six had SD, one had PD, and zero had 
CRu. Additionally, extensive analysis revealed that when the response rates were measured by IWG criteria alone and compared to IWG criteria + PET, the IWG + PET assessments 
provided a more accurate response classification in patients with aggressive NHL.  
For this imaging companion study, the FDG -PET endpoint will be combined with IWG 
criteria to further assess and refine the improved response classification seen in the 54-
patient stu dy. 
12.3.2 Secondary Endpoints  
As secondary endpoints, metabolic response after Cycles 6 and 2 is defined by decreases in tumor SUV in the index tumors. In responders after Cycle 6, the ratio of tumor SUVmax to 
ABP SUVmean is ≤ 1.25 in all index tumors, and no FDG -PET uptake greater than 
background is seen in any other lesion. In responders after Cycle 2, tumor SUVmax is decreased ≥ 85% from baseline for index tumors, or the ratio of tumor SUVmax to ABP 
SUVmean is ≤ 1.75 in all index tumors, and no new avid lesions are seen.  
Because of uncertainty regarding the optimal values of tumor SUVmax decrement and tumor SUVmax to ABP SUVmean ratio, ROC curves will be calculated to determine the best values of these measurements as correlates of PFS and other measurem ents of clinical 
outcome. 
13.0 R
EMOVAL OF PATIENTS FROM PROTOCOL THERAPY  
13.1 Duration of Treatment 
13.1.1 CR/CRu & PR: Complete all required treatment cycles.  
13.1.2 Disease Progression  
Remove from protocol therapy any patient with rapid disease progression during treatment. 
PET positivity is not a criterion for treatment failure. Document details, including tumor 
measurements, on CALGB Form C -260 (Remarks Addenda). Patients with isolated disease 
progression in the CNS without evidence of systemic progres sion will remain on study and 
receive CNS directed treatment.  
13.2 Extra ordinary Medical Circumstances 
If, at any time the constraints of this protocol are detrimental to the patient’s health and/or the 
patient no longer wishes to continue protocol therapy , protocol therapy shall be discontinued. In 
this event:  
• Notify the Study Chair. 
Version Date: 02/15/2018  62 Update #18 
CALGB 50303  
• Document the reason(s) for discontinuation of therapy on CALGB Form C -260 (Remarks 
Addenda). 
• Continue to follow the patient for response, progression, toxicity, survival  and secondary 
malignancy, as indicated in Section 5.2 . 
14.0 S TATISTICAL CONSIDERATIONS  
14.1 Clinical Endpoints  
14.1.1 Sample Size and Power Estimates  
The primary clinical endpoint will be event- free survival (EFS) measured from 
randomization until documented progression or death from any cause. Sample size is 
determined based on this endpoint. Patients will be randomized with equal probability to 
treatment with R -CHOP or DA- EPOCH -R. Patients will be stratified according to the 
International Prognostic Index. 
Fifty -five percent (55%) of patients treated with R -CHOP are expected to be event- free at 
three years. This corresponds under exponential survival to median EFS of 3.5 years. With 430 patients (96 patients enrolled over 4.5 yea rs and followed for 3 years) a hazard ratio 
(HR) of 1.53 for R -CHOP versus DA -EPOCH -R is detectable with 90% power (2- sided 
logrank test, α=0.05). Two hundred forty -two (242) events are expected at the time of the 
final analysis. The targeted sample size w ill be inflated to 478 patients to allow for a 10% 
pathologic ineligibility rate. Accrual is expected to be approximately 106 patients per year (approximately 96 eligible). Analysis will be “intent- to-treat” as randomized for eligible 
patients (i.e., with an histologic diagnosis of diffuse large B cell lymphoma). 
As of protocol update #14, the following change has been made: 
Sample Size Increase: Given the fewer than predicted PET scans and biopsies on 50303 , 
accrual will be extended to 45 additional patients, for a total of 5 23 (=478+45 ) patients. 
Extended accrual will be limited to institutions and patients participating the required imaging companion study CALGB 580603. 
As of protocol update #17, the following change has been made: 
Revised final analysis timing due to low event rate:  At the protocol specified interim 
analysis at the time of the May 2015 Alliance DSMB meeting, the pooled event rate was 
much lower than that specified by the study design. The observed number of events at this time was 158 (based on protocol assumptions this would have been the time for final 
analysis with 242 events). In order to provide a timely final analysis, the final analysis plan 
was revised to reduce the study power from 90% to 80%. With 178 events, we have 80% 
power if  the hazard ratio between the two arms is 1.53 as specified by the original design. 
Based on the estimated pooled event rates, the final data analysis is now expected in May 
2016. By the current Kaplan- Meier estimate, there are no events after 6 years, so that we do 
not expect more events after 6 years of additional follow -up. So, the maximum number of 
events expected based on the current survival estimate is 194, which will occur about May 
2019 (i.e. after 6 years of additional follow -up). 
14.1.2 Secondary  Analysis  
Secondary endpoints will be response rate, overall survival (OS), and toxicity. Overall survival will be measured from randomization until death from any cause. 
Different treatment effects are expected in different biological subgroups. In a seco ndary 
analysis, the two arms will be compared adjusting for the subgroups, ABC and GCB. The 
interactions between treatment and the subgroups will be tested using a Cox regression model. We will also conduct the log- rank test for the treatment effect within  each subset.  
Version Date: 02/15/2018  63 Update #18 
CALGB 50303  
14.2 Interim Analysis 
14.2.1 Primary Endpoint  
Ten interim analyses are planned, five during the accrual period and five during the follow -
up period. Interim analyses for the primary endpoint of EFS will be conducted beginning 
when 18% of the expected total number of events (n=242) are observed. This should occur 
at approximately 2.5 years, during the accrual period. After this time, interim analyses will 
be conducted every six months corresponding with scheduled meetings of the Alliance  Data 
and Safety Monitoring Board (DSMB). It is estimated that these analyses will occur when 
0.18, 0.25, 0.33, 0.42, 0.52, 0.61, 0.70, 0.78, 0.86, and 0.93 of the expected total number of events have been observed. The Lan -DeMets analogue of the O’Brien -Fleming boundaries 
will be used (1 -sided α=0.05) truncating at 3.5. These boundaries are as follows: 3.5, 3.5, 
3.5, 3.28, 2.93, 2.70, 2.50, 2.40, 2.26, and 2.18. The final analysis will be conducted at the 2.10 boundary. 
14.2.2 Futility  
Futility testing will be co nducted at the times of interim analyses. The futility statistics 
calculated for HR=1.53 will be compared with the critical values with 1-sided α =0.0025 at 
the first 5 interim analyses and with 1 -sided α =0.005 at the following 5 interim analyses. 
This futi lity rule has about 86% of probability to reject DA -EPOCH -R when the two 
regimens have similar efficacy. If survival on one treatment arm is found to be superior at an interim analysis conducted during the accrual period and determination is made to curtai l 
enrollment to the inferior treatment arm, enrollment will continue on the superior regimen 
until the targeted sample size of 215 patients is reached.  
14.2.3 Toxicity  
Toxicity data will be provided to the DSMB from the first meeting after patient accrual.  If 
there exists significant evidence that one regimen has 10% or higher grade 5 toxicity from 
any cause at two -sided α=0.01 level, the study will be reviewed as grounds for amendment 
or early stopping. Grade 3 or 4 neutropenia/thrombocytopenia themselves should not be 
grounds for stopping the trial as they are goals of EPOCH -R to give the maximum 
deliverable doses of the chemotherapy by escalating with each course. However, if there are serious sequelae, such as an increase in hospitalizations due to toxic ities, serious/life -
threatening infections (pneumonia, sepsis, or bleeding, in excess of 20% in one regimen over the other at two- sided α=0.01 level), then the study will be reviewed for amendment or 
early stopping.  
14.2.4 Accrual Monitoring  
Accrual to this Phase III trial will be monitored according to the NCI guidelines. In addition, the proportion of eligible patients with usable biopsi es will be monitored. If at any time the 
proportion of patients with usable biopsies falls significantly below the assumed value of 0.75, consideration will be given to further modifying eligibility requirements or to 
increasing the targeted sample size.  
14.3 Molecular Characterization Studies  
The Staudt laboratory has recently profiled 197 DLBCLs using Affymetrix U133 A and B 
arrays, and this dataset has enabled us to perform power calculations to estimate the number of 
DLBCL tumors that we would need to analyze in order to achieve the molecular profiling goals of the trial.  
An endpoint of the trial is to test whether the gene expression signatures that were previously 
associated with sur vival following CHOP therapy [62] are associated with survival in eith er of 
the treatment arms of the prospective trial. The four gene expression signatures that were found 
to be correlated with survival were the germinal center B cell signature, the proliferation 
Version Date: 02/15/2018  64 Update #18 
CALGB 50303  
signature, the MHC class II signature and the lymph node signature [44]. These gene expression 
signatures were identified in the Affymetrix data set and their associations with survival are 
shown in Table 1: 
     
 Survival  # events/arm  # of patients   
 association  needed to detect  required/arm  Power to detect  
 relative risk per 2 - survival association  assuming75%  survival assocation  
 fold change in  (p<0.05) with 90%  biopsy rate and  assuming 215  
Signature  expression  power  30% event rate  patients/arm  
Germinal Center B 
Cell 0.36 27 119 0.99 
Proliferation  0.54 28 123 0.99 
MHC class II  3.42 37 163 0.96 
Lymph node  0.53 43 189 0.93 
     
GCB vs ABC DLBCL  1.54 56 248 0.86 
Table 1 shows the number of biopsies that we would need to be profiled in order to detect a 
significant association of these signatures with survival (p<0.05) in a new set of DLBCL patients with 90% power. These numbers were used to calculate how many eligible patients would need 
to be enrolled in the trial in order to detect these associations in each treatment arm assuming a 
75% success rate in ob taining biopsies and a 30% event rate. In addition, the survival difference 
between the GCB and ABC DLBCL subgroups in response to CHOP treatment [62,63] was used to calculate the number of biopsies that would be needed in order to observe the association with 
survival (p<0.05) with 90% power in the prospective clinical trial. As can be seen from this 
Table, a trial size of 430 eligible patients would allow all of these prognostic features to be 
evaluated in each treatment arm of the prospective trial with at least 86% power. A second goal 
of the trial is to develop new molecular predictors of survival for both of the therapeutic regimens being evaluated. Previous gene expression profiling in DLBCL involved patients 
treated with CHOP chemotherapy alone. Both  therapeutic regimens being evaluated in the 
proposed prospective trial differ from CHOP chemotherapy in important respects: one regimen 
adds rituximab to CHOP and the other regimen adds etoposide to CHOP and is delivered by 
continuous infusion using a dos e escalation scheme. Therefore, the previous predictors of 
survival following CHOP chemotherapy may not necessarily apply to these new regimens.  
The survival data from the proposed trial will be used to discover and validate new molecular 
predictors of sur vival for each therapeutic regimen. For such an analysis, both arms of the trial 
will be divided into a training set and a validation set of c ases, as was done previously [62 ]. The 
training set will be used to discover associations between gene expression and survival. The 
validation set will be used to test the prognostic models that are generated using the training set data. Using this procedure, the danger of over fitting the statistical models of survival to the data will be avoided.  
We will not know be forehand which gene expression signatures will be associated with survival 
in each arm. However, we can model the discovery of such signatures and their validation based 
on our experience with molecular profiling in the context of CHOP chemotherapy. Let us  assume 
that we wish to discover and validate a new gene expression signature that is associated with survival to the same degree as the proliferation signature. To discover an association of this 
magnitude with a statistical significance of p=0.01 and with 90% power, we would need to 
include 113 tumor biopsies in the training set. A p- value cutoff of 0.01 was chosen for the 
discovery phase based on our previous experience in creating a gene expression -based  outcome 
Version Date: 02/15/2018  65 Update #18 
CALGB 50303  
predictor for DLBCL [62]. At this signifi cance cutoff, all of the gene expression signatures in 
Table 1 were identified as associated with survival, but spurious associations between gene 
expression and survival were largely avoided. In the validation phase, we wish to verify the 
association of a  gene expression signature with survival (p<0.05) with 80% power. It is expected 
that multiple gene expression signatures will be discovered in the training set that influence survival. Therefore, a power of 80% will insure that most of these univariate pr edictors of 
survival will be validated within this prospective trial. Using the example of the proliferation 
signature, we would need to include 47 tumor biopsies in the validation set. Based on these 
modeling assumptions, 160 biopsies would need to be profiled in each arm of the clinical trial. 
This translates into a total trial accrual of 426, approximately 430 eligible patients, assuming a 
75% biopsy success rate.  
In summary, an accrual of 349 eligible patients to the prospective trial would be required  to test 
the importance of previously identified molecular predictors of outcome in DLBCL. An accrual 
of approximately 430 eligible patients would be required to discover and validate new molecular 
predictors of survival for both treatment regimens in the prospective trial.  
The intent of the genomic characterization is exploratory, aiming to identify somatic DNA 
mutations, copy number alterations, microRNA expression patterns, and DNA methylation events that are associated with biological or clinical attrib utes of the DLBCL tumors.  Recurrent 
genomic abnormalities that are present in at least 5% of patients will be identified and prioritized 
for analysis.  DLBCL cases will be divided into two subgroups based on the presence or absence 
of the abnormality.   
The data will be preprocessed for statistical analysis using the computing software appropriate 
for the used technology platforms. Associations with progression- free and overall survival will 
be assessed using the Kaplan -Meyer method.  A Fisher’s exact test  will be used to determine the 
association between these two patient subgroups and components of the International Prognostic 
Index (IPI) as categorical variables (age > 60; ECOG performance status > 1; Ann Arbor stage 
> II; Number of extranodal sites > 1;  LDH > 1X normal) as well as the IPI score (low (0 -1), 
intermediate (2 -3), high (4- 5)).  A Fisher’s exact test will also be used to determine the 
association between genomic abnormalities and previously defined molecular subtypes of DLBCL (ABC vs. GCB subt ypes).  
Joint prediction model will be developed using the gradient lasso method which provides variable selection and prediction model fitting [95, 96]. The developed prediction models will 
be validated using a cross -validation method (e.g. 10 -fold cross v alidation). The possible over-
fitting bias in the cross- validation result will be adjusted by using permutation method. Kaplan-
Meier curves will be estimated for the high - and low -risk groups as defined by the fitted 
prediction model and the IPI score groups and the log -rank test will be applied to compare the 
survival distributions among the groups to investigate if the discovered genomic markers are independent prognostic factors for PFS and OS.  
14.4 Study Size Requirements to Achieve Pharmacogenetic Goal s 
The primary objective of the pharmacogenetic portion of this study is the assessment of the discrepancy in event free survival (EFS), within both treatment arms, between the two genotypic groups (Group 1 and Group 2). For notational simplicity, let us de note individuals with ABCB1 
3454 CC genotypes by group 1 and individuals with CT or TT genotypes as group 2. The 
hypotheses of interest can be canonically presented as testing H
0: ∆=1 versus H 1: ∆>1, where ∆  
is the hazard ratio between group 1 and group 2 within an arm. 
Assuming that within each arm, the EFS in both groups follow exponential laws, with potentially 
different means, the hazard ratio is given by ∆i=M i,2/Mi,1 , where M i,1 and M i,2 denote median 
EFS for groups 1 and 2 in treatment arm i (1= R- CHOP and 2= DA- EPOCH -R) respectively.  
Version Date: 02/15/2018  66 Update #18 
CALGB 50303  
Out of the 430 eligible patients accrued to the study, we expect to have about 344 (roughly 80%), 
which corresponds to n=172 per treatment arm, available for pharmacogenetic sampling. The 
putative prevalence rates for groups 1 and 2 are 0.30 and 0.70 respectively [64]. This 
corresponds to n 1=52 and n 2=120 patients accrued to groups 1 and 2 in each arm. 
Needless to say, given the small sample size only large discrepancies (as quantified by the hazard ratio, will be detectable with large power. The accrual and follow -up periods are 4.5 and 3 years 
respectively. Under the given setup, we will consider the power of two- sided log- rank test, 
assuming exponential survival for both groups, for testing H
0: ∆i=1 versus the local alt ernative 
H1: ∆i=∆, for ∆>1, at a level of significance of α=0.025 (as a crude adjustment for testing the 
hypothesis for each of the two arms, we have used 0.05/2), for various choices of M 1,i and ∆. 
Table 2 illustrates, for M 1,i ε (2.5,3.0,3.5,4.) years, the smallest hazard ratio ∆ that is detectable 
with at least a power of 0.6 and 0.7: 
Table 2 Power analysis of pharmacogenetic studies  
M1,i ß M2,i Power  
2.5 1.66 4.12 0.60 
2.5 1.76 4.40 0.70 
3.0 1.70 5.10 0.60 
3.0 1.81 5.43 0.70 
3.5 1.75 6.13 0.60 
3.5 1.87 6.55 0.70 
4.0 1.80 7.20 0.60 
4.0 1.93 7.72 0.70 
Secondary Objectives : We will also look at the above questions in the context of other 
genotypes in additional candidate genes of putative importance. The pharmacogenetic analysis 
related to these candidate genes will be conducted as a secondary exploratory analysis of gene-
toxicity, gene -response, and gene -survival relationships. The association between genes 
implicated in metabolism, transporter and clinical phenotype (systemic toxicity, response, a nd 
survival) will be performed by construction of hazard ratios or other appropriate non- parametric 
techniques.  
14.5 Overview of FDG -PET/CT Study (CALGB 580603) 
This is a multi -center, prospective study in which 170 patients who consent will undergo 
PET/CT scans at baseline, post- Cycle 2, and post -Cycle 6. Scans will be read without the 
baseline scan, and then again with the baseline scan and knowledge of other relevant clinical 
information. Response (both PET and CT) will be assessed by consensus readings made in the 
context of the baseline scan and knowledge of clinical data. To be classified as a responder, all 
index tumors of the patient must meet the criteria for response and no other evidence of 
lymphoma progression should be present. The accrual goal of 300 patients was changed to 170 
patients because of an unexpectedly low accrual rate to CALGB 580603 among the patients who 
had entered into CALGB 50303 by November 2008. The revised sample size of 170 patients is 
based on the assumption that the FDG -PET study can accrue about 55% of patients that will 
ultimately accrue to CALGB 50303.  
The primary focus of this FDG -PET/CT companion will be a comparison of the ability of PET 
plus IWG criteria after Cycle 6 to predict occurrence of an event or no event wit hin three years 
to that of IWG criteria alone. An event is defined here as progression or death from any cause. Secondary endpoints include the predictive ability, sensitivity and specificity of PET after Cycle 
2. Sensitivity and specificity describe the ability to distinguish between those who have and 
Version Date: 02/15/2018  67 Update #18 
CALGB 50303  
those who do not have an event within three years. ROC curves will also be constructed as 
secondary endpoints for results that are on a continuous scale.  
14.5.1 FDG -PET/CT Imaging Endpoints and Analyses  
14.5.1.1 Test of Sensitivity and Specificity of PET + IWG Criteria vs IWG Criteria Alone  
Let for a patient, D=1 if the event time is shorter than 3 years and D=0 otherwise, and X=1 if the patient is a non- responder by an imaging method (PET + IWG or IWG) and 
X=0 otherwise. Responders are those with a complete response (CR) or complete 
response unconfirmed (CRu). Sensitivity of the imaging is defined as p=(X=1 D=1) 
and specificity is defined as q=(X=0 D=0). 
Response with PET + IWG criteria evaluated will be defi ned according to the criter ia 
outlined by Juweid et al. [75]. The consensus read will be used as the primary 
assessment of response.  
Only patients who have both PET and IWG criteria evaluated will be used for the 
analyses in this companion study. The study  is designed to establish (1) non- inferiority 
of the sensitivity for PET + IWG criteria, and (2) the superiority of the specificity of PET + IWG criteria compared to that of IWG criteria alone.  
14.5.1.2 Semi -Quantitative Measurements of FDG Uptake  
The predictive ability and accuracy of SUV -based measurements will be estimated. 
Sensitivity/specificity and responder and non- responder predictive values, 
P(D=0X=0) and P(D=1 X=1), respectively, will be estimated, with response defined 
as the ratio of tumor SUVm ax to ABP SUVmean for all index tumors ≤ 1.25 (and no 
evidence of lymphoma by visual reading of total scan). ROC curves will be estimated using SUVmax decrement and the tumor SUVmax ratio to ABP SUVmean ratio. 
14.5.1.3 Accuracy of Cycle 2 PET Scan  
The predictive ability and accuracy of SUV -based measurements after Cycle 2 will be 
estimated. Here, response is defined as a tumor SUVmax decrease of ≥ 85% from 
baseline or a ratio of tumor SUVmax to ABP SUVmean ≤ 1.75.  
Chi-square test(s) will be conducted to de termine if Cycle 2 PET/CT measurements 
can predict clinical response, and EFS and OS using a cutoff of 3 years. The log -rank 
test will be used to compare the raw data of EFS and OS between Cycle 2 PET+ and 
PET- patient groups. 
Response at Cycle 2 will be compared to that at Cycle 6 and patient status at three years post -enrollment (i.e., progression free or not progression free at three years). 
ROC curves will also be estimated to compare Cycle 2 PET outcome with Cycle 6 PET 
outcome in terms of EFS at 3 years using the methods of Delong et al. [92] if there is 
no censoring withi n 3 years or Heagerty et al. [93 ] in the presence of censoring within 
3 years. The correlation between Cycle 2 PET outcome and Cycle 6 PET outcome will 
be tested by using 2x2 Chi -squa re test(s) for binary variables and by using regression 
methods for continuous variables.  
14.5.1.4 Evaluating Treatment Effect 
Regression analysis will consider the effect of treatment on the predictive values. This 
will be evaluated with either regression  models for predictive values [91 ] or with a Cox 
model. A multivariate analysis using a Cox regression model will be conducted 
Version Date: 02/15/2018  68 Update #18 
C A L G B 5 0 3 0 3  
i ncl u di n g P E T + I W G criteria, I W G criteria, treat me nt, a n d ot her pre dict ors t o see if 
a n y of t he i ma gi n g criteria are i n de pe n de nt pre dict ors.  
1 4. 5. 1. 5  E v al u ati n g I nter- I nstit uti o n al Re pr o d uci bilit y of P E T/ C T Me as ure me nts  
C o nc or da nce rate will be esti mate d bet wee n t he rea di n g fr o m eac h i nstit uti o n a n d t hat 
fr o m t he C ore La b.  T he varia nce of t he esti mate d c o nc or da nce rate will be a dj uste d 
f or p ossi ble cl usteri n g effect a m o n g differe nt i nstit uti o ns (e. g., J u n g a n d A h n) [ 9 4 ].  
1 4. 5. 2 S a m ple Size C o nsi der ati o ns  
A  t otal  of  m = 1 7 0  patie nts  will  be  accr ue d  t o  t his  F D G -P E T/ C T  c o m pa ni o n  st u d y.  T he 
a d diti o n of P E T t o I W G is e x pecte d t o i m pr o ve t he s pecificit y, b ut n ot t he se nsiti vit y. S o, 
t he p o wer a nal yses bel o w are base d o n t he paire d t w o -sa m ple tests f or ( 1) t he n o n -i nferi orit y 
of P E T + I W G i n se nsiti vit y, H 0: p 1= p 2-0 vers us H 1: p 1> p 2-0, a n d ( 2) t he s u peri orit y of 
P E T + I W G i n s pecificit y, H 0: q 1= q 2 vers us H 1: q 1> q 2. Here, p 1 a n d p 2 ( q 1 a n d q 2) are t he 
se nsiti vities  (s pecificities)  of  P E T  +  I W G  a n d  I W G,  res pecti vel y.  We  ass u me  t hat  a 
differe nce of 0= 0. 1 or s maller i n  se nsiti vit y is c o nsi dere d t o be wit hi n t he n o n -i nferi orit y 
li mit.  
Pair e d t w o -sa m ple tests are use d f or t he s u peri orit y a n d n o n -i nferi orit y tests. F or e xa m ple, 
f or t he patie nt i( = 1, …, m) w h ose e ve nt ti me is s h orter t ha n 3 years ( D i= 1), t he n o n -i nferi orit y 
test rej ects H 0: p 1= p 2-0 if m 1/ 2 ( P 1- P 2)/ S is lar ger t ha n z 1- α, w here P k is t he sa m ple esti mate 
of p k a n d S 2 is t he mea n s u m of s q uares of X 1i - X 2i +0. T he p o wer of t hese tests de pe n ds o n 
t he c orrelati o n c oefficie nt bet wee n X 1i  a n d X 2i . Preli mi nar y data are base d o n J u wei d et al . 
[ 7 5]. T he rele va nt ta bles are pr o vi de d bel o w: 
T hree -ye ar E F S t a bles  
Pr o gressi o n or deat h b y year 3 ( D = 1): 
 I W G Criteri a  
N o n -res p o n der  Res p o n der  
P E T + I W G 
Criteri a  N o n -res p o n der  1 3  1 
Res p o n der  2 4 
 
N o pr o gressi o n ( or deat h) b y year 3 ( D = 0): 
 I W G Cri teri a  
N o n -res p o n der  Res p o n der  
P E T + I W G 
Criteri a  N o n -res p o n der  4 1 
Res p o n der  1 1  1 8  
T he  esti mate d  se nsiti vities  are  P 1= 0. 7  a n d  P 2= 0. 7 5  fr o m  t he  first  ta ble  ( D = 1),  a n d  t he 
esti mate d s pecificities are Q 1= 0. 8 5 a n d Q 2= 0. 5 6 fr o m t he sec o n d ta ble ( D = 0). Fr o m b ot h 
ta bles, t he c orrelati o n c oefficie nt bet wee n X 1i  a n d X 2i  is a b o ut 0. 3. Ass u mi n g 5 5 % are e ve nt 
free at 3 years, a b o ut 7 7 of N = 1 7 0 patie nts will be i n t he D = 1 gr o u p a n d a b o ut 9 3 will be i n 
t he D = 0 gr o u p. I n t he f oll o wi n g p o wer calc ulati o ns, we ass u me o ne-si de d α= 0. 0 5 a n d a 
c orrelati o n c oefficie nt of 0. 3. Wit h 7 6 patie nts i n t he D = 1 gr o u p, t he n o n -i nferi orit y test of 
P E T  +  I W G  i n  se nsiti vit y  has  5 5 %  p o wer  t o  detect  a n  alter nati ve  h y p ot hesis  of 
H1: p 1= p 2= 0. 7 5, a n d 8 4 % p o wer t o detect H 1: p 1= 0. 8, p 2= 0. 7 5. N o te t hat, beca use of t he s mall 
Versi o n Date: 0 2 /1 5/ 2 0 1 8  6 9  U p date # 1 8 
CALGB 50303  
sample size, the non- inferiority test will not have enough power unless PET + IWG has a 
larger sensitivity than IWG (i.e. p 1>p2). 
With 93 patients in the D=0 group, the superiority test of PET + IWG in specificity has 82% 
powe r to detect an alternative hypothesis of H 1:q1=0.7, q 2=0.55, and 93% power to detect 
H1:q1=0.75, q 2=0.55. 
15.0 A DVERSE EVENT REPORTING (AER) 
Investigators are required by Federal Regulations to report serious adverse events as defined in the table below.  CTCAE term (AE description) and grade: The descriptions and grading scales found in 
the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized until March 31, 2018 for AE reporting. CTCAE version 5.0 will be utilized for AE reporting 
beginning April 1, 2018. All appropriate treatment areas should have access to a copy of the CTCAE version 5.0. A copy of the CTCAE version 5.0 can be downloaded from the CTEP web site 
 All reactions 
determined to be “reportable" in an expedited manner must be reported using the CTEP Adverse 
Event Reporting System (CTEP -AERS ). Reporting of cases of secondary AML/MDS should be done 
using CTEP- AERS . New primary malignancies should be reported using Study Form C-1001. 
The Alliance  requires investigators to route all adverse event reports (AERs) through the 
Central Office for Alliance -coordinated studies.  
CALGB 50303 Adverse Event Reporting Requirements  
Phase 2 and 3 Trials: CTEP -AERS  Expedited Reporting Requirements for Adverse Events 
That Occur Within 30 Days
1 of the Last Dose of Treatment  
  
Grade 1   
Grade 2   
Grade 2   
Grade 3   
Grade 3  Grades  
4 & 52 Grades  
4 & 52 
Unexpected  
and 
Expected   
 
Unexpected   
 
Expected  Unexpected  Expected  
Unexpected  Expected  With  
hospitali-
zation  Without 
hospitali-  
zation  With  
hospitali
-zation  Without 
hospitali
-zation  
Unrelated  
Unlikely  Not 
Required  Not 
Required  Not 
Required  10 
Calendar 
Days  Not 
Required  10 
Calendar 
Days  Not 
Required  10 Calendar 
Days  10 
Calendar 
Days  
Possible  
Probable  
Definite  Not 
Required  10 Calendar 
Days  Not 
Required  10 
Calendar 
Days  10 
Calendar 
Days  10 
Calendar 
Days  Not 
Required  24-Hrs; 
5 Calendar 
Days  10 
Calendar 
Days  
1 Adverse events with attribution of possible, probable, or definite that occur greater  than 30 days after the last 
dose of treatment require reporting as follows:  
CTEP -AERS  24-hour notification followed by c omplete report within 5 calendar days for:  
• Grade 4 and Grade 5 unexpected events  
 CTEP -AERS  10 calendar day report:  
• Grade 3 unexpected events with hospitalization or prolongation of hospitalization  
• Grade 5 expected events  
 
2 Although a CTEP -AERS  24-hour n otification is not required for death clearly related to progressive disease, a full 
report is required as outlined in the table.  
March 2005  
Note: All deaths on study require both routine and expedited reporting regardless of causality. Attribution to tre atment or other cause should be provided.  
• Expedited AE reporting timelines defined: 
Version Date: 02/15/2018  70 Update #18 

CALGB 50303  
 “24 hours; 5 calendar days” – The investigator must initially report the AE via CTEP -
AERS  within 24 hours  of learning of the event followed by a complete CTEP -AERS  
report within 5 calendar days  of the initial 24 -hour report. 
 “10 calendar days” - A complete CTEP- AERS  report on the AE must be submitted 
within 10 calendar days  of the investigator learning of the event.  
• Any medical event equivalent to CTCAE grade 3, 4, or 5 that precipitates hospitalization 
(or prolongation of existing hospitalization) must be reported regardless of attribution and 
designation as expected or unexpected with the exception of any events identified as 
protocol- specific expedited adverse even t reporting exclusions (see below). 
• Any event that results in persistent or significant disabilities/incapacities, congenital anomalies, or birth defects must be reported via CTEP -AERS . 
• Use the NCI protocol number and the protocol -specific patient ID p rovided during trial 
registration on all reports.  
Additional Instructions or Exclusions to CTEP -AERS  Expedited Reporting Requirements 
for Phase 2 and 3 Trials: 
• Grade 3 or 4 myelosuppression and hospitalization resulting from grade 3 or 4 
myelosuppression do not require CTEP -AERS , but should be submitted as part of study 
results.  
• Grade 3 constipation and hospitalization resulting from such do not require CTEP -AERS , 
but should be submitted as part of study results. 
• Grade 3 sensory or motor neuropathy and hospitalization resulting from such do not require CTEP -AERS , but should be submitted as part of study results. 
• Grade 3 nausea or vomiting and hospitalization resulting from such do not require CTEP -
AERS , but should be submitted as part of study result s. 
• A list of specific expected adverse events can be found in Section 10.0
 (Drug Formulation, 
Availability, and Preparation). 
• For the purposes of expedited adverse event reporting, the CAEPR for rituximab may be 
found in Section 15.1  below.  
• Exacerbation or reactivation of serious viral infections (e.g., hepatitis, JC) as described in Section 10.10
 should be reported via CTEP -AERS  within 10 calendar days of the 
investigat or learning of the event. 
• CTEP -AERS  reports are to be submitted electronically 
 
• The reporting of adverse events described in the table above is in addition to and does not 
supplant the reporting of adverse events as part of the report of the results of the clinical 
trial, e.g., study summary forms or cooperative group data reporting forms (see Section 5.2  
for required CALGB forms).  
• All adverse events reported via CTEP -AERS  (i.e., seri ous adverse events) should also be 
forwarded to your local IRB.
Version Date: 02/15/2018  71 Update #18 

CALGB 50303  
15.1 Comprehensive Adverse Events and Potential Risks List (CAEPR) for Rituximab (NSC 
687451) 
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a single list of reporte d and/or potential adverse events (AE) associated with an agent using a uniform 
presentation of events by body system. In addition to the comprehensive list, a subset , the Agent 
Specific Adverse Event List (ASAEL), appears in a separate column and is ident ified with  bold 
and italicized  text. This subset  of AEs (ASAEL) contains events that are considered 'expected' 
for expedited reporting purposes only. Refer to the 'CTEP, NCI Guidelines: Adverse Event 
Reporting Requirements' 
 for 
fur
ther clarification. Frequency is provided based on 986 patients. Below is the CAEPR for 
Rituximab.  
 
Version 2.1, March 19, 20101 
 
 Adverse Events with Possible  
 Relationship to Rituximab  
 (CTCAE 4.0 Term)  
[n= 986]  
   
 EXPECTED AEs FOR 
CTEP -AERS  REPORTING  
Agent Specific Adverse Event 
List 
(ASAEL)  
 
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)   Expected  
BLOOD AND LYMPHATIC SYSTEM DISORDERS    
 Anemia    Anemia  
 Blood and lymphatic system 
disorders - Other (Hyperviscosity: 
Waldenstrom’s)    Blood and lymphatic system 
disorders - Other 
(Hyperviscosity: 
Waldenstrom’s)  
 Febrile neutropenia    Febrile neutropenia  
CARDIAC DISORDERS    
 Myocardial infarction    Myocardial infarction  
 Sinus tachycardia    Sinus tachycardia  
 Supraventricular tachycardia    Supraventricular tachycardia  
GASTROINTESTINAL DISORDERS    
 Abdominal pain    Abdominal pain  
 Diarrhea    Diarrhea  
 Nausea    Nausea  
 Vomiting    Vomiting  
GENERAL DISORDERS AND ADMINISTRA TION SITE CONDITIONS    
Chills     Chills  
 Edema limbs     
 Fatigue    Fatigue  
Fever     Fever  
Infusion related reaction     Infusion related reaction  
 Pain    
IMMUNE SYSTEM DISORDERS    
 Allergic reaction    Allergic reaction  
  Anaphylaxis    
 Serum sick ness   Serum sickness  
INFECTIONS AND INFESTATIONS    
Version Date: 02/15/2018  72 Update #18 

CALGB 50303  
 Infection2 
 
 
   Infection2 
 Infections and infestations - Other 
(Activation of Hepatitis B, C, 
CMV, parvovirus B19, JC virus, 
varicella zoster, herpes simplex, 
West Nile virus)    Infections and infest ations - 
Other (Activation of Hepatitis 
B, C, CMV, parvovirus B19, JC 
virus, varicella zoster, herpes 
simplex, West Nile virus)  
 Infections and infestations - Other 
(Infection in HIV Positive 
Patients)     
INVESTIGATIONS    
Lymphocyte count 
decreased     Lymphocyte count decreased  
 Neutrophil count decreased    Neutrophil count decreased  
 Platelet count decreased    Platelet count decreased  
 White blood cell decreased    White blood cell decreased  
METABOLISM AND NUTRITION DISORDERS    
 Hyperglycemia     
 Hypocalcemia    Hypocalcemia  
 Hypokalemia     
  Tumor lysis syndrome   Tumor lysis syndrome  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS    
 Arthralgia    Arthralgia  
 Back pain     
 Myalgia    Myalgia  
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CY STS AND 
POLYPS)    
 Tumor pain    Tumor pain  
NERVOUS SYSTEM DISORDERS    
 Dizziness    Dizziness  
 Headache    Headache  
 Lethargy     
  Nervous system disorders - 
Other (progressive multifocal 
leukoencephalopathy)    
 Seizure    Seizure  
RENAL AND URINARY DI SORDERS    
 Acute kidney injury     
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS    
  Adult respiratory distress 
syndrome    
 Allergic rhinitis     
 Bronchospasm    Bronchospasm  
 Cough    Cough  
 Dyspnea    Dyspnea  
 Hypoxia    Hypoxia  
 Pneumonitis    Pneu monitis  
 Sore throat     
SKIN AND SUBCUTANEOUS TISSUE DISORDERS    
Version Date: 02/15/2018  73 Update #18 
CALGB 50303  
  Erythema multiforme   Erythema multiforme  
 Hyperhidrosis    Hyperhidrosis  
 Pruritus    Pruritus  
 Rash maculo -papular    Rash maculo -papular  
 Skin and subcutaneous tissue 
disorders - Othe r (angioedema)     
  Stevens -Johnson syndrome   Stevens -Johnson syndrome  
  Toxic epidermal necrolysis   Toxic epidermal necrolysis  
 Urticaria    Urticaria  
VASCULAR DISORDERS    
 Flushing    Flushing  
 Hypertension    Hypertension  
 Hypotension    Hypotension  
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all Principal 
Investigators at the time of revision.  The current version can be obtained by contacting   
Your name, the nam e of t he investigator, the protocol and the agent should be included in the e- mail.  
 
2Infection includes all 75 sites of infection under the INFECTIONS AND INFESTATIONS SOC.  
 
3Gastrointestinal obstruction includes Colonic obstruction, Duodenal obstruction,  Esophageal obstruction, Ileal 
obstruction, Jejunal obstruction, Obstruction gastric, Rectal obstruction, and Small intestinal obstruction under the 
GASTROINTESTINAL DISORDERS SOC.  
 
4Gastrointestinal perforation includes Colonic perforation, Duodenal perforation, Esophageal perforation, Gastric 
perforation, Ileal perforation, Jejunal perforation, Rectal perforation, and Small intestinal perforation under the GASTROINTESTINAL DISORDERS SOC.  
 Also reported on rituximab trials but with the relationship to rituximab still undetermined:  
 BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Bone marrow hypocellular; Hemolysis  
CARDIAC DISORDERS  - Atrial fibrillation; Atrial flutter; Cardiac disorders - Other (cyanosis); Left ventricular 
systolic dysfunction; Sinus bradycardia; Ventricular fibrillation  
EYE DISORDERS  - Conjunctivitis; Eye disorders - Other (ocular edema); Uveitis; Watering eyes  
GASTROINTESTINAL DISORDERS  - Constipation; Dyspepsia; Dysphagia; Gastrointestinal obstruction
3; 
Gastrointestinal perforation4; Mucositis or al 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Flu like symptoms; Non -cardiac 
chest pain  
INFECTIONS AND INFESTATIONS  - Infections and infestations - Other (Opportunistic infection associated with 
>=Grade 2 Lymphopenia)  
INJURY, POISONING AND PROCEDURAL COMPLICATIONS  - Fracture 
INVESTIGATIONS  - Alkaline phosphatase increased; Aspartate aminotransferase increased; Blood bilirubin 
increased; Cardiac troponin I increased; Cardiac troponin T increased; Creatinine increased; Investigations - Other 
(hype rphosphatemia); Investigations - Other (LDH increased); Weight loss  
METABOLISM AND NUTRITION DISORDERS  - Anorexia; Hypercalcemia; Hyperkalemia; Hypermagnesemia; 
Hypernatremia; Hyperuricemia; Hypoglycemia; Hypomagnesemia; Hyponatremia  
MUSCULOSKELETAL AND CO NNECTIVE TISSUE DISORDERS - Arthritis  
NERVOUS SYSTEM DISORDERS  - Nervous system disorders - Other (Cranial Neuropathy NOS); Peripheral 
motor neuropathy; Peripheral sensory neuropathy; Pyramidal tract syndrome; Reversible posterior leukoencephalopathy syndrome; Syncope  
PSYCHIATRIC DISORDERS  - Agitation; Anxiety; Depression; Insomnia  
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS  - Epistaxis; Pharyngolaryngeal pain; Pleural 
effusion; Pulmonary edema; Respiratory, thoracic and mediastinal disorders - Other (b ronchiolitis obliterans)  
Version Date: 02/15/2018  74 Update #18 

CALGB 50303  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  - Alopecia; Skin and subcutaneous tissue disorders - Other 
(paraneoplastic pemphigus) 
VASCULAR DISORDERS  - Phlebitis; Thromboembolic event; Vasculitis  
 Note : Rituximab in combination with othe r agents could cause an exacerbation of any adverse event currently known 
to be caused by the other agent, or the combination may result in events never previously associated with either agent.  
Version Date: 02/15/2018  75 Update #18 
CALGB 50303  
16.0 R EFERENCES  
1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, 
Jr., Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy 
regimens for advanced non -Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006. 
2.  Martelli M, Gherlin zoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, Falini B, Storti 
S, Meloni G, Rizzo M, Molinari AL, Lauria F, Moretti L, Lauta VM, Mazza P, Guardigni L, Pescarmona E, Pileri SA, Mandelli F, Tura S. Early autologous stem -cell transplantation versus  
conventional chemotherapy as front -line therapy in high -risk, aggressive non -Hodgkin's 
lymphoma: an Italian multicenter randomized trial. J Clin Oncol. 2003;21:1255-1262. 
3. Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H, Karakas T, Metzner 
B, Hossfeld DK, Bischoff HG, Franke A, Reiser M, Muller P, Mantovani L, Grundeis M, Rothmann F, von Seydewitz CU, Mesters RM, Steinhauer EU, Krahl D, Schumacher K, Kneba 
M, Baudis M, Schmitz N, Pfab R, Koppler H, Parwaresch R, Pfreundschuh M, Havemann K. 
Randomized study to evaluate the use of high -dose therapy as part of primary treatment for 
"aggressive" lymphoma. J Clin Oncol. 2002;20:4413-4419. 
4. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molin a TJ, Gisselbrecht C, Reyes F. Intensive conventional chemotherapy (ACVBP regimen) 
compared with standard CHOP for poor -prognosis aggressive non -Hodgkin lymphoma. Blood. 
2003;102:4284-4289. 
5. Pfreundschuh M TL, Kloess M et al. 2- weekly vs. 3 -weekly CHOP w ith and without etoposide 
in for patients >60 years of age with aggressive non -Hodgkin's lymphoma (NHL): Results of 
the completed NHL-B-2 trial of the DSHNHL. Blood. 2002;99:Abstract 3060. 
6. Pfreundschuh M TL, Schmits R, et al. 2- weekly vs. 3- weekly CHOP with and without 
etoposide in young patients with low -risk (low LDH) aggressive non -Hodgkin's lymphoma: 
Results of the completed NHL -B-1 trial of the DSHNHL. Blood. 2002;99:Abstract # 340. 
7. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste 
E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large -B-cell lymphoma. 
N Engl J Med. 2002;346:235-242. 
8. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo- Lopez A, Gilman P, Lowe A, Kunkel 
LA, Fisher RI. Phase II study of rituximab in combination with chop chemotherapy in patients 
with previously untreated, aggressive non -Hodgkin's lymphoma. J Clin Oncol. 2001;19:389-
397. 
9. Habermann TM WE, Morrison VA, Cassileth PA, Cohn JB, Dakhil SR, Gascoyne RD, Woda B, Fisher RI, Peterson BA, Horning SJ. Phase III Trial of Rituximab- CHOP (R -CHOP) vs. 
CHOP with a Second Randomization to Maintenance Rituximab (MR) or Observation in Patient s 60 Years of Age and Older with Diffuse Large B -cell Lymphoma (DLBCL). 
Proceedings American Society of Hematology. 2003;102:Abstract 8. 
10. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Gaulard P, Coiffier B. Rituximab plus CHOP (R -CHOP) 
overcomes bcl -2--associated resistance to chemotherapy in elderly patients with diffuse large 
B-cell lymphoma (DLBCL). Blood. 2003;101:4279-4284. 
11. Lai GM, Chen YN, Mickley LA, Fojo AT, B ates SE. P -glycoprotein expression and schedule 
dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991;49:696-703. 
Version Date: 02/15/2018  76 Update #18 
CALGB 50303  
12. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson 
WH. Role of a doxorubicin- containing regimen in relapsed and resistant lymphomas: an 8 -year 
follow-up study of EPOCH. J Clin Oncol. 2000;18:3633-3642. 
13. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little 
RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, 
Chabner BA, Wittes R, Balis F. Dose -adjusted EPOCH chemotherapy for untreated large B -
cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685-2693. 
14. Wilson WH PS, Gutierrez M, et al. Dose- Adjusted EPOCH -Rituximab in Untreated Diffuse 
Large B -cell Lymphoma: Benefit of Rituximab Appears Restricted to Tumors Harboring Anti -
apoptotic Mechanisms. Proceedings American Society of Hematology. 2003;102. 
15. Wilson WH, Teru ya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M. 
Relationship of p53, bcl -2, and tumor proliferation to clinical drug resistance in non-Hodgkin's 
lymphomas. Blood. 1997;89:601-609. 
16. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, 
Marolleau JP, Diebold J, Reyas F, Gaulard P. Prognostic significance of bcl -2 protein 
expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de 
l'Adulte (GELA). Blood. 1996;87:265-272. 
17. Miller TP,  Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg 
CR, Levy N, Nathwani BN, et al. Prognostic significance of the Ki -67-associated proliferative 
antigen in aggressive non -Hodgkin's lymphomas: a prospective Southwest Oncology Group 
trial. Blood. 1994;83:1460-1466. 
18. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T. 
Mutations of the p53 gene as a prognostic factor in aggressive B -cell lymphoma. N Engl J Med. 
1997;337:529-534. 
19. Loni L, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drugs in non-Hodgkin 
lymphomas. Br J Cancer. 2001;85:1425-1431. 
20. Wilson WH, Gutierrez M, O'Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML. The role of rituximab and chemotherapy in aggressive B -cell ly mphoma: a preliminary report of 
dose-adjusted EPOCH-R. Semin Oncol. 2002;29:41-47. 
21. Jaffe ES, Harris NL, Stein H, Vardiman JW eds. Tumours of Haematopoietic and Lymphoid Tissues. In: P. K, L.H. S eds. World Health Organization Classification of Tumours (ed First). 
Lyon: IARC Press; 2001. 
22. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf -Peeters C, 
Falini B, Gatter KC. A revised European -American classification of lymphoid neoplasms: a 
proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392. 
23. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, 
Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, Lewis DB, 
Tibshirani R, Sherlock G, Chan WC, Greiner  TC, Weisenburger DD, Armitage JO, Warnke R, 
Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of 
diffuse large B -cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-
511. 
24. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller -
Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger 
DD, Sanger WG, Dave  BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez -Guillermo 
Version Date: 02/15/2018  77 Update #18 
CALGB 50303  
A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke 
T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse 
large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947. 
25. Miller TP LM, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non -Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) 
randomized trial. Proceedings American Society of Hematology. 2001;98:Abstract # 3024. 
26. Horning SJ GJ, Kim K et al. Final report of E1484: CHOP v CHOP + Radiotherapy (RT) for limited stage diffuse aggressive lymphoma. Proceedings American Society of Hematology. 
2001;98:Abstract # 3023. 
27. Reyes F LE, Munck, JN, Morel P, Coiffier B, Lederlin P, Simon D, Bosly A, Fabiani B, Bordessoule D, Ganem G, Tilly H. Superiority of Chemotherapy Aone with the ACVBP Regimen over Treatment with Three cycles of CHOP plus Radiation in Low Risk Localized 
Aggressive Lymphoma: The LNH93 -1 GELA Study. Proceedings American Society of 
Hematology. 2002;100:Abstract 343. 
28. Zinzani PL, Martelli M, Magagnoli M, Pescarmona E, Scaramucci L, Palombi F, Bendandi M, 
Martelli MP, Ascani S, Orcioni GF, Pileri S A, Mandelli F, Tura S. Treatment and clinical 
management of primary mediastinal large B -cell lymphoma with sclerosis: MACOP -B 
regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood. 1999;94:3289-3293. 
29. Raz I, Siegal T, Polliack A. CNS involvement by non -Hodgkin's lymphoma. Response to a 
standard therapeutic protocol. Arch Neurol. 1984;41:1167-1171. 
30. Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC. CNS involvement in primary mediastinal large B -cell lymph oma. J Clin Oncol. 1999;17:2479-2485. 
31. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera 
J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk 
factors, treatment, and outcome of ce ntral nervous system recurrence in adults with 
intermediate -grade and immunoblastic lymphoma. Blood. 1998;91:1178-1184. 
32. Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, Tilly H, Sonet A, Lederlin 
P, Attal M, Briere J, Reyes F. Incidence and risk factors of central nervous system relapse in 
histologically aggressive non -Hodgkin's lymphoma uniformly treated and receiving intrathecal 
central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol. 2000;11:685-690. 
33. Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects . 
N Engl J Med. 2003;348:538-549. 
34. Watters JW, McLeod HL. Cancer pharmacogenomics: current and future applications. Bioc him 
Biophys Acta. 2003;1603: 99-111. 
35. Dresser MJ. The MDR1 C3435T polymorphism: Effects on P -glycoprotein 
expression/function and clinical significance . AAPS PharmSci. 2001; 3:3. 
36. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of A BC transporters 
and its role in cancer chemotherapy . Drug Resist Updat. 2003;6: 71-84. 
37. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J, Bowman P, Burckart GJ. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant 
patients. Hum Immunol. 2002;63: 765-770. 
Version Date: 02/15/2018  78 Update #18 
CALGB 50303  
38. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne, A Cascorbi I, Gerloff 
T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug -
resistance gene: multiple sequence variations and correlation of one allele with P -glycoprotein 
expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97: 3473-3478. 
39. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pan taleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A. The 
Swiss HIVCS, Response to antiretroviral treatment in HIV -1-infected individuals with allelic 
variants of the multidrug resistance transporter 1: a pharmacogenetics study . Lancet. 2002;359: 
30-36. 
40. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1 . N Engl J Med. 2003;348: 1442-1448. 
41. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schakel U, 
Ehninger G, Schaich M. MDR1 gene polymorphisms affect therapy outcome in acute myeloid 
leukemia patients. Cancer Res. 2002 62: 4955-4962. 
42. Lenz G, et al. Oncogenic CARD11 m utations in human diffuse large B cell lymphoma. Science. 
2008; 319: 1676-1679. 
43. Davis RE, et al. Chronic active B -cell receptor signalling in diffuse large B -cell lymphoma. 
Nature. 2010; 463: 88-92. 
44. Ngo VN, et al. Oncogenically active MYD88 mutatio ns in human lymphoma. Nature. 2011. 
470; 115-119.  
45. Yap DB, et al. Somatic mutations of EZH2 Y641 act dominantly through a mechanism of 
selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2010. 
46. Sneeringer CJ, et al.  Coordinated activities of wild -type plus mutant EZH2 drive tumor -
associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B -cell 
lymphomas. Proc Natl Acad Sci USA. 2010; 107:20980-20985. 
47. Morin RD, et al. Somatic mutations altering EZ H2 (Tyr641) in follicular and diffuse large B -
cell lymphomas of germinal -center origin. Nat Genet. 2010; 42: 181-185. 
48. Lenz G, et al. Molecular subtypes of diffuse large B -cell lymphoma arise by distinct genetic 
pathways. Proc Natl Acad Sci USA. 2008; 105: 13520-13525. 
49. Alizadeh AA, et al. Distinct types of diffuse large B -cell lymphoma identified by gene 
expression profiling. Nature. 2000; 403: 503-511. 
50. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller -
Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, 
Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez- Guillermo 
A, Grog an TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke 
T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse large -B-cell lymphoma. N Engl J Med. 2002;346:1937-1947. 
51. Lenz G, et al. S tromal gene signatures in large B -cell lymphomas. N Engl J Med. 2008; 359: 
2313-2323. 
52. Jima DD, et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood. 2010; 166:e118-127. 
Version Date: 02/15/2018  79 Update #18 
CALGB 50303  
53. Zhang J, et al. Patterns of microRNA expression characterize stages of human B -cell 
differentiation. Blood. 2009; 113: 4586-4594. 
54. Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation 
phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 
2010; 18: 553-567. 
55. Figeuroa ME, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010; 17: 13-27. 
56. Martin -Subero, et al. New insights into the biology and origin of mature aggressive B -cell 
lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood. 2009; 
113: 2488-2497. 
57. Li H & Durvin R. Fast and accurate short read alignment with Burros- Wheeler transform. 
Bioinformatics. 2009; 25: 1754-1760. 
58. Trapnell C, et al. Transcript assembly and quantification by RNA -Seq reveals unannotated 
transcripts and isoform switching during cell differentiation. Nature Biotechnology. 2010; 28: 511-515. 
59. Jacinto FV, Ballestar E, Esteller M. Methyl -DNA immunoprecipitation (MeDIP): hunting 
down the DNA methylome. Biotechniques. 2008; 44: 35, 37, 39 passim. 
60. Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK. Compatibility 
and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium 
chloride injection. Am J Health Syst Pharm. 1999;56:985-989. 
61. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, 
Grillo -Lopez A, Hagenbeek A, Cabanillas  F, Klippensten D, Hiddemann W, Castellino R, 
Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international 
workshop to standardize response criteria for non- Hodgkin's lymphomas. J Clin Oncol. 
1999;17:1244. 
62. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller -
Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ , Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez -Guillermo 
A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse 
large -B-cell lymphoma. N Engl J Med. 2002;346:1937-1947. 
63. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression- based 
method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;in press.  
64. McLeod HL, Sargent DS, Marsh S, Fuchs C, Ramanathan RK, Williamson S, Findlay B, Thibodeau SG, Petersen R. Pharmacogenetic analysis of systemic toxicity and response after 
5-Fluorouracil (5- FU)/CPT- 11, 5FU/Oxaliplatin (oxal), or CPT -11/oxal therapy for advanced 
colorectal cancer (CRC: Results from an intergroup trial. Am Soc Clin Oncol. 2003;22: 1013. 
65. Feugier P, Van Hoof A, Sebban C, et al. Long -term results of the R -CHOP study in the 
treatment of elderly patients with diffuse large B -cell lymphoma: A study by the Groupe 
d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117-4126. 
66. Pfreundschuh M, Kloess M, Schmits R, et al. Six, not eight cycles of bi -weekly CHOP with 
rituximab (R -CHOP) is the preferred treatment for elderly patie nts with diffuse large B -cell 
Version Date: 02/15/2018  80 Update #18 
CALGB 50303  
lymphoma (DLBCL): Results of the RICOVER -60 trial of the German High -Grade Non -
Hodgkin Lymphoma Study Group (DSHNHL). ASH Annual Meeting Abstracts. 2005;106:13.  
67. Wilson WH, Dunleavy K, Pittaluga S, et al. Dose- adjusted EPOC H-rituximab is highly 
effective in the GCB and ABC subtypes of untreated diffuse large B -cell lymphoma. ASH 
Annual Meeting Abstracts. 2004;104:159.  
68. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize 
response cr iteria for non -Hodgkin’s lymphomas. NCI Sponsored International Working Group. 
J Clin Oncol. 1999;17:1244. 
69. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG -PET imaging for 
cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785-2808. 
70. Haioun C, Itti E, Rahmouni A, et al. [18F]Fluoro -2-deoxy-D- glucose positron emission 
tomography (FDG -PET) in aggressive lymphoma: an early prognostic tool for predicting 
patient outcome. Blood. 2005;106:1376-1381. 
71. Meignan M, Haioun C, Itti E, Rahmouni A, Reyes F. Value of [18F]fluorodeoxyglucose -
positron emission tomography in managing patients with aggressive non- Hodgkin’s lymphoma 
Clin Lymphoma Myeloma. 2006;6:306-313. 
72. Hutchings M, Loft A, Hansen M, et al. FD G-PET after two cycles of chemotherapy predicts 
treatment failure and progression- free survival in Hodgkin lymphoma. Blood. 2006;107:52-59. 
73. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine -18 fluorodeoxyglucose ([18F]FDG) after first -line chemotherapy in non-
Hodgkin’s lymphoma: is [18F]FDG -PET a valid alternative to conventional diagnostic 
methods? J Cin Oncol. 2001;19:414-419. 
74. Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol. 
2005;23:4577-4580. 
75. Juweid ME, Chson BD. Positron- emission tomography and assessment of cancer therapy. N 
Engl J Med. 2006;254:496-507. 
76. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non -Hodgkin’s 
lymphoma by integrated International Workshop Criteria and fluorine -18-fluorodeoxyglucose 
positron emission tomography. J Clin Oncol. 2005;23:4652-4661. 
77. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus Recommendations for the Use of 
18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute 
Trials. J Nucl Med. 2006;47:1059-1066. 
78. Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [(18)F] -
fluorodeoxyglucose after first -line treatment d istinguish Hodgkin’s disease patients who need 
additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol. 2001;115:272-278. 
79. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron 
emission tomography using fluorine 18- fluorodeoxyglucose in patients with aggressive 
lymphoma treated with high -dose chemotherapy and stem cell transplantation. Blood. 
2003;102:53-59. 
80. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 1 8F-FDG uptake after a few cycles 
of polychemotherapy is predictive of treatment failure in non- Hodgkin’s lymphoma. 
Haematologica. 2000;85:613-618. 
Version Date: 02/15/2018  81 Update #18 
CALGB 50303  
81. Cremerius U, Fabry U, Neuerburg J, et al. Prognostic significance of positron emission 
tomography using f luorine-18- fluorodeoxyglucose in patients treated for malignant lymphoma. 
Nuklearmedizin. 2001;40:23-30. 
82. Cremerius U, Fabry U, Wildberger JE, et al. Pre -transplant positron emission tomography 
(PET) using fluorine-18- fluoro -deoxyglucose (FDG) predicts outcome in patients treated with 
high-dose chemotherapy and autologous stem cell transplantation for non -Hodgkin’s 
lymphoma. Bone Marrow Transplant. 2002;30:103-111. 
83. Naumann R, Vaic A, Beuthien- Baumann B, et al. Prognostic value of positron emission 
tomography in the evaluation of post -treatment residual mass in patients with Hodgkin’s 
disease and non -Hodgkin’s lymphoma. Br J Haematol. 2001;115:793-800. 
84. de Wit M, Baumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole -body positron 
emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann 
Oncol. 1997;8 Suppl 1:57-60. 
85. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging. 2003;30 Suppl 1:S89-96. 
86. Kos takoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis 
after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 
2002;43:1018-1027. 
87. Talbot JN, Haioun C, Rain JD, et al. [18F] -FDG positron ima ging in clinical management of 
lymphoma patients. Crit Rev Oncol Hematol. 2001;38:193-221. 
88. Kostakoglu L, Goldsmith SJ. Fluorine -18 fluorodeoxyglucose positron emission tomography 
in the staging and follow -up of lymphoma: is it time to shift gears? Eur J Nucl Med. 
2000;27:1564-1578. 
89. Foo SS, Mitchell PL, Berlangieri SU, Smith CL, Scott AM. Positron emission tomography 
scanning in the assessment of patients with lymphoma. Intern Med J. 2004;34:388-397. 
90. Lang O, Bihl H, Hultenschmidt B, Sautter -Bihl ML. Clinical relevance of positron emission 
tomography (PET) in treatment control and relapse of Hodgkin’s disease. Strahlenther Onkol. 
2001;177:138-144. 
91. Leisenring W, Alonzo T, Pepe MS. Comparisons of predictive values of binary medical 
diagnostic tes ts for paired designs. Biometrics. 2000;56:345-351. 
92. DeLong ER, DeLong DM, Clarke -Pearson DL.  Comparing the areas under two or more 
correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 
1988;44(3):837-845. 
93. Heagerty PJ, Lumley T, Pepe MS.  Time -dependent ROC curves for censored survival data 
and a diagnostic marker. Biometrics. 2000;56(2):337-344. 
94. Jung SH, Ahn C.  Estimation of response probability in correlated binary data: A new approach. 
Drug Information Journal.  2000;34:599-604. 
95. Kim J, Kim Y, Kim Y. A gradient-based optimization algorithm for LASSO. J Comput Graph 
Stat. 2008; 17: 994-1009. 
96. Sohn I, Kim J, Jung SH, Park C. Gradient lasso for Cox proportional hazards model. 
Bioinformatics. 2009; 25: 1 775-1781. 
 
  
Version Date: 02/15/2018  82 Update #18 
CALGB 50303  
APPENDIX I C ANCER TRIALS SUPPORT UNIT (CTSU)  PARTICIPATION PROCEDURES  
 
CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT INFORMATION: 
To submit site registration documents:  For patient enrollments:  
 
  
 
Hour
s: 9:00AM – 5:30PM Eastern Time, Monday –Friday 
(excluding holidays)  
[Registrations received after 5:00PM ET wi ll be handled the next 
business day. For CTSU patient enrollments that must be 
completed within approximately one hour, or other extenuating circumstances, call 
 between 9:00AM and 
5:30PM.]  
Submit study data directly to the Lead Cooperative Gr oup unless otherwise specified in the protocol:  
 
 
 
Sites
 should submit Teleforms via Fax or Mail. See section 5.2  Data S ubmission Section for details on forms 
submission.  
Do not submit study data or forms to CTSU Data Operations. Do not copy the CTSU on data submissions.  
For patient eligibility or treatment related questions: Contact the CALGB Study Chair.  
For questions unrelated to patient eligibility, treatment, or data submission  contact the CTSU Help Desk by 
phone or e -mail:  
CTSU General Information Line:  All calls and correspondence 
will be triaged to the appropriate CTSU re presentative.  
The CTSU Web site is located at:  
Registration/Randomization  
Prior to the recruitment of a patient for this study, investigators must be registered members of the CTSU. Each investigator must have an NCI investigator num ber and must maintain an “active” investigator registration status 
through the annual submission of a complete investigator registration packet (FDA Form 1572 with original signature, current CV, Supplemental Investigator Data Form with signature, and Financial Disclosure Form with original signature) to the Pharmaceutical Management Branch, CTEP, DCTD, NCI. These forms are available on the CTSU registered member Web site or by calling the PMB at  Monday through Friday between 8:30AM and 
4:30PM Eastern time.  
Each CTSU investigator or group of investigators at a clinical site must obtain IRB approval for this protocol and 
submit IRB approval and supporting documentation to the CTSU Regulatory Office before they can enroll patients. 
Study centers can check the status of their registration packets by querying the Regulatory Support System (RSS) site registration status page of the CTSU member Web site at . 
All forms and documents associated with this study can be downloaded from the CALGB 50303 Web page on the CTSU registered member Web site  Patients can be registered only after pre- treatment 
evaluation is complete, all eligibility criteria have been met, and the study site is listed as “approved” in the CTS U 
RSS.  
Version Date: 02/15/2018  83 Update #18 

CALGB 50303  
Requirements for CALGB 50303 site registration:  
• CTSU IRB Certification  
• CTSU IRB/Regulatory Approval Transmittal Sheet  
Pre-study requirements for patient enrollment on CALGB 50303:  
• Patient must meet all inclusion criteria, and no exclusion crit eria should apply.  
• Patient has signed and dated all applicable consents and authorization forms.  
• All baseline laboratory tests and pre -study evaluations performed within the time period specified in the protocol 
and fresh (frozen) tumor biopsy must be available or attempted.  
• As of protocol update #14, and starting August 1, 2012, registration to the companion study CALGB 580603 is 
required to register to the treatment study CALGB 50303, and will be performed at the same time as registration 
to the treatment study. Registration to CALGB 580603 must be done at time of patient enrollment. Sites must 
submit the institutional approval letter provided by the Imaging Core Laboratory to the CTSU with each patient 
enrollment for CALGB 50303 and 580603.  
• As of protocol update #14, and starting August 1 , 2012, all sites that enroll patients must be approved ( or have 
previously been approved) by the Alliance  Imaging Core Laboratory at the Ohio State University Medical Center. 
See the “Special Materials and Substudies” section below for further information on procedures .  
CTSU PROCEDURES FOR PATIENT ENROLLMENT  
1. Contact the CTSU Patient Registration Office by calling  between 9:00AM and 5:30PM Eastern 
Time, Monday -Friday. Leave a voicemail to alert the CTSU Patient Registrar that an enrollment is forthcoming. 
For immediate registration needs, e.g.,  within one hour, call the registrar cell phone at  
2. Complete the following forms: 
• CTSU Patient Enrollment Transmittal Form  
• CALGB 50303 Eligibility Checklist  
• CALGB Registration Worksheet (indicate participation on companion studies C ALGB 60405 and CALGB 
580603)  
• Copy of approval letter from the Alliance  Imaging Core Laboratory for the FDG -PET/CT Imaging 
Companion  
3. Fax these forms to the CTSU Patient Registrar at  between the hours of 9:00AM and 5:30PM, 
Mon -Fri, Easte rn Time (excluding holidays); however, please be aware that registrations received after 5:00PM 
will be processed the next day. Registration is limited to the operating hours of the CALGB Registration Office 
(9:00AM – 5:00PM ET). The CTSU registrar will ch eck the investigator and site information provided to ensure 
that all regulatory requirements have been met. The registrar will also check that forms are complete and follow -
up with the site to resolve any discrepancies.  
4. Once investigator eligibility is confirmed and enrollment documents are reviewed for compliance, the CTSU 
registrar will contact the CALGB, within the confines of CALGB’s registration hours. The CTSU registrar will access the CALGB’s on -line registration system, to obtain assignment of treatment arm and assignment of a 
unique patient ID (to be used on all future forms and correspondence). The CTSU registrar will confirm registration by fax.  
• Protocol treatment must begin within 7 days of randomization.  
Registration to Companion Study (CALGB 60405)  
• Sites must offer participation in the companion studies to all patients.  
• Registration to the companion stud y CALGB 60405 for those patients who have agreed to participate, will be 
performed at the same time as registration to the treatment s tudy. Although it is preferable that patients be 
registered to CALGB 60405 at the same time they are registered to CALGB 50303, registration to CALGB 60405 may occur up to 60 days following registration to the treatment trial.  
Version Date: 02/15/2018  84 Update #18 

CALGB 50303  
Procedures for late enrollme nt on CALGB 60405 (pharmacogenomics companion):  
- Submit CTSU Patient Enrollment transmittal form (with note indicating delayed registration to CALGB 60405 
companion study).  
- Submit revised CALGB 50303 Registration Worksheet (indicating patient consent fo r CALGB 60405).  
Note: Although it is preferable that patients are registered to 60405 at the same time they are registered to CALGB 50303, registration to CALGB 60405 may occur up to 60 days following registration to the treatment trial.  
D
ATA SUBMISSION AND RECONCILIATION  
1. All case report forms (CRFs) and transmittals associated with this study must be downloaded from the C50303 
Web  
page located on the CTSU registered member Web site . Sites must use the current 
form versions and adhere  to the instructions and submission schedule outlined in the protocol.  
2. Submit all completed CRFs (with the exception of patient enrollment forms), clinical reports, and transmittals dire 
ctly to the Alliance Statistics and Data  Center (see contact table and Section 5.2  of protocol), unless an 
alternate location is specified in the protocol. Do not send study data to the CTSU. A completed CTSU -CALGB 
coversheet should accompany all data submissions.  
3. The Alliance Statistics and Data  Center will send (generally via e -mail but may be sent via postal mail or fax) 
query notices and delinquency reports directly to the site for reconciliation. Please send query responses and delinquent data to the Alliance Statistics and Data  Center (via postal mail or fax) and do not copy the CTSU Data 
Operations. Each site should have a designated CTSU Administrator and Data Administrator and must keep their 
CTEP AMS account contact information current . This will ensure timely communication between the clinical 
site and the Alliance Statistics and Data  Center.  
S
PECIAL MATERIALS OR SUBSTUDIES  
1. Mandatory Histologic Review (Protocol Section 5.3 ) 
 • Fresh (frozen) tumor biopsy sample is mandatory.  
 • Failure to submit a pathology block within 60 days of patient registration will be considered a major protocol violation.  
 • Collect, prepare, and submit specimens as outlined in the protocol.  
 • Do not send specimens, supporting clinical reports, or transmittals to the CTSU.  
2. Specimen Collection for Correlatives (Protocol Section 5.4
) 
 • Pharmacogenomic Substudy, CALGB 60405, requires patient consent and separate registration.  
 • Collect, prepare, and submit specimens as outlined in the protocol.  
 • Do n ot send specimens, supporting clinical reports, or transmittals to the CTSU.  
3. FDG -PET/CT Imaging (Protocol Section 8.0 ) 
 • Imaging Substudy, CALGB 580603, requires separate registration   
 • See instructions outlined in Protocol Section 8. 0. regarding participation on this study. Sites must submit 
required documentation to the Imaging Core Laboratory and receive institutional approval.  
 • Submit institutional approval letter for imaging substudy participation to the CTSU with each patient 
enrollment on CALGB 580603.  
 • Do not send images to the CTSU.  
Version Date: 02/15/2018  85 Update #18 

CALGB 50303  
SERIOUS ADVERSE EVENT (AE)  REPORTING (SECTION 15.0) 
1. CTSU sites must comply with the expectations of their local Institutional Re view Board (IRB) regarding 
documentation and submission of adverse events. Local IRBs must be informed of all reportable serious adverse 
reactions.  
2. CTSU sites will assess and report adverse events according to the guidelines and timelines specified in the protocol. You may navigate to the CTEP Adverse Event  Expedited Report System (CTEP -AERS ) from either the 
Adverse Events tab of the CTSU member home page (https://www.ctsu.org) or by selecting Adverse Event 
Reporting Forms from the document center drop down list on the protocol number Web page.  
3. Do not send adverse event reports to the CTSU.  
4. Secondary AML/MDS/ALL reporting: Report occurrence of secondary AAML, MDS, or ALL via the NCI/CTEP 
AML -MDS Report Form in lieu of CTEP -AERS . Submit the completed  form and supporting documentation as 
outlined in the protocol.  
D
RUG PROCUREMENT (SECTION 10.0) 
Commercial Agents : Doxorubicin, Etoposide, Vincristine, Cyclophosphamide, Prednisone, Rituximab, Filgrastim, 
Pegfilgrastim, Methotrex ate 
1. Information on drug formulation, procurement, storage and accountability, administration, and potential toxicities 
are outlined in Section 10.0  of the protocol.  
2. You may navigate to the drug forms by selecting Pharmacy F orms from the document center drop down list on 
the CALGB 50303 Web page.  
REGULATORY AND MONITORING  
Study Audit  
To assure compliance with Federal regulatory requirements [CFR 21 parts 50, 54, 56, 312, 314, and HHS 45 CFR 46] 
and National Cancer Institute (NCI)/Cancer Therapy Evaluation Program (CTEP) Clinical Trials Monitoring Branch (CTMB) guidelines for the conduct of clinical trials and study data validity, all protocols approved by NCI/CTEP that 
have patient enrollment through the CTSU are subject to audit.  
Responsibility for assignment of the audit will be determined by the site’s primary affiliation with a Cooperative 
Group or CTSU. For Group- aligned sites, the audit of a patient registered through CTSU will become the responsibility 
of the Group receiving credit for the enrollment. For CTSU Independent Clinical Research Sites (CICRS), the CTSU 
will coordinate the entire audit process.  
For patients enrolled through the CTSU, you may request the accrual be credited to any Group for which you have an 
affiliation provided that Group has an active clinical trials program for the primary disease type being addressed by 
the protocol. Per capita reimbursement will be issued by the credited Group provided they have endorsed the trial, or by the CTSU if the Group  has not endorsed the trial.  
Details on audit evaluation components, site selection, patient case selection, materials to be reviewed, site preparation, on -site procedures for review and assessment, and results reporting and follow -up are available for 
download from the CTSU Operations Manual located on the CTSU Member Web site.  
Health Insurance Portability and Accountability Act of 1996 (HIPAA)  
The HIPAA Privacy Rule establishes the conditions under which protected health information may be used or disclos ed by covered entities for research purposes. Research is defined in the Privacy Rule referenced in HHS 45 
CFR 164.501. Templated language addressing NCI -U.S. HIPAA guidelines are provided in the HIPAA Authorization 
Form located on the CTSU Web site. 
The H IPAA Privacy Rule does not affect participants from outside the United States. Authorization to release 
Protected Health Information is NOT required from patients enrolled in clinical trials at non -U.S. sites.  
Version Date: 02/15/2018  86 Update #18 
CALGB 50303  
Clinical Data System (CDS) Monitoring  
This stu dy will be monitored by the Clinical Data System (CDS -web). Cumulative CDS data will be submitted 
quarterly to CTEP by electronic means. The sponsoring Group fulfills this reporting obligation by electronically 
transmitting to CTEP the CDS data collected f rom the study- specific case report forms.  
 
Version Date: 02/15/2018  87 Update #18 
CALGB 50303  
APPENDIX II CALGB  580603  PET/CT  INSTRUMENT TECHNICAL SPECIFICATIONS FORM  
(From ACRIN  Credentialing Application, 2005)  
Page 1 of 5  
 
 
Institution:        Date:  
 Institution Address:  
   Institution Contact Name an d Telephone Number:  
 E-mail:        Fax:  
   PET Center Name:       Date:  
 PET Center Address:  
   
PET Center Contact Name and Telephone Number:  
 
E-mail:        Fax:  
   
Type of Scanner:  
(e.g., GE Discovery ST, Siemens Biograph, Philips Gemini, GE Advance, Sie mens/CTI ECAT, etc.)  
 
 Transmission Source:  
(e.g., 
68GE-rods, 137Cs-point, CT)  
  Method of Attenuation Correction:  
(e.g., segmentation, subtraction of emission contribution to transmission scan, CTAC)  
  
 
Routine QC Testing Performed  
 
Daily:  
 
Monthly:  
 
Quar terly:  
 Yearly:  
 
Other:  
 
Version Date: 02/15/2018  88 Update #18 
CALGB 50303  
APPENDIX II 
CALGB 580603 PET/CT INSTRUMENT TECHNICAL  SPECIFICATIONS FORM  
(From ACRIN  Credentialing Application, 2005)  
Page 2 of 5  
UNIFORM PHANTOM SCAN INFORMATION  
 
Phantom Length:     Phantom Diameter:  
 
Phantom Volume:  
 Radionuclide:  
 Scan Date:    Scan Time:     Scan Duration:  
  
For Water- Fillable Phantoms, Provide the Following Data : 
 
Assayed Activity in Syringe before injection:  mCi  Time:  
 
Assayed Activity in Syringe after  injection:  mCi  Time:  
 
 
 
For Ge -68/Ga- 68 Calibratio n Phantoms, Provide the Following Data : 
 
Calibration Date:     Time:  
 
Calibration Activity:  mCi  Time:  
 
           Std Dev of SUV  
Number of Pixels in  Slice #  Average SUV in ROI1    (if available)  
ROI:  
  1   ________        ________  
  2   ________        ________  
  3   ________        ________  
  4   ________        ________  
  5   ________        ________  
  6   ________        ________  
  7   ________        ________  
  8   ________        ________  
Report info for EVERY  9   ________        ________  
slice of the phantom  10   ________        ________  
  11   ________        ________  
  12   ________        ________  
  13   ________        ________  
  14   ________        ________  
  15   ________        ________  
  16   ________        ________  
  17   ________        ________  
  18   ________       ________  
  19   ________        ________  
  20   ________        ________  
 
1 A circular or elliptical region of interest (ROI) covering most of the interior of the phantom.  
Version Date: 02/15/2018  89 Update #18 
CALGB 50303  
APPENDIX II 
 
CALGB 580603 PET/CT INSTRUMENT TECHNICAL  SPECIFICATIONS FOR M 
(From ACRIN  Credentialing Application, 2005)  
 
Page 3 of 5  
 
 
FOR CALGB IMAGING CORE LABORTORY USE ONLY:  
 
Phantom Images Review : 
 
Date:  
Comments:  
 
   
 
         Approved  
         Disapproved  
  _________________________________________        _____________ ______  
 Signature                                                            Date  
 
 
  
Version Date: 02/15/2018  90 Update #18 
CALGB 50303  
APPENDIX II 
CALGB 580603 PET/CT INSTRUMENT TECHNICAL  SPECIFICATIONS FORM  
(From ACRIN  Credentialing Application, 2005)  
Page 4 of 5  
 
WHOLE BODY FDG -PET TEST PATIENT #1 : 
 
 File Name:     Patient Height:   Patient Weight:  
 FDG Dose (mCi):    Dose Assay Time:  
 Blood glucose prior to FDG administration (mg/dL):  
 Injection Time:    Start Time of Emission Scan:  
 ACQUISITION  No. of Bed Positions:  
  EMISSION TIME (MIN/BED):   TRANSM ISSION TIME (MIN/BED):  
 
 
RECONSTRUCTION ALGORITHM:  
(e.g., 2D FBP, 2D OSEM, 3D FORE/OSEM, 3D 
RAMLA)  PIXEL SIZE (mm)  
X-Y: 
 
Z: 
 
 Scatter Correction Applied:     Yes  No 
 
(Include algorithm type, e.g., model -based, tail -fit, Bergstrom): 
 
 Randoms Correction Applied:    Online  Smoothed Randoms (offline)    None  
 
 
FOR CALGB IMAGING CORE LABORTORY USE ONLY:  
 
Test Patient #1  Review:  
 Date:  
Comments:  
 
 
         Approved  
         Disapproved  
 
 
_________________________________________        ___________________  
 Signature                                                            Date  
 
 
Version Date: 02/15/2018  91 Update #18 
CALGB 50303  
APPENDIX II 
CALGB 580603 PET/CT INSTRUMENT TECHNICAL  SPECIFICATIONS FORM  
(From ACRIN  Credentialing Application, 2005)  
Page 5 of 5  
 
 
WHOLE BODY FDG -PET TEST PATIENT #2 : 
 
 
File Name:     Patient Height:   Patient Weight:  
 
FDG Dose (mCi):    Dose Assay Time:  
 Blood glucose prior to FDG administration (mg/dL):  
 
Injection Time:    Start Time of Emission Scan:  
 
ACQUISITION  No. of Bed Positions:  
  EMISSION TIME (MIN/BED):   TRANSMIS SION TIME (MIN/BED):  
  
RECONSTRUCTION ALGORITHM:  
(e.g., 2D FBP, 2D OSEM, 3D FORE/OSEM, 3D 
RAMLA)  PIXEL SIZE (mm)  
X-Y: 
 Z: 
 
 
Scatter Correction Applied:     Yes  No 
 
(Include algorithm type, e.g., model -based, tail -fit, Bergstrom): 
 
 Randoms Correction Applied:    Online  Smoothed Randoms (offline)    None  
 
 
FOR CALGB IMAGING CORE LABORTORY USE ONLY:  
 
Test Patient #2  Review:  
 Date:  
Comments:  
           Approved  
         Disapproved  
  _________________________________________        ________________ ___ 
 Signature                                                            Date  
 
Version Date: 02/15/2018  92 Update #18 
CALGB 50303  
APPENDIX III CALGB  580603  IMAGING SITE PERSONNEL FORM  
 
Responsible CRA Contact  
Complete Address  
E-mail 
Phone Number  
Fax Number  Radiology Department Contact  
Complete Address  
E-mail 
Phone Number  
Fax Number  
  
 
 
Please provide the information requested above. Provide the middle initial for individuals who commonly use them. Also, please add or correct the degree/title as necessary. This information will be retained by the Allian ce Imaging Core Lab at 
IROC Ohio . 
 
Once completed, you may send this form to:  
    
  
   
     
  
   
 
Call
 the Imaging Core Laboratory at  with any questions. Thank you 
for your assistance.  
Version Date: 02/15/2018  93 Update #18 
